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With nearly 1,350 complete genome sequences available our understanding of
biology at the molecular level has never been more complete. A consequence of these
sequencing projects was the discovery of large functionally unannotated segments of
each genome. The genes (and proteins they encode) found in these unannotated regions
are considered “hypothetical proteins”. Current estimates suggest between 12%-50% of
the known gene sequences are functionally unannotated. Incomplete functional
annotation of the various genomes significantly limits our understanding of biology.
Pragmatically, identifying the functions of these proteins could lead to new therapeutics;
making functional annotation of paramount importance.
This dissertation describes the development of new methods for protein functional
annotation independent of homology transfer. The hypothesis is proteins with similar
function have significantly similar active sites. Nuclear magnetic resonance ligand
affinity screening was employed to identify and define protein active sites. The methods
developed were tested on a series of functionally diverse, annotated proteins including,
serum albumins (H. sapiens, B. taurus),

and

amylases (B. licheniformis, A. oryzae, B.

amyloliquefaciens H. vulgare, I. batatas), primase C-terminal domain (S. aureus),
nuclease (S. aureus) and the type three secretion system protein PrgI (S. typhirium).

Functional annotation using protein active sites require a high-resolution threedimensional structure of the protein. In addition to method development, this dissertation
describes the NMR solution structure of Staphylococcus aureus primase carboxyterminal domain (CTD). The primase CTD is essential for bacterial DNA replication and
distinctly different from eukaryotes. With the rapid rise in antibiotic resistance, the
primase CTD of S. aureus is an attractive antibiotic target. The methods used for
functional annotation were used to screen S. aureus primase CTD to identify the
compound acycloguanosine as a binding ligand to primase CTD.
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“Evolution is an obstacle course not a freeway….” S.J Gould
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CHAPTER 1:
GENERAL INTRODUCTION

1.1 General introduction to functional genomics. Protein science has a long
history inevitably intertwined with the advancements in chemistry, biology and physics.
The term “protein” was initially used by Jöns Jakob Berzelius and Gerhardus Johannes
Mulder who performed the first elemental analysis of a protein in 1839.1 Surprisingly, all
proteins Berzelius and Mulder studied contained the general empirical formula;
C400H620N100O120.1
Nearly a century after Mulder‟s work, Jensen et. al. discovered the first amino
acids in a protein.2 This discovery eventually lead to the first complete amino acid
sequence of a protein elucidated by F. Sanger in 1955. 3, 4 Sanger followed up his work
on protein sequencing with developing techniques for DNA sequencing 5,

6

and

successfully completed the first entire sequenced genome in 1977. 7 Twenty-two years
later, Haemophilus influenzae became the first living organism to have its entire genome
sequenced.8

The following 6 years uncovered the complete genome sequences for

Escherichia coli9, Drosophila melanogaster10, and in 2001 Homo sapiens.11
Since the first published genome in 19777 there has been an explosion in the
number of complete genome sequences (figure 1.1). As of August 2010, a total of 1350
genomes have been completed and published representing all branches in the tree of life
with nearly 6500 additional sequencing projects currently in progress. 12 In addition to
individual species sequencing efforts, the technological advances in genome sequencing
and relative low cost have help push the development of metagenomics. Metagenomics
is the sequencing of samples collected directly from their environment. This has led to

2
the complete sequencing of the human gut “microbiome”13 and the identification of
various soil14 and ocean15, 16 microbes that could not be cultured in a laboratory setting.

Figure 1.1 The rapid increase in sequenced genomes. Since the first genome of a
living organism was sequenced in 1995 there has been a dramatic increase in the total
number of completed genomes. The data was collected from the current status of the
GOLD database12 (August 2010) which listed a total of 1350 completed genomes.

A consequence of these sequencing projects was the discovery of large
functionally unannotated segments of each genome.

The genes (and proteins they

encode) found in these unannotated regions are considered “hypothetical proteins”. The
term hypothetical protein is synonymous with novel gene product, unknown protein, noncharacterized protein or putative uncharacterized gene product. Current estimates suggest

3
the percent of unannotated proteins found in all sequenced genomes is between 12%50%.17-19 For example, an estimated 50% of the genes in the Escherichia coli genome
have not been experimentally annotated. 20, 21
The large number of hypothetical proteins initially suggested these proteins were
adaptations to specific environmental niches and therefore species specific.22 Considering
the large degree of biodiversity this seemed like a reasonable assumption.22, 23 However,
most hypothetical proteins are not species specific, but rather found in a range of
phylogenetic distributions generating families of “conserved hypothetical proteins”.24
For example the E. coli hypothetical protein yrdC is a member of a hypothetical protein
family. Homologous sequences to yrdC are also found in Bacillus subtilis, yeast, and
humans.24

Proteins such as yrdC are annotated as conserved hypothetical proteins

because no member in the family is completely functionally annotated. 24, 25
The most accurate and manually edited source for indentifying conserved
hypothetical protein families, the Cluster of Orthologous Groups database (COG), 26
reports 2143 uncharacterized, putative or predicted orthologous families in bacteria. 25, 27
The large number of hypothetical and conserved hypothetical proteins significantly limits
our understanding of biology. From a pragmatic viewpoint, identifying the functions of
these proteins could lead to new therapeutics; making functional annotation of these
proteins of paramount importance.
1.2 Introduction to protein functional annotation. The most basic level of
functional annotation involves associating experimental evidence for a particular
biochemical, biological process, or interaction to a specific gene.
experimental methods exist to annotate protein function.

A number of

These include various
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enzymatic assays,28, 29 protein-protein interaction hybrid assays,30, 31 knockout studies,32,
33

gene silencing methods using antisense oligodeoxynucleotides,34 ribozymes35 or RNA

interference

36-38

and recently metabolomic data.39-41

While powerful and direct, often a single biochemical method cannot fully
annotate a gene. For example, with knockout and gene silencing studies a function is
inferred from the change in observed phenotype between the wild-type and knockout
organsim.42 Knockout studies of essential genes are relatively straightforward with the
appropriate control experiments because if the gene is no longer active the cell dies.43
However, these studies only prove the knockout gene is essential for survival. These
studies do not suggest a molecular function. For knockout studies of non-essential genes
the issue becomes even more problematic. If multiple different genes carry out a
particular function the knockout of gene may give no change in phenotype. Often this
happens when a redundant gene compensates for the knockout. 44
Functional annotations from enzymatic assays generally describe the substrate
used in the study or reaction mechanism. For example, the general function ascribed to
the enzyme responsible for catalyzing the oxidation of ethanol to acetaldehyde using
nicotinamide adenine dinucleotide (NAD+) as a coenzyme, is alcohol dehydrogenase.45
In humans, the alcohol dehydrogenase family consists of 7 unique genes each bind a
range of alcohol substrates.45 The problem becomes, if a gene has multiple in vitro
functions, which one is the “correct” in vivo function? For alcohol dehydrogenase this
problem is even larger with multiple genes binding a range of substrates.
The enzyme classification (EC) scheme attempts to standardize functional
annotation from experimental methods. 46 The enzyme classification scheme annotates
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proteins based on 6 broad functional classes (oxidoreductases, transferases, hydrolases,
lyases isomerases and ligases).

The functional annotation of the enzyme is further

refined based on substrate and reaction chemistry. For the alcohol dehydrogenase
example, all 7 genes in human are classified with the EC number of E.C 1.1.1.1 with each
number designating a specific level of functional annotation (scheme 1.1)

Scheme 1.1. Example of enzyme classification (EC) nomenclature.
EC 1.1.1.1 Alcohol dehydrogenase
E.C 1.-.-.Oxidoreductases
E.C 1.1.-.Acting on the CH-OH group of donors
E.C 1.1.1.With NAD(+) or NADP(+) as acceptor
E.C 1.1.1.1
Alcohol dehydrogenase

The EC method provides a concise method to annotate experimental functions
down to specific reaction chemistry. However, the problem becomes, what level of
enzyme activity (Km, Vmax etc…) is needed to assign an EC number? Additionally, for
Escherichia coli, only 30% of the genome encodes for enzymes, the remaining 70%
encodes for transport proteins, response regulators, structural proteins, and other nonenzyme functions.47
The sheer number of unannotated proteins significantly limits complete
biochemical analysis of every gene within an organism. A search of the NCBI protein
sequence database for the term “hypothetical” retrieves nearly 1.5 million hits (August
2010). Correspondingly, nearly 2730 unique structures deposited in the Protein Data
Bank (PDB) are annotated as hypothetical (August 2010).

The large number of

unannotated proteins makes pure experimental work impractical and supports the
necessity of bioinformatics and hybrid bioinformatic/experimental methods. 21
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Since the early stages of protein and gene sequencing, it was shown sequences
directly relate to the evolution of a protein and in some instances the organism. 48-51 This
triggered the development of many sequence comparison methods attempting to
accurately measure sequence relatedness.52-59

Today, multiple sequence alignments

(MSA) are routinely used to identify sequence similarity, build phylogenetic
relationships, and to measure evolutionary clocks.60-65

In addition to sequence based

approaches, the three dimensional structure of a protein is related to molecular and
organism evolution.

A number of reports have shown a protein structure can also

generate structure based phylogenetic trees66-70 and protein domain complexity scales
with organism complexity.71 Mapping the evolutionary relationship between proteins is
fundamental to current automatic functional annotation methods.
Current bioinformatic methods for functional annotation rely on gene and protein
sequence, structure or hybrid sequence/structure similarity searches to automatically
annotate protein function.72

These methods use the evolutionary conservation of a

protein to infer a generalized function; „inheritance through homology‟. 73-75 Homology is
a hypothesis of the evolutionary relatedness between two or more proteins based on
relative sequence or structure similarities.76, 77 The degree sequence similarity needed to
infer homology is still being debated. However, for highly similar sequences (≥ 70%)
this method is effective at annotating function. 78
Functional annotation using homology transfer is the standard method of
automated functional prediction. Many databases exist for automated functional
prediction including, PFAM,79 Gene Ontology,80-82 UniProt/RefSeq/Swiss-Prot,83
ProFunc,84 and STRING.85 Similarly, the COG/KOG26 and eggNOG17 databases often
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get used for functional prediction because they contain large sets of orthologous genes.
These databases and others have been reviewed in depth previously. 86 Each database
uses different methods of protein representation, different algorithms for comparison and
different scoring functions, in the majority of cases the result is a generalized functional
annotation.
These automated functional annotation tools are necessary for managing the large
volume of sequence data and remain the most popular. 87 However, these methods often
lead to spurious annotations because homology does not necessarily imply conservation
of function.88 Additionally, these methods are often error prone and based on a small set
of experimentally annotated proteins.87,

89-92

The maximum reported error rate for

automatic functional annotation is 63% for all unannotated genes. 87,

91

For enzymes

approximately 30% of current automatic functional annotations are incorrect. 90
Differences in protein active site structure leading to different ligand specificities and
enzyme efficiencies are suspected to be a major source of errors in automatic functional
annotations.78, 90, 93
In addition to the problems stated above, many of the automatic function
prediction methods have reached an apparent maximum effectiveness. 94 Essentially, (i)
proteins with known function become overly populated in the databases so no new
information is reported, or (ii) hypothetical proteins only match other hypothetical
proteins. Figure 1.2 shows a structure based similarity search of the protein Bcl-xL,
which only retrieves other Bcl-xL proteins. Alternatively, a search of a hypothetical
protein YtfP from E. coli only retrieves other proteins of unknown function. Similar
results are obtained using sequence similarity.

8

9

Figure 1.2 Structure based similarity searching to predict protein function. (A) The
anti-apoptosis protein Bcl-xL (1YSN) was compared to the Dali FSSP database95-98 to
identify potential new functions. The only significant hits (Z>2.0) were redundantly
solved protein structures of the same sequence or Bcl-2 homologs. (B) The structure of
the hypothetical protein YtfP (1XHS) was compared to the same database with the most
significant hits having no known function or a range of predicted functions. This
example highlights two common problems with current structure based database
searches: (i) a protein with known function is overly populated so no new information is
reported, or (ii) hypothetical proteins only match other hypothetical proteins.

10
1.3 Annotation of function using ligand binding.

A major source of error in

automatic function prediction is differences in active site structure and ligand specificity.
Could using active site information increase functional annotation? Proteins interact with
biological molecules including other proteins, DNA, RNA or small molecule ligands.
Therefore, the active site of a protein must be intrinsically linked to the function of the
protein.99
Active site similarity tools for functional prediction and annotation are a rapidly
growing trend.100-106

Using ligands to probe protein function is an evolutionary

independent method to predict protein function. This should reduce the error rate of
traditional homology based methods because active site annotations are not limited to
correct ortholog detection.107 Additionally, traditional homology based methods do not
account for post-translational modifications or the occurrence of gene sharing. Both of
which have dramatic biological significance. 108-110
A corollary to function prediction using ligand binding is using similar functions
to predict off-target side effects of drugs.105, 106, 111, 112 Recent observations of potential
drug leads binding a range of protein targets with similar function further support the idea
of using ligand binding to predict protein function. Attempts have been made to relate
ligand binding to sequence or structure similarity with minimal success. 113 To date only a
handful of studies have attempted to relate ligand binding with protein function. 106, 114-117
The work reported in this dissertation uses this most basic definition of protein
function to establish a uniform method for identifying functional similarity.

The

hypothesis is proteins with similar function will bind to a set of similar biologically
relevant small molecules at a specific active site. The hypothesis is supported by reports
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showing functional regions of a protein are more stable relative to the remainder of the
protein sequence undergoing random drift.118, 119 The correlation between ligand binding
sites, ligand structure and protein function has also been demonstrated by a network of
ligand binding-site.120 A variety of computational methods have attempted to exploit the
stability of functional regions by identifying ligand binding sites as a method to predict
function.121,

122

Unfortunately, the combined requirements of predicting the ligand, the

binding site, and a similarity to an annotated proteins leads to a high level of ambiguity.
This dissertation will discuss the development of high-throughput screening
methods to detect ligand binding and discovery protein active sites. There is an inherent
similarity between the methods used to detect ligand binding for functional annotation
and drug discovery. In this dissertation the high-throughput NMR screening method to
detect ligand binding were originally developed to identify binding ligands and protein
active sites for attractive drug targets.
Drug discovery is a uniquely complex problem in science and medicine.123,

124

This is further complicated by the fact that each disease is distinct and requires its own
efficient strategy to successfully develop safe therapeutics.125 A central theme in drug
discovery research is attempting to identify highly specific ligands (nM-pM KD) that bind
a biological target.

Therefore, the methods used to detect ligand binding in drug

discovery research are also amenable to identifying binding ligands for functional
annotation. In this dissertation, the techniques developed for high-throughput NMR
screening were used to identify binding ligand to a number of functionally diverse
proteins including, serum albumins (H. sapiens, B. taurus),

and

amylases (B.

licheniformis, A. oryzae, B. amyloliquefaciens H. vulgare, I. batatas), primase C-terminal
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domain (S. aureus), nuclease (S. aureus) and the type three secretion system protein PrgI
(S. typhirium).
1.4 General principles of high-throughput nuclear magnetic resonance
screening.

From target selection to pre-clinical trials, nuclear magnetic resonance

(NMR) has established itself as an invaluable tool for the chemist working in the drug
discovery industry.126,

127

The flexibility provided by NMR comes from various

molecular probes that include chemical shifts, relaxation parameters (T 1, T2), spatial
information (nuclear Overhauser effects, NOE), and diffusion rates. Each parameter is
uniquely sensitive to the local chemical and physical environment of a sample and
provides structural information at atomic resolution for both small (<1000 Da) and large
(> 1000 Da) biological molecules. Additionally, in recent years NMR has proven more
valuable to the drug discovery process than simply a tool for structural studies of
biological molecules.126 This is most apparent with the increase use of NMR as a critical
component for high-throughput screening (HTS). The current methods for NMR affinity
screening methods are listed in table 1.1.
NMR affinity screening methods complement structural biology efforts by
validating chemical leads prior to initiating a structure-based drug design program.128-133
Target focused screening techniques, such as SAR by NMR,134 RAMPED-UP NMR,135
STD-NMR,136 and NMR-SOLVE137 were developed to identify ligands that bind a
therapeutic target in a biologically relevant manner (table 1.1). This is often done by
observing chemical shift changes in two-dimensional 2D 1H-15N HSQC spectra of the
protein in the presence and absence of a small molecule ligand. Target based NMR
screening methods provide invaluable information about the nature of a ligand binding

13
site.134, 138-143 However, these methods often require high concentrations (≥ 100 M) of
expensive
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N isotope enriched protein and demand large amounts of data collection

time. Therefore target based screening methods are often better suited for secondary
follow-up screens.115, 144, 145
Unlike the target focused methods, ligand focused techniques detect binding
events by identifying changes in the free 1H ligand spectrum upon the addition of a
protein. Many ligand focused methods have been developed that exploit various NMR
molecular probes including saturation transfer differences,136,
changes,147-150 diffusion rate changes,151
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F NMR,149,

152

146

line-broadening

spin labels,150 and transfer

NOEs153 (table 1.1). The ligand focused methods are relatively quick (1-5 min), do not
require 15N enriched samples, and are sensitive at much lower protein concentrations (≤ 5
M). Therefore, these methods have rapidly become invaluable to high-throughput
screening with a high success rate of identifying potential inhibitors.154-159
This dissertation will focus on using and developing screening methods for highthroughput NMR screening to functionally annotate proteins with no known function.
The two central methods used are the 1D line broadening experiment and the 2D 1H-15N
HSQC experiment. These methods will be used in tandem for each screen to detect and
confirm ligand binding. The tiered approach to NMR screening maximizes the total
number of hits identified while reducing the overall sample and data collection
requirements.144
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Table 1.1 Various NMR screening methods and the NMR parameter used to detect ligand binding.

Screening
Technique
MS/NMR
Multi-Step NMR
RAMPED-UP
NMR
SAR by NMR
SMILI-NMR
STINT-NMR
SLAPSTIC
AIDA-NMR
TINS
3-FABS
Affinity NMR
FAXS
INPHARMA
NOE pumping
SALMON
STD NMR
WaterLOGSY

Labeled
Protein?

Limited by
Protein MW?

Yes

Yes

145

Yes

Yes

144

Chemical shift changes, screening multiple proteins

Yes

Yes

135

Chemical shift changes
In-cell chemical shift changes
In-cell chemical shift changes
Line-broadening change (T2) due to protein spin
label
Line-broadening change (T2) due to protein-protein
complex formation, labeled protein or Trp reporter
in ligand binding site
Line-broadening change (T2) due to binding to an
immobilized protein target
Chemical shift changes, requires fluorinated ligands
Change in translational diffusion
Line-broadening change (T2) due to ligand
competition, requires fluorinated ligands
Transfer nuclear Overhauser effect (NOE)
Transfer nuclear Overhauser effect (NOE)
Saturation transfer difference from solvent
Saturation transfer difference from protein
Saturation transfer difference from solvent

Yes
Yes
Yes

Yes
Yes
Yes

134

Yes

No

150

Yes/No

Yes

147, 148

No

Yes

163

No
No

No
No

152

No

No

149

No
No
No
No
No

No
No
No
No
No

164

NMR Parameter used to Detect Ligand Binding
Retention on size-exclusion column & chemical
shift changes
Line-broadening change (T2) & chemical shift
changes

Ref.

160
161, 162

151

153
165
136
146
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1.5 Summary of work. The challenges of functional annotation described above
are a product of having only a limited collection of bioinformatic tools based on a small
set of experimentally characterized proteins.

This dissertation focuses on the

development and implementation of new experimental approaches to extend functional
annotation of unknown proteins. First, in chapter 2 I will discuss the development of a
technique to measure relative dissociation constants (KD) from an NMR high-throughput
ligand affinity screen. The method is used to qualitatively select the best binding
ligand(s) that will be used to probe the active sites of the various targets and identify a
biological function.
Chapters 3 and 4 will discuss the implementation and optimization of the
Functional Annotation Screening Technology by NMR (FAST-NMR).166 The FASTNMR method is a tiered approach to high-throughput NMR affinity screening to identify
binding ligands and proteins active sites. The protein active sites are compared to a
database of active sites using the Comparison of Active Site Similarity (CPASS) tool. 103
Functional similarity is inferred through similarities in protein active sites.
In chapter 3 I show the utility of the FAST-NMR method by establishing a
functional similarity between the type III secretion system (T3SS) protein PrgI from S.
typhirium and the human apoptosis regulating protein Bcl-xL. This relationship would
not have been identified with current methods because sequence and structure similarity
are below the limit of acceptable homology. In chapter 4, I validate the FAST-NMR
method by expressing, purifying and screening the S. aureus nuclease protein. I show the
FAST-NMR method correctly identifies the best binding ligand thyamdine-5‟triphosphate and active site of the protein. Additionally, the FAST-NMR binding site

16
correctly identified a nucleotide (thymidine-3‟,5‟-diphosphate) bound nuclease structure
(1TR5) as the best match in the CPASS search. I will also discuss the implementation to
two new pulse sequences and improvements to automated data collection.

These

improvements to the screening technology dramatically increase throughput and
flexibility of FAST-NMR.
The FAST-NMR method was initially developed as a tool for functional
annotation. However, the generalized tiered approach to NMR screening used by FASTNMR is also valuable to drug discovery. In chapter 5 I will discuss the structure,
dynamics and high-throughput screening of the DnaG primase C-terminal domain from
Staphylococcus aureus. The C-terminal domain of primase specifically interacts with the
DnaC helicase to initiate primer synthesis and is therefore an attractive drug target for
antibiotic development.

Using the FAST-NMR screening methods I show

acycloguanosine binds to the C-terminal domain of primase at the important helicase
interaction site. This result was used to identify a set of structurally similar compounds
for further antibiotic development.
A surprising result from the S. aureus primase CTD structure was the observation
of a potential phylogenetic dependence on protein structure similarity. In chapter 6 I
expand on this observation by completing a thorough analysis of functionally identical
protein structures and report a maximum sequence and structure similarity between the
two bacterial phyla, Firmicutes and Proteobacteria.

Additionally, the results from

chapter 6 were used to show a constant rate of structural drift during protein evolution.
Finally, in chapter 7 I discuss a new technique for functional annotation that
evolved from the FAST-NMR methodology, but is independent of sequence, structure or
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evolutionary information. The method involves the development of a robust scoring
system to measure ligand binding profile similarities. A ligand binding profile is defined
as a set of ligands that bind a protein from a high-throughput ligand affinity screen using
a standardized chemical library. Functional annotation is inferred by clustering unknown
proteins with previously annotated proteins that share similar ligand binding profiles. The
method was tested on two sets of control proteins, 2 serum albumins (H. sapiens, B.
taurus) and 5 amylases (B. licheniformis, A. oryzae, B. amyloliquefaciens H. vulgare, I.
batatas).
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CHAPTER 2:
ESTIMATING PROTEIN-LIGAND BINDING AFFINITY USING HIGHTHROUGHPUT SCREENING BY NMR

2.1 INTRODUCTION
In chapter 1 the general principles for using NMR as a high-throughput screening
tool were discussed in the context of functional annotation and drug discovery.

For a

high-throughput screen to be successful a hit must efficiently alter the biological activity
of a protein or other biological target molecule and disrupt its normal function.1 This is
generally accomplished by a small molecule changing the dynamics of a protein

2

or

interfering with a critical protein-protein interaction.3 For a small molecule hit identified
from a high-throughput screen to become a viable drug candidate it must elicit these
effects while simultaneously demonstrating in vivo efficacy in the absence of toxic sideeffects. Thus, an important component of the drug discovery process is the verification
that a small molecule ligand actually binds the protein target in a selective and
biologically relevant fashion.
Selectively is measured by binding affinity which is governed by the equilibrium
parameters of a binding interaction. The equilibrium state of a binding interaction is
described by the concentration of the free ligand [L] F, free receptor [P]F, and the receptorligand complex [PL]. For single-site binding, the relative ratios of these concentrations
are governed by the kinetic on (kon) and off (koff) rates between the free and bound forms
as described in eq 2.1.

[2.1]
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The strength of a ligand‟s binding affinity is quantified by the dissociation
constant (KD), or simply the ratio of koff and kon rates.

KD

k off
k on

[L] F [P]F
[PL]

[2.2]

The selectivity of a ligand to a particular target biological molecule is inversely
proportional to the strength of the KD. Highly selective compounds will have a KD in the
pM-nM range while weaker ligands will exhibit binding in the M-mM range. Often a
HTS will rely on the identification of M-mM binding ligands coupled with structural
information to develop high affinity ligands through combinatorial approaches.
Similar to traditional measurements,4 NMR methods rely on the collection of
multiple data points to accurately determine a KD for a protein-ligand interaction. This
approach is usually impractical in a high–throughput mode that requires a rapid method
for characterizing and ranking binding affinities. Examples of high-throughput KD
measurements using 1D NMR experiments have been described that use
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compounds5, 6 or the displacement of known low-affinity inhibitors.

Unfortunately,

7, 8

F-containing

these approaches are typically limited in practice because known low-affinity inhibitors
or a large library of “drug-like” and structurally diverse

19

F-containing compounds are

not available for a wide range of protein targets. To increase the utility and throughput of
NMR affinity screening a rapid and universal method to determine binding affinity was
still needed.
This chapter discusses a new NMR screening method that can determine the
relative ranking of binding affinities using a variation of traditional 1D 1H NMR linebroadening experiments.9, 10 This approach correlates the ratio of NMR peak intensities
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for free and bound ligands to the fraction of bound ligand in a protein-ligand complex.
This method is illustrated by using human serum albumin (HSA) as a model protein.
HSA is also an important secondary target for efficacy screening and a well-established
system for monitoring protein-ligand interactions.11

2.2 THEORY
2.2.1 Single point K D measurements. Binding interactions between a protein
(MW > 5000 Da) and a low molecular weight ligand (MW < 500 Da) can be examined
by using the decrease in NMR peak intensity that occurs upon the addition of a protein to
a solution with constant ligand concentration. NMR line-broadening experiments follow
an opposite protocol from typical experiments that measure KD values, where variable
protein concentrations are added to solutions that contain a constant ligand concentration.
Thus, a different form for the standard Langmuir binding isotherm (eq 2.2) was required.
Rearrangement of eq 2.2 produces the following binding isotherm, in which fB
represents the “fractional occupancy”, or the fraction of bound ligand.
fB

[PL]
[L]T

1
KD
1
[P]F

[2.3]

It is assumed in many types of binding studies the total ligand concentration [L] T
is approximately equal to the free ligand concentration; however, this assumption is not
applicable to the NMR line-broadening experiments used in this study because [L]T is not
necessarily in

excess of the maximum complex concentration [PL]. Also, a direct

measurement of the free protein concentration is not possible for the method described in
this report. Therefore, eq 2.3 was derived to describe this situation in terms of the total
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protein concentration [P]T and total ligand concentration [L]T that are known to be present
in the system (see appendix 2A and 2B for definition of variables and equation derivation
respectively).
fB

[PL]
[L]T

1
2K D

1
([P]T [L]T

KD )

([P]T [L]T

[2.4]
K D )2

4K D [L]T

Equation 2.4 can be simplified to approximate the fractional occupancy in terms
of the total ligand concentration [L]T and total protein concentration [P]T by using a
Taylor series expansion and the assumption that [L] T > [P]T.

fB

[PL]
[L]T

[P]T
([L]T K D )

[2.5]

The fractional occupancy for a protein-ligand complex can be measured using a
ratio of NMR peak intensities (1-IB/IF), where IB is the sum of ligand NMR peak
intensities in the presence of the protein and IF is the sum of NMR peak intensities for the
free ligand. Therefore, Bexpt (the NMR peak intensity ratio) represents an easily
measurable response of ligand binding that can be described in terms of the fraction of
bound ligand (fB) and the NMR linewidth for the free ( F) and bound ( B) states (see
Appendix B for derivation).

Bexpt =1

IB
IF

1

1
ν
1 f B ( B 1)
νF

[2.6]

Combining eq 2.5 and eq 2.6 leads to a new binding isotherm for this system, as
shown below,
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Bexpt

1

IB
IF

1

1
c[P]T
1
[L]T K D

where c

νB
1
νF

[2.7]

The unit-less NMR linewidth ratio constant (c), as defined in eq 2.7, accounts for
the proportional change in ligand linewidth upon binding of a ligand to a protein. Once a
ligand is bound, the free ligand linewidth ( F) of a ligand resonance adopts the linewidth
of the protein ( B) and the increase in linewidth produces a corresponding decrease in
peak intensity measured by the ratio of NMR peak intensity (B).
The dissociation equilibrium constant for a protein-ligand complex that is
calculated using eq 2.7 is based on relative changes in NMR peak intensity by fitting the
given binding isotherm to a complete protein titration curve. This is impractical in the
context of an NMR high-throughput screen where only a single titration point is
measured. However, eq 2.7 can be rearranged to solve for KD to yield an estimate for KD
that is based on [P]T, [L]T, c and Bsingle, where Bsingle is the fractional occupancy at a
single protein concentration. The resulting expression is shown in eq 2.8.
KD

c[P]T
Bsingle

c[P]T

[L]T

[2.8]

For proteins such as HSA that possess multiple non-specific binding sites, the
decrease in ligand signal at a relatively high protein concentration will be an average of
specific and non-specific binding. To correct for this effect, the non-specific binding term
n[P]T that corresponds to a linear increase in fraction bound with the addition of protein is
simply added to eq 2.7, as shown in eq 2.9.
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B 1

IB
IF

1

1
c[P]T
1
[L]T K D

n[P]T

[2.9]

2.3 EXPERIMENTAL
2.3.1 Materials. The HSA (essentially fatty acid free, ≥ 96% pure), choline
bromide (~ 99% pure), clofibrate, furosemide, phenol red, phenylbutazone, phenytoin (~
99% pure), sodium salicylate, tolbutamide, uridine 5‟-monophosphate (98-100% pure)
and warfarin (> 98% pure) were purchased from Sigma (St. Louis, MO). The
bromophenol blue (ACS reagent grade, 95% pure), bromocresol green (ACS reagent
grade, 95% pure), and ibuprofen were from Sigma-Aldrich (Milwaukee, WI). The
dimethyl sulfoxide-d6 (99.9% D), deuterium oxide (99.9 atom% D) and naproxen (98%
pure) were obtained from Aldrich (Milwaukee, WI). The 3-(trimethylsilyl)propionic2,2,3,3-d4 acid sodium salt (98% D) was purchased from Cambridge Isotope (Andover,
MA). The potassium phosphate dibasic salt (anhydrous, 99.1% pure) and monobasic salt
(crystal, 99.8% pure) were purchased from Mallinckrodt (Phillipsburg, NJ).
2.3.2 Apparatus. All NMR spectra were collected on a Bruker 500 MHz Avance
spectrometer (Billerica, MA) equipped with a triple-resonance, Z-axis gradient cryoprobe
and using a Bruker BACS-120 sample changer and IconNMR software for automated
data collection. Spectra were collected at 298 K using 512 transients, a sweep-width of
6009 Hz, 16 K data points and a relaxation delay of 2.0 s. The residual H2O resonance
signal was suppressed with presaturation during the recycle delay and a composite pulse
train prior to the 90o excitation pulse. The total experiment time, including sample
changing for each spectrum, was approximately 33 min.

48
2.3.3 Sample Preparation. All small-molecule ligands that were used in this
study were selected based on their previously reported KD values for HSA and their good
solubility in an aqueous solution.11 The small-molecule ligand samples were individually
prepared in 10 mL stock solutions that contained 20 µM ligand, 1% (v/v) dimethyl
sulfoxide-d6 (DMSO-d6), 10 µM 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt
(TSP) and pH 7.0 (uncorrected) 50 mM potassium phosphate buffer prepared in
deuterium oxide.
A series of ten HSA stock solutions were prepared in deuterium oxide by making
serial dilutions from a 200 μM master solution of HSA in deuterium oxide. The final
concentrations of HSA in these stock solutions ranged from 0 µM to 200 μM and were
prepared so that a 10 µL addition of the HSA stock solution to 490 μL of a free ligand
solution resulted in final concentrations of 0 µM, 0.1 µM, 0.2 µM, 0.4 µM, 0.6 µM, 0.8
µM, 1 µM, 2 µM, 3 µM, and 4 µM HSA, respectively. These mixtures were prepared
individually for each ligand in 1.5 mL microcentrifuge tubes and then transferred to
NMR tubes. The sample for each titration that contained 0 μM HSA was used as the
reference for calculating the free ligand intensities (I F) and free ligand linewidths ( F).
All binding studies performed with these solutions were conducted at 25ºC.
2.3.4 1D 1H NMR binding curves. Spectra were processed with the ACD/1D
NMR manager (Advanced Chemistry Development, Inc., Toronto, Ontario). A linear
prediction algorithm was applied to the FID in the forward direction and the resulting
FID was Fourier transformed. The NMR spectrum was phase-adjusted and baselinecorrected. The residual water signal was removed for spectrum clarity by the solvent
removal function in ACD. This function zeros‟ the spectrum baseline at the residual
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water signal. All ligand resonance peaks were visually selected and peak positions were
measured relative to a TSP reference set to 0.0 ppm. Peak intensities were measured
relative to the DMSO-d6 peak at 2.69 ppm that was normalized to an intensity of 1.00.
The DMSO-d6 peak was completely recovered during the 1D 1H NMR experiment using
a 2.0 s recycle delay. This is >3x the T 1 for DMSO in D2O at 298K (0.3-0.5 s) and is
acceptable for complete relaxation.12, 13 Individual peak intensities in the aromatic region
for each ligand were summed to obtain the free (I F) and bound (IB) intensities at each
titration point. The peak-intensity ratios were plotted versus total protein concentration
and fit to eq 2.9 using the program KaleidaGraph version 3.52 for Windows (Synergy
Software., Reading, PA) to estimate the KD value for each protein-ligand complex. The
average NMR linewidth ratio (c) for each ligand was estimated by using eq 2.7, where

B

was taken to be approximately 94.2 Hz using a previously measured correlation time for
HSA of 41 ns.14 The value for

F

was calculated as described in the next section. The fit

of each binding curve was constrained so that KD ≥ 0 in these studies.
2.3.5 Measuring a free ligand NMR linewidth ( F). To measure the free ligand
linewidth ( F) for use in eq 2.7, the NMR spectrum for each free ligand (i.e., as obtained
in a solution containing no HSA) was processed as described above to avoid any
distortion in linewidth resulting from processing. NMR peak linewidths were measured
using the ACD/1D NMR manager peak fitting routine. The average peak linewidth was
used to report

F for

each ligand and to calculate the NMR linewidth ratio.

2.3.6 Simulated high-throughput screening by NMR. To simulate the outcome
of an NMR high-throughput screening assay, a single protein concentration [P] T from the
full titration curve was used. On average, the 0.2 M HSA titration point yielded a large
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response for all 12 ligands without reaching saturation. The static total ligand
concentration [L]T was 20 M. A simulated response curve was generated by fitting a
range of KD values to a range of ideal Bsingle values calculated using eq 2.8. The measured
Bsingle value for each ligand at the 0.2 M HSA titration point was used to calculate a
single-point binding constant from eq 2.8 and compared to the simulated response curve.
This simulated experiment used both the individual c values calculated for each ligand
from the full titration experiment and an average c value calculated from the 12 NMR
titration curves. The single-point dissociation equilibrium constant for each ligand was
calculated using this average c value.

2.4 RESULTS AND DISCUSSION
2.4.1 Measuring KD from 1D 1H NMR line-broadening experiments. The
development of NMR-based screening assays that monitor changes in chemical-shifts or
linewidth as a means to identify or verify initial chemical leads has evolved to become an
increasingly important component of drug discovery efforts in the biotechnology and
pharmaceutical industry.15, 16 Nevertheless, the direct measurement of a binding affinity
from a high-throughput NMR screen is generally lacking. 5, 6, 8, 17, 18 A decrease in the
intensity of a ligand's NMR signal in the presence of a protein is commonly used in
NMR-based screens to monitor the formation of a protein-ligand complex. 1D 1H NMR
spectra of small-molecules (MW ≤ 500 Da) usually have extremely sharp peaks due to
slow dipole-dipole relaxation (T2).19 Binding to a high molecular weight agent like a
protein induces peak broadening and a corresponding decrease in the ligand's NMR
signal intensity because the bound ligand now experiences the shorter relaxation time of
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the protein. This effect is illustrated in figure 2.1 using binding by the protein HSA to the
drugs phenytoin and naproxen as examples.
The observed increase in ligand linewidth in such an experiment will depend on a
number of factors that include the dissociation equilibrium constant for the protein-ligand
interaction, KD. In general, the observed change in the ligand's linewidth (

obs)

for the fast

exchange limit will follow the result shown below.
νobs

νF

f B (ν B

νF )

where

fB

[P]T
[L] T K D

In eq 2.10, fB is the fraction of the bound protein-ligand complex,
NMR linewidth, and

B

[2.10]

F

is the free ligand

is the linewidth for the bound state of the ligand (see the

appendix B for an explanation regarding the above expression for fB). Eq 2.10 shows that
an increase in the observed ligand linewidth will be related to the free and bound ligand
linewidths and the value of KD for the protein-ligand complex. If it is assumed the
linewidth of the protein-ligand complex is significantly larger than that for the free
ligand, the ratio of the ligand linewidth in the presence and absence of the protein should
represent the remaining free ligand concentration, as indicated by eq 2.7.
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Figure 2.1. Relative line broadening of in response to protein binding. 1D 1H NMR
spectra for titration of 20 M of the drugs phenytoin (A) and naproxen (B) with
increasing concentrations of HSA. The concentrations of HSA were as follows: (i) 0 µM,
(ii) 0.4 µM, (iii) 1 µM, (iv) 2 µM, and (v) 4 µM. As the protein concentration increases,
the intensity of the ligand NMR signal decreases due to the bound ligand adopting the
shorter relaxation time of the protein. The decrease in the ratio of NMR signal intensity
I
( B 1 ) is proportional to the degree of binding such that tighter binding ligands (B) will
IF
relax more quickly than weaker binding ligands (A).
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This relationship assumes there is a lack of any significant contribution of
chemical or dynamic exchange to the observed change in linewidth. This is a reasonable
assumption in the context of a high-throughput NMR screen against a single protein
target. First, initial chemical leads tend to be weak binders in the fast exchange regime,
where the linewidth change of the ligand will be dominated by the linewidth of the
protein. Second, biologically relevant binders will interact with the same or similar
binding sites on the protein. Under these circumstances, the ligand may experience a
relatively constant contribution of chemical and dynamical line-broadening. Thus, the
minimal contribution of linewidth from exchange processes should not affect the relative
ranking of the ligand binding affinities that are obtained when using such an experimental
approach.
The validity of this method for high-throughput screening by NMR was examined
by using twelve ligands with previously determined binding affinities to HSA. 11,

20-23

These ligands were used to examine the relationship between the estimated values for KD
and the relative ratios of the NMR Peak intensity. Samples containing 20

M of any

given ligand were titrated with solutions that contained 0 to 4 μM of HSA to develop full
binding curves for each of the twelve ligands. As a control, two suspected non-binding
ligands (i.e., choline bromide and uridine-5‟-monophosphate) were also screened in the
presence of HSA with no observable decrease in signal (data not shown). The KD values
that were obtained by this method (see table 2.1) were experimentally determined by
directly fitting the resulting binding curve of each ligand to eq 2.9. These fits gave a sum
of residuals squared that ranged between 0.977 and 0.998 over the ten concentrations of
HSA that were tested. Figure 2.2 shows the results that were obtained for three of the
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tested ligands, which have previously reported dissociation equilibrium constants that
ranged from 0.7 to 36.8 M. These figures and the corresponding fits illustrate the ability
of this approach to be used with ligands that have weak-to-moderate strength binding to
proteins such as HSA.

Figure 2.2. NMR ligand binding titration. Experimental fractional occupancy (B expt) for
naproxen (), tolbutamide (), and phenol red () versus the total concentration of
HSA. The best-fit lines were obtained using eq 2.9. The r2 for these best-fit lines are given
in the text and the KD values that were obtained from these lines are provided in table 2.1.

2.4.2 Co-variance of KD and the NMR linewidth ratio (c). Ideally, the
dissociation equilibrium constant (KD) and the NMR linewidth ratio (c) could be
simultaneously derived by fitting eq 2.7 to the experimental NMR binding curves.
Unfortunately, KD and c are completely covariant. This requires an approximation for c in
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order to calculate KD from the NMR binding curves. The linewidth of a protein ( P) may
provide a lower estimate of

B

linewidth ( P). Estimations of

P

if it is assumed that

B

is dominated by the protein

can be made from the correlation time ( c) of the protein

by using the intramolecular dipole-dipole relaxation rate constant (T2-1). 24
T2

1

3 2
b {3J(0) 5J(ω 0 ) 2J(2ω 0 )}
20

[2.11]

Where

b=-

τc
μo hγ2
, J(ω)
and
3
4π r
1 ω2 τ c 2

B0

[2.12]

In these equations, J( ) is the normalized spectral density function,
-1

permeability,

), ħ is Plank‟s constant, B0

is the static magnetic field strength and r is the hydrodynamic radius of the protein. In
addition, the Stokes-Einstein equation can be used to relate

c

to the molecular weight

(MW) for a globular protein,25

τc

4π ηr 3
3kT

with, τc

*

MW
(ns)
2400

where T is the temperature, k is the Boltzmann constant,
r is the radius and

[2.13]

is the viscosity of the solvent,

is the shape constant.

The reliability of eq 2.13 to approximate a protein correlation time from its
molecular weight is illustrated from a comparison between 27 experimental

c

values 26, 27

and correlation times predicted using eq 2.13 (figure 2.3A). A linear best-fit was obtained
with an R2 of 0.81 in this case. For a high-throughput screen,
the molecular weight of a protein by using this approximation for

p

can be estimated from
c

with a shape constant
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of 1.32 combined with eq 2.11 and 2.12. The shape constant was determined by
optimizing a linear fit between the experimental and predicted

c

values shown in figure

2.3A by varying . The result is an approximate correlation between

P

and MWP, as

shown in eq 2.14.

νP 1.26 MWP

[2.14]

This dependency of linewidth on the size and shape of a protein is plotted in
figure 2.3B. For HSA (MW, 66 kDa), the correlation time (41 ns) has previously been
measured using time-resolved fluorescence.14 This correlation time was used to calculate
the value used for

P,

which was 94.2 Hz.

57

58

Figure 2.3. Approximation of protein linewidth based on molecular weight. (A)
Comparison of 27 experimental protein correlation times determined using NMR
dynamics data with correlation times predicted from protein MW using eq 2.13 and a
shape constant of 1.32. A best-fit line is shown with a slope of 1 and an R2 of 0.81. (B) A
plot of linewidth versus protein molecular weight based on eq 2.13 for spherical proteins
with of 1 (solid line) and elliptical proteins with of 1.32 (dashed).
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The free ligand linewidth ( F) can be measured directly from the NMR spectra of
the free ligand using an average ligand linewidth. Average

F

values measured from the

free ligand NMR spectra are reported in table 2.1. However, for large and diverse
chemical libraries it may not be feasible to measure an accurate linewidth for each
compound. Alternatively,

F

is generally between 1 and 2 Hz for many small-molecules

(MW, 500 < Da), which provides a reasonable estimate for

F

to calculate an average

value for c.
2.4.3 Sensitivity of KD and NMR linewidth Ratio (c). A closer examination of
eq 2.7 indicates the NMR linewidth ratio (c) acts as a scaling factor in the calculation of
KD, with a larger c value resulting in a proportionally larger KD value. Unfortunately,
small variations or errors in the measurement of

F

will result in proportionally larger

variations in both c and KD. In the context of high-throughput screening by NMR, an
incorrect estimate of c will result in a systematic underestimation or overestimation of
KD. However, the relative ranking of the ligand binding affinities will be maintained. In
addition, a lower limit to c is inherently defined by eq 2.7.
2.4.4 Comparison of estimated KD values with literature values. Table 2.1
shows the dissociation equilibrium constants that were measured for twelve ligands
known to bind HSA by using the 1D 1H NMR line-broadening method that is described
herein. Previously reported KD values from the literature are also listed for these twelve
ligands.20-22, 28-52
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Table 2.1.

Comparison of KD values determined by NMR and reported in the literature under similar conditions

Ligand

Literature KD (µM)

Line width (Hz)

c

Measured KD
(µM)

Ibuprofen

0.350 0.3345 0.3749 0.545 0.5234 1.047 1.2530 1.2640 1.7441 1.8933 2.0830
2.835 4.7641 5.56 35 5.6838 8.3333 7.1729 18.250 23.8153 25.6453

2.3 ± 0.2

41.5

0.5 ± 1.0

Naproxen

0.8342 1.2547 7.0939 10.646 23.744

1.8 ± 0.6

51.3

0.7 ± 1.2

Clofibrate

1.3247

1.7 ± 0.1

54.3

1.7 ± 3.4

Bromophenol Blue

0.6743

2.5 ± 0.4

37.8

3.0 ± 2.3

Furosimide

5.2636 52.6328

1.5 ± 0.8

57.6

3.4 ± 3.0

Warfarin

1.6139 2.1737 2.2737 2.9436 3.0337 3.431 3.746 3.8532 4.7637 5.331 6.831

2.3 ± 0.9

41.7

4.0 ± 2.8

Phenylbutazone

0.6736 1.931 5.4332 8.431 1131 15.1334

3.7 ± 0.6

25.2

6.5 ± 2.9

Salicylate

5.2636 15.1537 32.1537 35.7137 14146

1.4 ± 0.8

63.6

7.2 ± 2.9

Bromocresol Green

0.6348 1.4343

2.7 ± 0.3

35.1

7.4 ± 2.1

Tolbutamide

2536 31.2539

2.7 ± 0.4

34.9

10.2 ± 1.2

Phenol Red

35.743

1.6 ± 0.5

58.7

36.8 ± 6.5

Phenytoin

5020 58.820 62.520 71.4353 96.1520 11120 1342.320 153.8520 21120
24420 568.220

2.0 ± 0.6

46.8

131.6 ± 12.5
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In general, there is good agreement between the KD values that were estimated by
NMR and those values reported in the literature. Variations in temperature, pH or buffer
conditions may partly explain the range of KD values observed in the literature. There
may have also been differences in the fatty acid content of the HSA preparations, which
can affect the reported KD values. Thus, 1D 1H NMR line-broadening measurements
appear to provide reliable preliminary estimates for binding affinities as part of a highthroughput screening assay.
One limitation of the model that was used for this analysis is the assumption of
only a single site interaction between the ligand and protein. There are many cases for
which multisite binding or other effects (e.g., allosteric interactions) are present that give
rise to more complex binding models.11,

19

Multisite binding also contributes to the

relatively large range of KD values reported in the literature for HSA ligands. In these
situations, the KD values listed in table 2.1 (for both the NMR and literature results)
should be regarded as weighted averages and as measures of the global affinity for a
particular ligand with HSA. This averaging effect may be more pronounced for the NMR
method than for other techniques because of the practical limit in ligand concentration
that could be used to provide a measurable signal. There is also a practical limit to the
number of concentrations and data points that could be sampled to give a binding curve.
This effect may explain why the NMR-derived KD values tend to be lower than the
literature values, because the use of higher concentrations for the NMR studies would
give a higher weight and likelihood to the detection of weaker interactions between the
ligand and protein.
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A number of other practical limitations also need to be considered in the use of
NMR for these binding studies. For instance, the NMR resonances that are specifically
involved with protein binding have been shown to exhibit the most dramatic changes in
linewidth.9, 10 Therefore, there are inherent errors caused by summing all peak intensity
and selectively excluding ligand peaks due to an overlap with buffer and protein
resonances. In addition, errors in the measurement of peak intensity might arise at lower
ligand concentrations due to the difficulty of accurately identifying and selecting peaks
under these conditions. The result could be either a low or high estimate for KD,
depending on the disparity in linewidth changes and on which peaks are excluded. Using
overlapping peaks would introduce an alternative error because the observed intensity is
the sum of multiple peaks that cannot be easily de-convoluted. Also, the analysis of
hundreds to thousands of NMR spectra in a high-throughput screening assay precludes a
manual inspection to selectively determine which peaks to include or exclude.
2.4.5 Estimating KD based on single-point 1D 1H NMR line-broadening
Measurements. Since NMR-based screens are a common component of the drug
discovery process in the pharmaceutical industry, single-point estimates of ligand binding
affinities could be an extremely valuable tool to initially rank and prioritize chemical
leads. During the iterative drug optimization process, it is typical to focus on a small set
(i.e., 3-5 compounds) of structurally distinct chemical classes that are amenable to
synthetic modification and that exhibit drug-like characteristics.54 For this work, an NMR
screen could be used to verify the presence of a specific and biologically-relevant
interaction involving a protein target and to rank the relative binding affinity of the
screened ligands to simplify the selection of promising lead compounds. This approach
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was illustrated in this study by simulating NMR high-throughput screening results for the
twelve compounds that were used in the previous binding study.
First, using an average c value of 45.7 ±11.6 and an HSA concentration of 0.2
M, single point KD values were calculated for a range of B single values using eq 2.8. The
results of this calculation are shown in figure 2.4. Superimposed on the single point curve
in figure 2.4A are the KD values reported in table 2.1 plotted versus the experimental B
values at 0.2 M HSA. Superimposed on the single point curve in figure 2.4B are the KD
values from table 2.1, where the corresponding c values were used to determine a best-fit
to eq 2.9. This represents the typical protocol that would be used in a high-throughput
screen and shows that an average value of c is acceptable for use when individual
estimates of c may not be practical. A comparison of figure 2.4B with the theoretical
curve based on eq 2.8 indicates the single-point method can provide a reasonable
approximation for KD.
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Figure 2.4. Use of NMR in a single-point binding analysis for several small-molecule
ligands with known interactions with the protein HSA. The curves in (A) and (B)
represents the ideal single-point KD values calculated from eq 2.8 with 0.2 M HSA and
an average c value of 45.7 ± 11.6. (A) The KD values and errors reported in table 2.1 are
superimposed on the ideal fit. The KD values are based on the best-fit to eq 2.9 using the
c values determined for each individual compound. (B) The KD for each compound was
re-calculated based on the best-fit to eq 2.9 using the c values from table 2.1. The error
bars in B represent the range of KD values measured from the range of c values with the
error in the free ligand linewidth, F, propagated.
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For the twelve compounds that were considered in figure 2.4B, all compounds
gave single-point estimates that agreed within a range of one standard deviation over the
range of binding affinities and concentrations that were tested. All twelve compounds had
experimental and single-point estimates for KD that agreed within two standard
deviations. A higher deviation was observed in figure 2.4A for ligands with higher KD
values. This occurs because of differences between the individual c values and the
average c values. Also, eq 2.9 is more sensitive to small changes in c at these high KD
values. This occurs because, at high KD values, vanishingly small differences in NMR
intensities correspond to large differences in KD. In other words, this method is reaching
a practical limit of detection since KD rapidly approaches infinity as NMR peak intensity
changes approach zero.
The relative ranking of the KD values were also the same for results that were
obtained by the single-point calculations or the full titration method. These results
indicate the single-point method can, at least in cases such as these, provide a preliminary
estimate of KD values and binding affinities that can be used in the context of a highthroughput screening assay. At a minimum, the relative changes in linewidth provide a
rapid and efficient mechanism to prioritize NMR screening leads for further evaluation.
However, it is still recommended that a more robust approach for measuring binding
affinities for promising leads follow the NMR ligand affinity screen. This precaution
follows, in part, from the fact that the accuracy of the KD values that are measured from
the single-point 1H NMR line-broadening experiments will be strongly dependent on
having a reasonable estimate for the value of NMR linewidth ratio (c) in such a study.
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Appendix A: Glossary of terms found in chapter 2
L

small-molecule ligand

[L]T

total ligand concentration

[L]F

free ligand concentration

P

protein target

[P]T

total protein concentration

[P]F

free protein concentration

[PL]

protein-ligand complex concentration

IB

NMR peak height of bound ligand

IF

NMR peak height of free ligand

KD

dissociation equilibrium constant for a protein-ligand complex

c

NMR linewidth ratio constant

B

NMR signal response dependent on fraction of bound ligand

Bsingle

NMR signal response dependent on fraction of bound ligand at a single

F

linewidth of the free ligand

B

linewidth of the bound protein-ligand complex

P

linewidth of the protein

obs

observed linewidth change upon addition of protein or ligand

fB

fraction bound complex in solution

fF

fraction of free ligand in solution

T2-1

dipole-dipole relaxation constant

c

correlation time
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J( )

normalized density function of T2-1

Bo

static magnetic field strength
Larmor frequency

MWP

molecular weight of a protein target
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Appendix B: Derivation of equations for rapid KD method found in chapter 2
The binding of a protein (P) with a single small ligand (L) can be represented by the
following reaction.
[PL]  [P] + [L]

[B1]

The dissociation equilibrium constant for this system is described by the expression in eq
B2, where the concentrations [P]F, [L]F and [PL] represent the concentration of free
protein, free ligand, and protein-ligand complex, respectively.

KD =

[P]F [L]F
[PL]

[B2]

Based on mass balance, eq B3 can be used to express [L]F and [PL] in terms of the total
ligand concentration and other concentrations in this system.
[P]T

[P]F

[PL]

[L]T

[L]F

[L]F

[L]T

[P]T

[P]F

[B3]

Substitution of these relationships into eq B2 gives eq B4.

KD =

[P]F [L]T -[P]T +[P]F

[B4]

[P]T -[P]F

Eq B4 can now be rearranged into the following form,
K D [P]T -[P]F =[P]F [L]T -[P]T +[P]F

[B5]

[P]2F + [L]T -[P]T +K D [P]F -K D [P]T =0

which makes it possible to solve for [P]F by using the quadratic formula, as indicated in
eq B6, where only the positive root has any meaning in a real protein-ligand system.

[P]F =

- [L]T -[P]T +K D ±

[L]T -[P]T +K D

2

+4K D [P]T

2

The bound fraction of ligand fB is next defined as given in eq B7.

[B6]
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fB =

[PL]
=
[PL]+[L]F

1
K
1+ D
[P]F

[B7]

If we substitute the positive root of eq B6 into eq B7, the result is eq B8.

fB =

1
2K D

1+

- [L]T -[P]T +K D + [L]T -[P]T +K D

2

+4K D [P]T
[B8]

1

=

-1

2K D
1+
[L]T -[P]T +K D

1+

4K D [P]T
[L]T -[P]T +K D

2

-1

A further simplification of eq B8 can be accomplished by expanding the square root as a
power series where x=

4K D [P]T
[L]T -[P]T +K D

2

about x = 0. This approach is valid as long as the

ligand is in considerable excess relative to the protein. The power series that is used here
is shown below.

x x2
1+x =1+ - +...
2 8
[B9]
If eq B9 is truncated at the second term, this allows the square root term in eq B8 to be
written in the approximate form that is given in eq B10.

1+

4K D [P]T
[L]T -[P]T +K D

2

1+

2K D [P]T
[L]T -[P]T +K D

2

[B10]

The overall result of this simplification is that eq B8 converts to the expression shown
below, there the fraction of bound ligand fB is now described in terms of only KD, the
total ligand concentration and the total protein concentration.
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[P]T
1
=
[L]T -[P]T +K D
[L]T +K D
1+
[P]T

fB

[B11]

If it is assumed the observed free and bound NMR linewidths are represented by
B,

F

and

respectively, and that exchange occurs between free and bound states, the general

solution to the NMR lineshape is bilorentzian. In the slow limit, the spectrum is
obviously just a sum of the spectra of free and bound species, weighted by their relative
abundances. If exchange rates become comparable to the inverse linewidths, then a
conventional solution of the pair of coupled linear differential equations, including auto
and cross relaxation terms but neglecting any chemical-shift difference between the
states, gives a time domain (free induction decay):
f (t)

ce

ce

[B12.a]

with
e

exp

c

c2

c1

1
4

c2

1
2

t

[B12.b]

c1

[B12.c]

K 11 2K 21 K 22 M L 0
ML 0

M PL 0

K 11 2K 12 K 22 M PL 0

[B12.d]

[B12.e]

2

K 11 K 22
2

K11

1
T2, f

k1 P

K 12 K 21

[B12.f]

[B12.g]
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1
T2,b

K 22

k

[B12.h]

1

K12

k

1

[B12.i]

K21

k1 P

[B12.j]

where ML and MPL are the magnetization of the free and bound species, respectively. In
the fast exchange limit, the solution is still formally biexponential, but the coefficient c–
goes to zero, and the free induction decay signal, normalized to unity at zero time,
becomes
f (t)

exp

1
T2, f

[L]
[L] [PL]

1
T2,b

[PL]
[L] [PL]

exp

ff
T2, f

fb
T2,b

[B13]

Fourier transforming, the fast exchange NMR signal height can be written as shown in eq
B14:
IB =

IF F
fF F +fB

[B14]
B

where IF is the height of the ligand signal in the absence of protein and I B is the observed
peak height of the bound complex. This is exactly the same as the height of the free
ligand signal in extreme slow exchange! Rearranging eq B14 explains the observed
decrease in NMR peak signal for a free small-molecule ligand upon its binding to a
protein. The relative ratio of NMR peak height (

IB
) is now in terms of the fraction of
IF

free ligand (fF) and the fraction of bound ligand (fB) and is dependent on the observed
increase in NMR linewidth upon the binding of a ligand to a protein.

81

1-

IB
IF

1

1

F

fF

F

fB

B

1
fF

fB

1
B

F

1 fB

1
fB

B

F

1

1
1 fB

[B15]
B

1

F

Inserting B11 into B15 provides a measure of the dissociation equilibrium constant for
the protein-ligand complex by relating the fraction of bound ligand to the observed
change in NMR peak height.
B 1-

IB
IF

1

1
[P]T
1
(
[L]T +K D

1
B
F

1)

1
c[P]T
1
[L]T +K D

where

c=

B

-1

[B16]

F

The NMR linewidth ratio, c, is then measured by using the free ligand NMR spectrum
and by assuming the linewidth of the bound complex approximates the linewidth of the
protein.
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CHAPTER 3:
STRUCTURAL AND FUNCTIONAL SIMILARITY BETWEEN THE
BACTERIAL TYPE III SECRETION SYSTEM NEEDLE PROTEIN PRGI AND
THE EUKARYOTIC APOPTOSIS BCL-2 PROTEINS

3.1 INTRODUCTION
The previous chapter discussed the development of a high-throughput screening
methodology to measure and rank relative binding affinities. One of the primary reasons
for developing such a method was for the use in the Functional Annotation Screening
Technology by NMR (FAST-NMR).1 The FAST-NMR method is a multi-step approach
to high-throughput screening using nuclear magnetic resonance (NMR). A target protein
is screened with a library of biologically functional compounds to identify which
compounds bind to the target protein, known as a “hit”. The first step in the FAST-NMR
approach is a 1D 1H line broadening experiment, similar to the experiments described in
chapter 2.
The 1D 1H line broadening experiment is a ligand focused experiment in which
the response of the free ligand is compared to a sample with the target protein added.
For FAST-NMR, the 1D 1H line broadening step is used to identify potential hits as an
initial screen. The method developed in chapter 2 is then used to prioritize which ligandprotein interactions are further studied using a secondary target focused 2D 1H-15N
HSQC screen based on relative binding affinity. The 2D 1H-15N HSQC monitors the
changes in the protein spectrum upon addition of the binding ligands. FAST-NMR also
utilizes the Comparison of Protein Active Site Structures (CPASS) software and database
to identify similar sequence and structure characteristics between experimentally
identified ligand binding sites for proteins of known and unknown function.2
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Functional regions of a protein are more stable relative to the remainder of the
protein sequence undergoing random drift.3,

4

The correlation between ligand binding

sites, ligand structure and protein function has also been demonstrated by a network of
ligand binding-site similarity described by Park & Kim.5 A variety of computational
methods have attempted to exploit the stability of functional regions by identifying ligand
binding sites as a method to predict function.6,

7

Unfortunately, the combined

requirements of predicting the ligand, the binding site, and a similarity to an annotated
proteins leads to a high level of ambiguity. The FAST-NMR approach attempts to
experimentally identify ligand binding sites to annotate proteins of unknown function.7-9
Applying the FAST-NMR method to previously annotated systems also enables
experimental ligand binding site data to identify functional relationships that otherwise
would not be recognized based solely on global sequence and structure similarity.
The type three secretion system (T3SS) is composed of 20-25 different proteins,
which are assembled in a highly choreographed mechanism similar to the assembly of
flagella.10-12 In Salmonella typhimurium, the needle complex is responsible for puncturing
a host‟s cell membrane to allow effector proteins (SipB, SipC, SipD) from S.
typhimurium to enter the host.13 Many of these effectors can activate bacterial induced
apoptosis of a hosts‟ cell by interacting with capsase-114 in a mechanism similar to
apoptosis in eukaryotic cells.15 The needle complex is a large homomultimer composed
of ~120 repeated copies of the monomeric protein PrgI, a small helical protein of 83
amino acids.16 The monomeric form of PrgI is a helix-turn-helix motif with two
symmetrically charged surfaces and a conserved loop region, PxxP domain, which are
important for needle assembly.16-18 The charged surfaces of PrgI responsible for needle
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assembly also provide a potential binding site for small molecule ligands. This makes
PrgI an attractive drug target to disrupt the formation of the needle complex and prevent
infection by S. typhimurium. However, to date there has been no reported ligands that
bind to either region of this protein-protein interaction site.
The PrgI needle complex protein from S. typhimurium T3SS was screened in our
FAST-NMR assay, which resulted in the identification of a functional similarity between
the ligand binding sites of PrgI and the anti-apoptosis protein Bcl-xL. Additionally, Dali19
and T-Coffee20 analysis found regions of structure and sequence similarity between the
two proteins consistent with the FAST-NMR results. The predicted active-site similarity
between PrgI and Bcl-xL was also used to experimentally verify that chelerythrine,21 a
ligand known to inhibit Bcl-xL and induce apoptosis, also binds PrgI. These results
provide experimental evidence that suggest a functional relationship between the
bacterial type III secretion systems and apoptosis. This is consistent with a general
conservation in function between PrgI and the Bcl-2 family of proteins that includes BclxL; both form membrane pores through oligomerization using a conserved helix-turnhelix motif to release effectors to stimulate cell death.

3.2 EXPERIMENTAL
3.2.1 FAST-NMR screen of PrgI.

The Salmonella typhimurium type three

secretion protein (T3SS) PrgI was screened with a functional library
NMR assay.7, 8 Unlabeled and

15

22

using the FAST-

N labeled monomeric PrgI was graciously provided by

Dr. Roberto DeGuzman (University of Kansas) along with the assigned 2D 1H-15N
HSQC spectrum. Sample preparation and experimental parameters for the NMR screen
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were executed in the same manner as described previously 8.

Briefly, each ligand

mixture was screened at 100 M/ligand concentration with 25 M protein in a 99.99%
D2O buffered solution of 20 mM d19-bis-Tris at pH 7.0 with 5% DMSO-d6 to maintain
ligand solubility and 11.1 M 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt as a
chemical shift reference. 1D 1H NMR spectra for each sample was collected using a
presaturation pulse sequence with 64 real transients, 8 dummy transients with 8 k data
points, a sweep width of 11.0 ppm and a recycle delay of 2.0 s. Data was Fourier
transformed, auto-phase and baseline corrected. Each 1D 1H NMR spectrum were
compared to the corresponding free ligand mixture reference spectrum and visually
analyzed to identify binding ligands. A binding event was identified by the decrease in
ligand intensity of the nuclease-mixture relative to the free ligand mixture. Total data
collection time including sample changing was approximately 10 min/spectrum. All 1D
1

H NMR spectra were collected on a Bruker 500 MHz Avance spectrometer (Billercia,

MA) equipped with a triple resonance, Z-axis gradient cryoprobe and using a Bruker
BACS-120 sample changer and IconNMR software for automated data collection. All
spectra were collected at 298 K.
All 2D

1

H-15N HSQC spectra were collected at 298K using the same

instrumentation with the standard 2D 1H-15N HSQC (hsequetf3gp) pulse sequence
implemented in Bruker TopSpin 1.3 with optimized sample specific 90 o pulse lengths. A
total of 16 real scans and 128 dummy scans were collected with 2 k data points with a
sweep width of 9.5 ppm in the 1H dimension and 128 data points with a sweep width of
28.0 ppm in the 15N dimension. A ligand free 2D 1H-15N HSQC spectrum was collected
using the same buffer conditions with 95% H2O/5% D2O to ensure the protein was
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properly folded prior to addition of ligands. Total experiment time was approximately 1.5
hrs/spectrum.
A total of 113 1D 1H NMR line-broadening spectra were collected to identify 5
binding ligands from the functional chemical library of 437 compounds. Measurement of
binding dissociation constants were completed as described in chapter 2 and as described
previously.23 Secondary 2D 1H-15N HSQC NMR experiments were collected only for the
5 compounds identified as binders in the line-broadening experiments. Chemical shift
perturbations (CSPs) (eq 3.1) from the 2D 1H-15N HSQC NMR experiments were used
to identify the PrgI ligand binding site, where only residues with a CSP greater than one
standard deviation from the mean were used

[3.1]
where NH is the difference between free and bound 1H amide chemical shifts (ppm) and
15N is the difference between free and bound 15N chemical shifts (ppm).
A rapid approach to determine a ligand binding orientation was employed to
determine a PrgI co-structure in the same manner as described previously.24 The CSPs
minimize the search space by using a significantly reduced AutoDock 3D grid. AutoDock
4.0 was used to generate 100 docked PrgI-ligand co-structures using the Lamarckian
search algorithm with a population size of 300 and 500,000 energy evaluations.25 The
AutoDockFilter (ADF) program then uses an NMR energy function based on the
magnitude of CSPs to select the best ligand conformation.

[3.2]
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where ADF calculates a pseudo-distance (dCSP) based on the magnitude of the NH CSP,
which is then compared to the shortest distance (dS) between any atom in the residue that
incurred an NH CSP and any atom in each docked ligand conformer. Comparison of
these CSP-directed and selected ligand-docked structures with experimental x-ray and
NMR structures has yielded an overall average rmsd of 1.17 ± 0.74 Å.24
A co-structure of the lipid derivative didecyldimethylammonium bromide
(DDAB) bound to PrgI was uploaded to the CPASS database (http://cpass.unl.edu) to
identify proteins with similar ligand binding sites by maximizing an rmsd weighted
BLOSUM6226, 27 scoring function (Sab).
[3.3]
where active site a contains n residues and is compared to active site b from the CPASS
database which contains m residues, pi,j is the BLOSUM62 probability for amino-acid
replacement for residue i from active site a with residue j from active site b,

i,j

is a

corrected root-mean square difference in the C coordinate positions between residues i
and j, and dmin/di is the ratio of the shortest distance to the ligand among all amino-acids
in the active site compared to the current amino-acid‟s shortest distance to the ligand. Sab
is only summed over the optimal alignment for residue i from active site a with residue j
from active site b. It is not summed over all possible combinations of i and j. If the
number of residues are not identical between active sites a and b (n ≠ m), then the
additional residues will not have a corresponding match. Each residue can only be used
once in the alignment. If active site a contains unmatched residues, then no contribution
is made to Sab which effectively reduces the maximal possible score that can be achieved
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for active site a. At the time of this study (May 2008), there were ~35,000 protein-ligand
structures in the CPASS database. CPASS was run on a 16 node Beowulf Linux cluster,
requires approximately 40 sec for each pair-wise comparison and took ~24 hrs to
complete a full search against the entire database.
3.2.2 Structure similarity searching Native protein structures for PrgI (PDB ID:
2JOW)

16

and Bcl-xL (PDB ID: 1YSN)28 were uploaded to the DaliLite29 web server

(http://www.ebi.ac.uk/DaliLite/) to identify regions of structure homology between the
two proteins. To identify structure similarity and possible homology with other proteins
within the PDB, the structures were also uploaded to the full Dali19 web server
(http://www.ebi.ac.uk/dali/). A truncated version of the Bcl-xL structure was generated
by identifying the amino acids within regions of structure similarity and removing these
residues from the native PDB file. The truncated PDB file was searched for regions of
similarity using the DaliLite web server (http://www.ebi.ac.uk/Tools/dalilite/index.html).
3.2.3 Sequence similarity searching using BLAST and T-Coffee. Sequences
from the T3SS and apoptosis regulation were downloaded from the NCBI server
(http://www.ncbi.nlm.nih.gov/) and included PrgI (gi|16766179), InvJ (gi|16766198) and
InvG (gi|474941) from S. typhimurium, and Bcl-xL, (gi|510901), Bak1 (gi|82571458),
Bid (gi|4557361) and Bax (gi|231632) from Homo sapiens respectively. A full BLAST
search was completed using these sequences associated with both systems as queries.30
All BLAST sequence searches used default settings. In addition, the sequences and
structures for Bcl-xL (PDB-ID: 1YSN), S. typhimurium PrgI (PDB-ID: 2JOW), B.
pseudomallei BsaL (PDB-ID: 2GOU) and S. flexneri MxiH (PDB-ID: 2CA5) obtained
from the PDB were uploaded to the T-Coffee20 web server (http://www.tcoffee.org/) to
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obtain a multiple sequence alignment using the EXPRESSO(3DCoffee) software.31 Only
the sequence region of the Bcl-xL structure that contained the pore-forming domain and
yielded the highest alignment score was used for the multiple sequence alignment.
3.2.4 Secondary binding site similarity between Bcl-xL and PrgI. To further
support a structural and functional similarity between Bcl-xL and PrgI, the BindingDB32
(http://www.bindingdb.org/) was searched for commercially available compounds to test
for binding to PrgI. The free 2D 1H-15N HSQC spectrum was collected using 100 M 15N
labeled PrgI in 20 mM bis-Tris buffer with 100 mM sodium chloride at pH 7.0. A second
PrgI sample was prepared in the same manner as above with the addition of 500

M

chelerythrine to generate the bound 2D 1H-15N HSQC spectrum. Chemical shift
perturbations and a PrgI-chelerythrine docked co-structure were determined as described
previously24 and was compared to the Bcl-xL-chelerythrine model 33.

3.3 RESULTS
3.3.1 Results from the FAST-NMR screen. The needle complex protein, PrgI,
from S. typhimurium is an attractive antibacterial target because the protein is exposed to
the cell surface and blocking this target could prevent injection of virulence factors into
the host.34 The interaction of PrgI with the host membrane stimulates the delivery of
effectors from the bacteria into the host cytosol to induce cell death. Recently an NMR
structure was determined for a monomeric form of PrgI,16 which enabled the screening of
PrgI using the FAST-NMR assay.8 FAST-NMR combines NMR ligand affinity
screening35 using a fragment-based functional library22 with structural biology and
bioinformatics2 to rapidly determine protein-ligand complexes24 and infer functional
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relationship between proteins based on similarities in functional epitopes. Also, the
resulting protein-ligand co-structure provides a valuable starting point for structure-based
drug design.
FAST-NMR applies a tiered approach to screening35 to minimize resources and
increase throughput (figure 3.1). First, PrgI was screened with the functional chemical
library using 1D 1H NMR line-broadening experiments. Five compounds (L-carnitine
inner salt, didecyldimethylammonium bromide, 1-methylimidazole, methiothepin
mesylate salt, sucrose) were found to bind PrgI by showing a significant decrease in 1H
peak intensity upon addition of 25

M of PrgI. This was determined by comparing

normalized 1H ligand peak intensities between the free and bound NMR spectra (figure
3.1A). However, the secondary 2D 1H-15N HSQC experiments identified the lipid
derivative didecyldimethylammonium bromide (DDAB) as the only specific PrgI binder
(figure 3.1B) based on the observation of a significant number of chemical shift changes
in the spectrum. The remaining four compounds elicited no change in chemical shifts in
the PrgI 2D 1H-15N HSQC spectrum, which suggest the compounds bound nonspecifically to PrgI. PrgI was found to bind DDAB with a K D of 553 M as calculated by
a 1D 1H line broadening method of chapter 2.23 Finding a lipid derivative that specifically
binds to PrgI is consistent with the protein‟s function; sensing new host cells and
signaling secretion through an interaction with the host membrane. 36
Chemical shift perturbations (CSPs) in the 2D

1

H-15N HSQC experiments

between free PrgI and the complex identified the PrgI residues that bind DDAB. Mapping
these CSPs onto the PrgI surface identified the DDAB binding site as corresponding to
residues at the bifurcation point of the two helices (figure 3.1C). Specifically, residues
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S6, L9, S13, K15, and D17 of helix 1 and N59, V65, K66, V67, F68, K69, D70, D72,
A73 and L76 of helix 2 showed significant CSPs in the presence of DDAB as calculated
by eq 3.1. This ligand binding site has been shown to be important for the formation of
the T3SS needle complex in which PrgI forms a repeating coiled-coils structure.11
According to recent alanine scanning and structural studies, the surface residues in the
region between the bifurcation point of the two helices and the conserved loop region,
PxxP domain, are important for needle assembly. 16-18 These residues bind to the backside
of the bifurcation point of the two helices in a stacked N-terminus to C-terminus
manner.16-18
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Figure 3.1: Identification of PrgI Binding Ligands. (A) DDAB NMR spectra in the
absence (top) and presence (bottom) of PrgI illustrating changes in NMR intensities
(boxed) upon binding PrgI. Both free and bound 1D 1H NMR spectra were normalized to
a constant DMSO signal intensity. (B) Expanded view of the superimposed 2D 1H-15N
HSQC spectra of the free and DDAB bound PrgI NMR samples. Residues that incur a
chemical shift perturbation are boxed. (C) Expanded view of PrgI surface rendered in
VMD37 where residues that incur a chemical shift change are colored blue and DDAB is
colored yellow. Co-structure based on NMR determined ligand binding site using
AutoDock and our AutoDockFilter program.
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The PrgI residues exhibiting significant CSPs upon binding DDAB were used to
guide and filter a molecular docking simulation based on our method to rapidly determine
protein-ligand co-structures.24 AutoDock 4.025 was used to calculate 100 docked
structures within a 3D grid defined by the CSPs. Our AutoDock Filter program (ADF)
selected the best conformer based on consistency with the magnitude of chemical shift
changes.24 The ligand is expected to be closest to the protein residues that incurred the
largest CSPs. The best PrgI-DDAB docked structure is shown in figure 3.1C, where
DDAB adopts an extended conformation that straddles both helices of PrgI.
3.3.2 Analysis of CPASS and structure similarity results. Comparison of
Protein Active Site Structures (CPASS) analysis of the PrgI-DDAB complex identified a
human Bcl-2 protein family member (the anti-apoptosis regulating protein Bcl-xL (PDBID:1YSN) complexed to an acyl-sulfonamide-based inhibitor (ABT-737))28 as the top hit
based on a ligand binding-site CPASS similarity score of 37.7%. The CPASS alignment
is shown in figure 3.2A and is based on maximizing the spatial orientation of similar
residue types between the two ligand binding sites. All other proteins with a CPASS
similarity > 30% were also evaluated, but Bcl-xL was the only protein that gave a
reliable CPASS score and showed some level of structure or sequence similarity to PrgI.
It is important to note the CPASS identified similarity between PrgI and Bcl-xL was
fundamentally dependent on the existence of a Bcl-xL-ligand complex in the PDB.
Ligand complexes for other members of the Bcl-2 protein family (Bax, Bid) currently do
not exist.
While DDAB and ABT-737 are distinctly different ligands, the compounds share
strong similarities in their mode of protein interactions. ABT-737 binds Bcl-xL edge-on
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in an elongated conformation where a minimal number of atoms contact the hydrophobic
binding cleft of Bcl-xL. In this manner, DDAB mimics this edge contact interaction of
ABT-737 with the similar hydrophobic binding cleft in PrgI. Also, ABT-737 binds in a
protein-protein binding interface similar to DDAB, where inhibiting protein interactions
is the drugs mechanism of action in cancer cells.28 Thus, the PrgI and Bcl-xL ligand
binding-sites are functionally similar.
A pairwise structure alignment using DaliLite29 yielded a non-significant Z-score
of 1.4 and only 6% sequence identity between PrgI (PDB ID:2JOW) and Bcl-xL (PDB
ID:1YSN). Nevertheless, the helix-turn-helix structure of PrgI (residues S13-V65)
overlaps the buried helix-turn-helix motif (N136-I182) in Bcl-xL that corresponds to
helices 5 (residues W137-D156) and 6 (residues L162-D176) (figure 3.2B). A focused
pairwise comparison between the full PrgI protein and the 5 and 6 helices of Bcl-xL
gave a low but significant Z-score of 3.3 with an root-mean-square-difference (rmsd) of
3.1Å. The sequence identity also increases from 6% to 9% between the full and focused
pairwise alignments, respectively.
While there is an overlap between the DaliLite alignment of PrgI with Bcl-xL and
the protein ligand binding sites identified by CPASS, these sites are not identical. This
arises because the CPASS similarity is not confined by the primary sequence of the two
proteins, but simply captures the spatial orientation of conserved residues around a ligand
binding site. This is illustrated by the non-sequential sequence alignment of the PrgI and
Bcl-xL ligand binding sites in figure 3.2. The exclusion of the sequence connectivity as a
constraint to determine an alignment illustrates the advantage of CPASS in identifying a
functional relationship over global sequence and structure alignments. 29, 30
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Figure 3.2. Active Site Similarity between PrgI and Bcl-xL. (A) CPASS alignment of
the S. typhimurium PrgI active-site complexed to DDAB with the active-site of human
Bcl-2 protein (Bcl-xL) complexed with acyl-sulfonamide-based inhibitor. The residues
aligned by CPASS are labeled and colored blue in the structures. The active site sequence
alignment is also shown below the structures. The ligands are colored yellow. (B)
Overlay of the human Bcl-2 protein (red) with S. typhimurium PrgI (turquoise) based on a
DaliLite alignment. (C) Multiple-sequence alignment of the three known T3SS structures
of S. typhimurium PrgI, B. pseudomallei BsaL, and S. flexneri MxiH with the human Bcl2 protein (Bcl-xL). The reliability of the each amino acid alignment is color-coded from
blue (poor) to red (good) using the CORE index. 38 The consensus alignment received a
score of 69, where a perfect alignment receives a score of 100.
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3.3.3 Sequence similarity results. A BLAST30 homology search using the PrgI
and Bcl-xL sequences did not yield any significant information relating PrgI to Bcl-xL.
The Bcl-xL sequence only identified homology to other Bcl-2 proteins. Similarly, the
PrgI sequence was only aligned to other T3SS needle proteins. This is consistent with a
ClustlW239 sequence alignment between PrgI and Bcl-xL that resulted in a low 14.3%
sequence similarity, which falls below the twilight zone of sequence similarity.40 Also,
focused BLAST searches did not provide any new information. Searching microbial
genomes using the Bcl-2 sequences or searching the human genome with T3SS
sequences did not identify any sequence alignments with significant E-values. Thus,
global sequence alignments did not readily result in identifying any relationship between
T3SS and apoptosis proteins. This highlights the power of active site similarity searches
to identify potentially new functional similarities in proteins.
Hidden Markov model (HMM) methods41 provide an alternative and more robust
approach to identify homology between distantly related proteins with low sequence
similarity relative to traditional BLAST searches. The T-Coffee web server
(http://www.tcoffee.org/) provides a consensus sequence alignment (M-Coffee) using
multiple HMM protocols.20 A reliable alignment of conserved residues (figure 3.2C) was
obtained between the known T3SS structures of PrgI (PDB ID: 2JOW), BsaL (PDB ID:
2G0U) from Burkholderia pseudomallei, and MxiH (PDB ID: 2CA5) from Shigella
flexneri with the human Bcl-xL (PDB ID: 1YSN) protein. The multiple-sequence
alignment was obtained using EXPRESSO(3DCoffee)

31

that combines structural

information with a HMM sequence alignment method. The reliability of the per residue
alignment is color-coded using the color index,38 where the majority of residues where in
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the average to good range. The alignment of Bcl-xL with the three T3SS structures
received a score of 53, where a score of 100 results from a perfect alignment. For
comparison, the alignment of the three known human T3SS proteins resulted in a range
of scores from 72 to 76. Conversely, scores that range from the 20 to the 30 indicate poor
or insignificant alignments. Thus, PrgI aligns preferentially to the other T3SS proteins,
but its alignment to the pore forming helices in Bcl-xL is significant and reliable.
Importantly, the sequence alignment of PrgI with Bcl-xL encompasses the same residues
involved in the ligand binding sites identified by CPASS and the structural similarity
identified by DaliLite.
3.3.4 Identification of a second PrgI ligand binding site. The identification of a
compound that binds similarly to both PrgI and Bcl-xL would further establish a
functional relationship between these two proteins. BindingDB32 was used to identify
potential inhibitors of PrgI based on the CPASS predicted active site similarity with BclxL. A total of 71 ligands were reported to bind Bcl-xL. A majority of the compounds
were piperazine derivatives and were not readily available. Two compounds,
chelerythrine and sanquinarine were identified as having affinity to Bcl-xL and were both
available from commercial suppliers. Chelerythrine was selected over sanquinarine based
on previous NMR screening and docking studies that suggested chelerythrine binds
between 4, 5 and 6 of Bcl-xL.33 This region of Bcl-xL was predicted to overlap with
PrgI based on the pairwise Dali alignment (figure 3.2B). Conversely, sanquinarine bound
the BH3 binding cleft of Bcl-xL and thus was not selected for this secondary binding
analysis.33
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A comparison between the free and chelerythrine bound PrgI 2D 1H-15N HSQC
spectra (figure 3.3A) identified a chelerythrine binding site on PrgI (figure 3.3B). The
PrgI residues that exhibited chemical shift changes upon binding chelerythrine include
residues A14, K15 in helix 1 and residues Y57, N59, A60, V65, K66, V67, F68, and D72
in helix 2. The AutoDock/ADF docked structure of PrgI with chelerythrine suggests PrgI
residues K15 and Y57 are the most important residues for chelerythrine binding based on
a close contact with the ligand (figure 3.3B). Many of the residues that show significant
CSPs for PrgI bound to chelerythrine overlap with the DDAB residues, however, the
chelerythrine binding site is on the opposite face of PrgI (figure 3.4). This indicates there
are two ligand binding sites on PrgI that is consistent with the two known protein-protein
interaction sites for PrgI self-oligermization. The chelerythrine AutoDock docking energy
decreased significantly compared to DDAB, -0.43 to -5.29 kcal/mol, respectively
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Figure 3.3. Verification the Bcl-xL inhibitor chelerythrine also binds PrgI. (A).
Expanded overlay of the 2D 1H-15N HSQC spectra for free PrgI (black) and PrgI bound
to chelerythrine (blue). CSPs greater than one standard deviation are boxed. (B) An
AutoDock/ADF docked structure of PrgI complexed with chelerythrine based on the
observed CSPs from (A). (C) The Bcl-xL region shown to bind chelerythrine is
highlighted while the reaming protein structure is transparent. Chelerythrine is colored
yellow and is drawn with licorice bonds. Side-chains for Y173 and V135 are shown as
licorice bonds and colored grey. (D) A ribbon diagram of the AutoDock/ADF docked
PrgI-chelerythrine co-structure. The PrgI-chelerythrine binding region that overlaps with
Bcl-xL is highlighted. Chelerythrine is colored yellow and is drawn with licorice bonds.
Side-chains for Y57 and K15 are shown as licorice bonds and colored grey. (E) An
expanded view of the overlay of Bcl-xL (red) with PrgI (blue) illustrating the structural
similarity of the chelerythrine binding sites.
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Figure 3.4. The two PrgI ligand binding sites identified using FAST-NMR. The two
PrgI ligand binding sites are highlighted on an electrostatic potential surface (blue
positive charge, red negative charge) calculated with the DelPhiController implemented
in Chimera 42. The didecyldimethylammonium bromide binding site (A) is found in a
region responsible for needle formation while the chelerythrine binding site (B) is found
on the opposite face of PrgI.
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The binding site of chelerythrine on PrgI is nearly identical to the binding site of
chelerythrine to Bcl-xL (figure 3.3C and 3.3D). In Bcl-xL the chelerythrine binding site
is described as being located in the BH groove of helix

4,

5 and

6, which is

composed of residues F131, R132, V135, Y173 and H177 (figure 3.3C).33 Pairwise
structure analysis between PrgI and Bcl-xL shows that Y173 of Bcl-xL and Y57 on PrgI
are overlapping residues and K15 from PrgI is proximal to V135 from Bcl-xL (figure
3.3E). The primary difference between the two proteins is the lack of -helix 4 in PrgI,
where helix 4 of Bcl-xL appears to act as a „cap‟ encasing the ligand and effecting its
relative binding orientation. Chelerythrine binds flat in the PrgI binding site, while the
compound points into the corresponding Bcl-xL binding site partially overlaying helix
4. Again, both of these structures are docked models based on NMR CSPs and require a
high-resolution x-ray or NMR structure to confirm the conformation of the chelerythrine
binding site. It is paramount to note that this similarity in chelerythrine binding between
the two proteins would have not been discovered if it was not for the identification of the
initial conserved ligand binding site between PrgI and Bcl-xL using the FAST-NMR
method in combination with the CPASS database.

3. 4 DISCUSSION
3.4.1 Ligand binding similarity of the Bcl-2 family of proteins with PrgI. A
structural and functional similarity between PrgI, a type three secretion system protein,
and Bcl-xL, a member of the Bcl-2 family of proteins involved in eukaryotic apoptosis,
was identified from a FAST-NMR ligand affinity screen in combination with a
bioinformatic analysis. This association is fundamentally based on the similarity in ligand
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binding sites depicted in figure 3.2A, where the conserved helix-turn-helix motif simply
provides secondary support of a PrgI and Bcl-2 functional link. While similar active sites
provide a measure of functional similarity, inferring homology based solely on the
observation of a similar helix-turn-helix motif is questionable. The helix-turn-helix is a
common motif and without a global sequence similarity, an evolutionary lineage based
solely on active site similarity cannot be readily established. However, identifying similar
ligand binding sites between the two proteins does provide support the proteins share a
common function and are expected to bind similar ligands.
The initial identification of the conserved DDAB ligand binding site between BclxL and PrgI was used to predict, test and confirm that chelerythrine binds PrgI in a
similar manner to Bcl-xL. This further supports the structural and functional similarity
between PrgI and Bcl-xL, but also demonstrates the utility of active site similarity as a
predictive tool for ligand binding. Chelerythrine was only tested for PrgI binding because
of the proposed active site similarity with Bcl-xL. Thus, these studies have identified the
first known ligands to bind PrgI (DDAB and chelerythrine). Both ligand binding sites are
associated with the functionally important PrgI self-oligomerization sites. Therefore,
compounds based on either the DDAB or chelerythrine scaffold may disrupt PrgI
oligomerization. These compounds may serve as valuable chemical leads to develop
novel antibiotics. Additionally, since the ligands bind in separate locations on the PrgI
surface (figure 3.4), the compounds present two distinct approaches for developing drugs
targeting PrgI. Unfortunately, because chelerythrine also binds Bcl-xL it is reasonable to
expect that an antibiotic designed using chelerythrine as a scaffold may produce
undesirable off-target side effects. This issue may be minimized or eliminated by simply

105
improving the PrgI binding affinity for chelerythrine derivatives. This illustrates another
important feature of the FAST-NMR protocol; active site similarity is a useful tool to
predict potential side effects due to off target inhibition in addition to predicting potential
drug leads. While computational methods for predicting potential drug toxicity43 are
useful because of their speed, validation requires experimental methods such as the
FAST-NMR approach.
3.4.2 Functional similarity of the Bcl-2 family of proteins with PrgI. The Bcl2 family of proteins are essential for eukaryotic apoptosis; where Bcl-xL is responsible
for repressing cell death activity.15 The in vivo binding partners of Bcl-xL include the
pro-apoptosis proteins Bax, Bak and Bid. It has been shown that expression levels of
repressor (Bcl-xL) and pro-apoptosis proteins (Bax, Bak and Bid) are reciprocal in nature
suggesting precise regulation of eukaryotic apoptosis.44 A combination of mutational and
structure work has shown the BH3 binding domain of Bcl-xL is critical for binding
interactions with other Bcl-2 proteins and apoptosis regulation.44
The structure of Bcl-xL very closely resembles the structures of Bax, Bid, Bcl-2,
and other members of the Bcl-2 family of proteins, which all resemble pore-forming
domains of bacterial toxins.45-47 Bcl-2, Bcl-xL, Bax and the truncated active form of Bid
(tBid) have all been shown to form pores in liposomes, but a similar cellular function has
only been observed for Bax.44, 48, 49 In healthy cells, Bax is a monomer in the cytosol.
Many different apoptotic signals result in the transfer of Bax to the outer mitochondrial
membrane where an interaction with Bid and the lipid membrane induces Bax to form a
supramolecular opening in the outer mitochondrial membrane.50,

51

This pore structure

causes the release of pro-apoptotic factors from the mitochondria into the cytoplasm to
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induce cell death52 and contains ~22 copies of Bax with a diameter of ~20 nm. The
interaction of Bcl-xL with Bax prevents Bax induced cell death, 53 where drugs that
disrupt Bcl-xL interacting with Bcl-2 proteins are a promising form of cancer therapy. 54
Bcl-xL has been described as a dominant-negative version of Bax.55
PrgI comprises the T3SS needle structure, which is formed by a PrgI
homomultimer composed of ~ 120 copies of the protein. 10-12 This needle structure senses
and punctures host membranes forming a pore to transfer proteins to induce cell death in
a mechanism similar to eukaryotic apoptosis. 13-15 A general conservation in function
between PrgI and the Bcl-2 protein family is thus maintained and readily apparent; both
form membrane pores via a helix-turn-helix motif through oligomerization to release
effectors to stimulate cell death. Additionally, PrgI requires PrgJ for oligomerization into
the needle11 while Bax requires Bid to induce pore formation. 51 Thus, a protein
interaction with other members of the Bcl-2 family is required to either promote (Bid) or
inhibit (Bcl-xL) Bax oligomerization. It is also interesting that PrgI was found to bind to
a lipid analog and lipids have been found to play a role in Bax oligomerization.51
Importantly, the experimentally observed ligand binding sites for both PrgI and
Bcl-xL are functionally equivalent and within the conserved helix-turn-helix motif. Both
sites correspond to functionally critical protein-protein interaction sites required for
oligomerization and pore formation. The DDAB binding site on PrgI overlaps with key
residues involved in PrgI oligomerization and needle assembly. Similarly, ABT-737 is an
inhibitor of apoptosis and functions by inhibiting Bcl-xL protein interactions.56 Thus, the
similarity in the ligand binding sites helps establish a functional link between the two
proteins.
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3.4.3 Structural similarity of the Bcl-2 family of proteins with PrgI. The Bax
pore-forming domain is conserved in Bcl-xL, Bcl-2 and Bid45, 57 and corresponds to the
helix-turn-helix motif (helices 5 and 6) that was identified by CPASS to be similar to
PrgI (figure 3.2A). Also, a comparison of the Bcl-xL and PrgI structure by Dalilite
resulted in the alignment of the PrgI structure with this conserved Bcl-2 helix-turn-helix
motif (figure 3.2B). Additionally, a multiple sequence alignment indicated a reliable
similarity between T3SS needle-forming proteins and the Bcl-2 pore-forming region
(figure 3.2C). Thus, the PrgI structure can be viewed as a minimalistic version of the Bcl2 structure, and corresponds to the functionally essential and conserved core poreforming domain.
Gene duplication along with insertion and/or deletions of sub-structures into
variable genetic regions are known methods for the evolution of protein function. 58,

59

These processes may explain the evolution of the Bcl-2 family of proteins from a smaller
PrgI-like ancestor. Since the PrgI structure overlaps with residues N136 to I182, this may
suggest N- and C-terminal insertions generated a Bcl-2 protein from a PrgI-like ancestor.
This is consistent with the hypothesis proposed by Aouacheria et al.,60 where the
ancestral toxic pore forming domain (helices 5 and 6) required developing a means to
prevent inappropriate apoptosis and to regulate cell death.
Presumably, a main function of the N- and C-terminal inserts into a PrgI-like
ancestor would be to stabilize the monomer form of Bax until an apoptotic signal occurs.
In effect, the insertions would provide a stronger control over the pore formation process.
This is consistent with what has been experimentally observed, both the N- terminus and
C-terminus residues of Bax are essential to maintain the monomer form of Bax in the
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cytosol.47, 61, 62 Deletion of the first 20 amino acids from the N-terminus results in Bax
being localized to the mitochondria.61,

62

Similarly, the Bax structure indicates the C-

terminal hydrophobic helix 9 is bent in a hydrophobic groove, but contains some critical
solvent exposed polar residues that are necessary to maintain solubility.47 In fact, a model
for the translocation of Bax from the cytosol to the mitochondria requires a
conformational change in Bax that opens up helix

9 and exposes the pore forming

region composed of helices 5 and 6.47, 63 Deletions of 21 residues from the C-terminus,
which includes part of helix 6, prevents oligomerization.64
While Bax oligomerizes to form a circular pore structure containing ~22 copies,
this oligomerization process does not extend to form layers like the PrgI needle structure.
The conformational change in Bax results in the globular domain remaining in the
cytosol and sterically prevents oligomerization perpendicular to the membrane.65 Thus,
the structural insert that maintains a monomer Bax in the cytosol also prevents an
unnecessary linear extension of the Bax oligomer out of the mitochondria membrane.
Conversely, regulating PrgI oligomerization is not necessary since the assembly of the
T3SS system is not detrimental to the cell. Therefore, a minimal pore-forming structure is
all that is necessary for the T3SS system. The length of the PrgI needle is controlled by
the proper assembly of the inner rod (PrgJ) that requires the InvJ protein. 66 The deletion
of InvJ results in long non-functional needles.
3.4.4 An evolutionary relationship between T3SS and eukaryotic apoptosis?
Based on the observed similarity in the structure and function between PrgI and the Bcl-2
protein family it is tempting to hypothesize the proteins share a common ancestor. The
structural comparison of PrgI with the Bcl-2 family of proteins discussed above suggests
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a possible evolutionary path. A common ancestral protein has been suggested for the Bcl2 protein family, where pore formation using helices 5 and 6 is the ancestral proteins
predicted primary function.60 Similarly, T3SS are also predicted to evolve from a single
gene67 that is a simple but versatile export system.68 Again, the helix-turn-helix is a
common and ancient motif69 demonstrating both its diverse utility and evolutionary
stability. Thus, it is plausible that a simple and ancient PrgI-like protein could be an
evolutionary precursor to both the Bcl-2 protein family and PrgI. It also appears unlikely
that PrgI and the Bcl-2 protein family would evolve through a convergent process since
the helix-turn-helix is such a simple and ancient motif69 and essential to the function of
both proteins. Evolving a readily available helix-turn-helix protein into either PrgI or the
Bcl-2 protein family seems like a simpler path than the conversion of a uniquely distinct
fold to incorporate a core helix-turn-helix motif. Also, the evolution of proteins from
simple structural components has been previously proposed70 and is consistent with other
general evolutionary trends where complex systems evolve from simpler systems. 71
By analogy, the sharing of a common ancestor by PrgI and the Bcl-2 family of
proteins would imply an evolutionary relationship between the T3SS and eukaryotic
apoptosis systems. T3SS is a prime example of a vestigial system and an important
illustration of the stepwise evolution of the flagella machinery.72,

73

Therefore, it is

reasonable to expect that other systems will be identified that share an evolutionary
relationship with T3SS. T3SS is also an ancient system and clearly predates the origin of
the mitochondria from prokaryote endosymbiosis.74,

75

-proteobacteria,74 which are

close relatives of the mitochondria, are known to contain T3SS.68, 76, 77 Could an obsolete
T3SS system contribute valuable components to the eukaryotic apoptosis system after
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endosymbiosis? An evolutionary link has already been observed between a mitochondrial
and T3SS protein.78, 79 Furthermore, a detailed analysis of the origin of apoptotic proteins
suggests a pivotal role for bacterial proteins in the evolution of eukaryotic apoptosis. 80
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CHAPTER 4:
OPTIMIZATION AND VALIDATION OF THE FAST-NMR METHOD

4.1 INTRODUCTION
The predicted functional similarity between PrgI and the Bcl-2 family of proteins
described in chapter 3 illustrates the enhanced benefit of combining experimental data
with bioinformatics. The Functional Annotation Screening Technology by NMR (FASTNMR) is an initial step in achieving high-throughput functional analysis of proteins,
independently of global sequence or structure homology transfer. FAST-NMR uses a
tiered approach to NMR screening to identify protein active sites. 1, 2 First, each protein is
screened with a library of approximately 437 compounds distributed across 113
mixtures.3,

4

Binding is detected using the 1D 1H NMR line broadening methods

discussed in chapters 2 and 3.2 The compounds that show the tightest binding are passed
to the second tier screening step (2D 1H-15N HSQC) to identify the protein active site.
The experimentally identified active site is compared to a database of known protein
active sites using the CPASS database and software.5 Finally, protein function is inferred
by identifying similar active sites in the CPASS database.
The tiered approach to screening, along with screening in mixtures, reduces the
total amount of time and sample requirements needed to identify a protein active site. 1, 3, 4
However, the reduction in data collection time is relative to screening a protein with
individual compounds. A significant bottleneck in the process remains the large data
collection time for screening all 113 mixtures and relatively large sample requirements
needed in the 2D 1H-15N screening step.
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NMR is a relatively insensitive technique that uses signal averaging to increase
signal-to-noise. Data collection time is directly proportional to the total number of scans
needed and the recycle delay between each scan. To maximize signal-to-noise and
suppress residual solvent signal; the initial FAST-NMR 1D 1H screening step required
64-128 scans with a recycle delay of 1.0-2.0 s (chapter 3). The total time to collect an
NMR spectrum for a mixture and move to the next sample is approximately 10-14 min
(2-6 min data collection, 8 min sample change and set up).

This correlates to

approximately 19-26 hrs of total 1D 1H experiment time for each protein screen.
The tiered approach to NMR screening saves experimental time and protein
sample by prioritizing which ligands from the 1D screen get passed to the 2D 1H-15N
HSQC conformation screens.1

However, the average number of hits for the 4 proteins

(PA1324, SAV1430, PrgI, and S. aureus primase CTD) screened with the initial method
was 16.75 ± 10.75 ligands with a range between 5-30 ligands. Using the tiered approach
method still requires large sample concentrations and experimental time. For the 30
ligands identified that bound SAV1430 the total amount of

15

N labeled protein was

approximately 30 mgs and nearly 80 hrs of data collection (2.5 hrs/HSQC with
8min/sample change).2 For PrgI, the protein with the lowest number of hits, the total
time for the 2D 1H-15N HSQC screen was approximately 11.5 hrs (1.5 hrs/HSQC with
8min/sample changing).6 Obviously, spending between 30-100 hrs of total experiment
time and the large protein requirement significantly limits the throughput of the FASTNMR method.
In this chapter I will discuss the optimization of the FAST-NMR method by
implementing two new pulse sequences and making significant updates to the automated
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NMR data collection. The improvements made to the screening method decreased the
total experimental time for the 1D 1H NMR screening step by approximately 8 hrs per
protein. Additionally, the improvements made to the 2D 1H-15N HSQC screening step
provides a greater flexibility in data collection by reducing the total amount of sample
needed or reducing to over experimental time.
I evaluated the improvements to FAST-NMR screening using Staphylococcus
aureus nuclease, a well-established model protein for NMR screening with a number of
previously solved free and ligand-bound NMR structures.7-9 I demonstrate the improved
FAST-NMR screening method can correctly identify the previously reported nuclease
ligand binding site in a high-throughput manner. Additionally, the binding site found by
FAST-NMR was used by CPASS to correctly identified the reference nuclease structure
from the CPASS ligand binding site database.5

4.2 EXPERIMENTAL
4.2.1 Materials. The bromocresol green (ACS reagent grade, 95% pure) was
purchased from Sigma-Aldrich (Milwaukee, WI). The dimethyl sulfoxide-d6 (99.9% D),
2,2-Bis(hydroxymethyl)-2,2′,2″-nitrilotriethanol-d19 (98% D), naproxen (98% pure) and
deuterium oxide (99.9% D) was obtained from Aldrich (Milwaukee, WI). The 3(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (98% D) was purchased from
Cambridge Isotope (Andover, MA). The potassium phosphate dibasic salt (anhydrous,
99.1% pure) and monobasic salt (crystal, 99.8% pure) were purchased from Mallinckrodt
(Phillipsburg, NJ).

E. coli cells containing the pET28a(+) plasmid with nuclease

sequence and kanamycin resistance gene was obtained from Dr. Greg Somerville‟s lab
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(see appendix A for nuclease sequence). The plasmid isolation kit, Quickclean 5M
miniprep, was purchased from GenScript (Piscataway, NJ). All competent cell lines were
purchased from Stratagene (La Jolla, CA). All unlabeled growth media components
including tryptone, yeast extract, agar, sodium chloride, and IPTG were purchased from
Aldrich. Cobalt affinity resin was purchased from ClonTech (Mountain View, CA).
4.2.2 Apparatus. Two different pulse sequences with improved solvent
suppression were implemented to decrease sample requirements and data collection time
in the FAST-NMR method. All NMR spectra were collected on a Bruker 500 MHz
Avance spectrometer (Billerica, MA) equipped with a triple-resonance, Z-axis gradient
Cryoprobe. All samples were tuned, matched and shimmed to optimize the observed
signal. All sample volumes were at a constant 600 L volume in a 178 mm long x 5 mm
OD NMR tube rated for 500-700 MHz (NE-UL5-7 New Era Enterprise, Vineland, NJ) to
minimize shimming between samples. All samples were collected at 298K. 1D 1H data
was processed using ACD labs v. 12.0 while 2D 1H-15N HSQC data was processed using
NMRPIPE10 and visualized using PIPP11 and CCCPNMR.12
4.2.3 Optimization of automated data collection. As described in chapter 2 and
3, the FAST-NMR method utilizes the Bruker BACS-120 sample changer and IconNMR
software for automated data collection. To increase throughput, the automatic receiver
gain adjustment was turned off and each sample was collected at a constant receiver gain.
Additionally, an automatic shimming routine using a single iteration of the Bruker
gradient shimming to optimize Z1 and Z2 field axes was developed to minimize the time
needed to shim a sample while providing adequate line shape.
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4.2.4 Implementation of the 1D 1H excitation sculpting pulse sequence. The
1D 1H excitation sculpting pulse sequence13 came as a standard and compiled pulse
sequence in the Bruker pulse sequence library (zgesgp). All 1H 90o pulse lengths were
optimized by finding a 360o spectral null at a constant power level of -4.3 dB. The
optimized 1H 90o pulse length was used to calculate all 1 H pulses used in the sequence. A
total of 64 real transients and 8 dummy transients at 8k data points were collected with a
recycle delay of 1.0 s. Total experiment time was approximately 1.25 min.
The excitation sculpting pulse sequence was compared to the presaturation pulse
sequence to examine differences in spectral quality, signal to noise and ability to measure
a single point binding constant (chapter 2). The presaturation sequence was executed in
the same manner as the excitation sculpting sequence with a recycle delay of 2.0 s to
maximize solvent suppression. Total experiment time was approximately 2.5 min.
A free ligand solution was prepared in a 5 mL stock containing 50 M naproxen,
5%

(v/v)

deuterated

dimethyl

sulfoxide-d6

(DMSO-d6),

11.1

M

3-

(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP) and 50 mM potassium
phosphate buffer pH 7.0 (uncorrected) in 99.98% deuterium oxide.

Five replicate

samples were made from the 5 mL stock solution and transferred to individual NMR
tubes. These 5 samples were used for calculating the average free ligand intensities (IF)
and average free ligand linewidths ( F). Data for each sample was collected using the
excitation sculpting sequence and presaturation sequence.
A bound ligand solution was prepared in a 5 mL stock solution containing 50 M
naproxen, 5 M human serum albumin (HSA), 5% (v/v) deuterated dimethyl sulfoxided6 (DMSO-d6), 11.1

M 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt (TSP)
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and 50 mM potassium phosphate buffer pH 7.0 (uncorrected) in 99.98% deuterium oxide.
Five replicate samples were made from this stock solution and transferred to individual
NMR tubes. These 5 samples were used to calculate the average bound ligand intensities
(IB).

Data for each sample was collected using the excitation sculpting sequence and

presaturation sequence.
4.2.5 Implementation of the 2D 1H -15N HSQC with WATERGATE and
water flip-back for solvent suppression. The 2D

1

H-15N HSQC utilizing

WATERGATE and water flip-back pulses came as a standard and compiled pulse
sequence in the Bruker pulse sequence library (hsqcfpf3gpphwg). All 1H 90o pulse
lengths were optimized in the same manner as describe above in section 4.2.2.1.
Additionally, all

13

C and

15

N pulse powers were optimized using the Bruker dec90 and

dec90F3 pulse sequences, respectively. A 100 M 15N labeled S. aureus nuclease sample
and 5 M

15

N labeled S. aureus nuclease sample were used to test the pulse sequence.

Both samples were prepared in a 95% H2O/5%D2O buffered solution of 50 mM KPO4
(pH 7.0) with 300 mM NaCl.
4.2.6 Expression of unlabeled and

15

N labeled S. aureus nuclease. The

pET28a(+) plasmid with the recombinant nuclease sequence and kanamycin resistance
gene was extracted from the stock E. coli cells using the method outlined in the Genscript
Quickclean 5M miniprep kit (appendix 4B). The plasmid was transformed into Bl21DE3-pLySs and Bl21-DE3-codon+ competent E. coli cells using the method described in
the Stratagene manual.

Transformed cells were grown at 37 oC for 12 hrs on LB agar

plates containing 50 mg/L kanamycin. Only the Bl21-DE3-codon+ cells produced any
colonies.
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Three different isolated colonies were selected from the agar plate, individually
inoculated into three different centrifuge tubes containing 25 mL of LB broth and left to
grow for 12 hrs in an incubated shaker at 37 oC. A 1 mL sample from each 12 hr growth
was inoculated into three different 25 mL cultures of LB broth and left to grow until an
O.D of 0.6 at 600nm was reached. Protein expression was induced by the addition of 500
mM IPTG. Induced cells were grown for an additional three hours and expression was
checked by running a 15% PAGE gel of the whole cells (figure 4.5A). The colony that
gave the best expression was used to make a 25 mL 40% glycerol stock suspension stored
in 1 mL aliquots for future expressions as previously described.14
A 1 mL glycerol stock sample was thawed and used to make a LB agar streak
plate. Unlabeled S. aureus nuclease was expressed by isolation of a single colony from
the streak, growing strain BL21(DE3)codon+/pET28a(+) in 25 mL LB broth containing
kanamycin at 50 mg/L at 37 oC for 12 hrs. A 5 mL sample of the 12 hr growth was
inoculated into 1 L cultures (2 L total) of LB broth containing kanamycin at 50 mg/L at
37 oC until an absorbance of 0.67 at 600 nm was reached (~4 hrs). Protein expression
was induced by the addition of 500 mM IPTG to each culture and shaken for an
additional 3.5 hrs at 37 oC (appendix 4C).

Cells were harvested by centrifugation at

10,000 G and stored frozen at -80 oC.
A 1 mL glycerol stock sample was thawed and used to make a LB agar streak
plate.

15

N-labeled S. aureus nuclease was expressed by isolation of a single colony from

the streak, growing strain BL21(DE3)codon+/pET28a(+) in 25 mL M9 minimal media
broth (2 mL 1M MgSO4, 100 uL 1M CaCl2, 10 mL 100x Basal Medium Eagle Vitamin
Solution (Gibco), 1.0 g

15

N-NH4Cl, 4 g d-glucose, 200 mL of 5xM9 salts) containing
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kanamycin at 50 mg/L at 37 oC for 12 hrs. A 5 mL sample of the 12 hr growth was
inoculated into 1 L cultures (2 L total) of M9 minimal media broth until an absorbance of
0.79 at 600 nm was reached (6.75 hr) (appendix 4C). Protein expression was induced by
the addition of 500 mM IPTG to each culture and shaken for an additional 3 hrs at 37 oC.
Cells were harvested by centrifugation at 10,000 G and stored frozen at -80 oC.
4.2.7 Purification of unlabeled and
unlabeled and

15

15

N-labeled S. aureus nuclease. Both

N-labeled S. aureus nuclease expressions were treated the same for

purification. Cells were thawed, re-suspend in equilibration/wash buffer (50 mM sodium
phosphate pH 7.0 and 300 mM NaCl) in 25 mL aliquots and sonicated on ice 3 times at
45 s intervals. The lysate was centrifuged for 30 min at 10,000 g and incubated with 10
mL Talon Cobalt affinity resin for 30 min at 4 oC. The protein bound resin was washed
by passing 4 column bed volumes of equilibration/wash buffer through the resin bed.
Nuclease was eluted with 5 column bed volumes of elution buffer (50 mM sodium
phosphate pH 7.0, 300 mM NaCl and 150 mM imidazole) and stored at 4 oC.
4.2.8 FAST-NMR screening of S. aureus nuclease. A FAST-NMR screen,
AutoDock ligand bound co-structures and CPASS analysis of the S. aureus nuclease
ligand binding site was completed using the methods described in chapter 3 with
additional modifications. Specifically, the FAST-NMR ligand affinity screen of nuclease
utilized the pulse sequences and experimental parameters described above. The increase
in solvent suppression efficiency required using less protein sample per screen due to
aliphatic protein resonance overlap with the ligand signals.

The total protein

concentration was reduced from 25 M in the PrgI screen to 5 M in the nuclease screen.
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A 10 mL volume of stock nuclease was buffer exchanged with equilibration/wash
buffer to remove residual imidazole. Each buffer exchange involved centrifuging the
nuclease sample at 5,000 G for 5 min to a volume of ~1 mL using a 15 mL Amicon
Ultra-15, 10,000 MW cutoff centrifugal filter unit (Millipore, Billerica, MA). After each
centrifugation, 10 mL of equilibration/wash buffer was added to the Amicon Ultra-15 and
the process was repeated 5 times. After the final buffer exchange the nuclease sample
was concentrated to 5 mL. The final concentration of the sample was approximately 1
mM nuclease in a buffered solution of 50 mM sodium phosphate pH 7.0 and 300 mM
NaCl.
1D 1H NMR ligand affinity screening was completed in a similar manner
described in chapter 3. Briefly, 5 M nuclease was added to each ligand mixture (100
M/ligand) in a 99.99% D2O buffered solution of 20 mM d19-bis-Tris at pH 7.0 with 5%
DMSO-d6 to maintain ligand solubility and 11.1 M 3-(trimethylsilyl)propionic-2,2,3,3d4 acid sodium salt as a chemical shift reference. A total of 113 mixture samples were
prepared.

1D 1H NMR spectra for each sample was collected using the excitation

sculpting sequence with 64 real scans, 8 dummy scans with 8 k data points, a sweep
width of 12.0 ppm and a recycle delay of 1.0 s. Data was Fourier transformed, autophase and baseline corrected. The 1D 1H NMR spectra were compared to free ligand
mixture reference spectra and visually analyzed to identify binding ligands. A binding
event was identified by the decrease in ligand intensity of the nuclease-mixture relative to
the free ligand mixture.

Total data collection time including sample changing was

approximately 6 min/spectrum
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All 2D 1H-15N HSQC affinity screens were completed by the addition of 500 M
ligand to a 100 M 15N labeled nuclease sample in a 95% H2O/5%D2O buffered solution
of 20 mM bis-Tris at pH 7.0 with 5% DMSO-d6 to maintain ligand solubility. 2D 1H-15N
HSQC spectra were collected using the WATERGATE/flip-back pulse sequence
described in section 4.2.5 with 8 real scans, 128 dummy scans, 1 k data points in the 1H
dimension and 128 data points in the

15

N dimension. The sweep width of the spectrum

was 12.0 ppm in the 1H dimension and 30.0 ppm in the 15N dimension. A recycle delay
for the pulse sequence was set to 1.0 s. Total data collection time was approximately 20
min/spectrum. Spectra were processed using the same parameters as described in section
4.2.4.

4.3 RESULTS AND DISCUSSION
As described in chapters 2 and 3, NMR affinity screening generally involves
collecting an NMR spectrum at a low analyte concentration in an aqueous buffer. This
poses a significant challenge when developing a high-throughput NMR screening
methods. The relative concentration of residual protons in 99.99% D2O is 1100 mM
compared to 20-100 M for the free ligand. The ~10-50 fold intensity difference between
solvent and analyte peaks decreases the limit of detection (figure 4.1A). A number of
solvent suppression techniques exist to selectively irradiate the solvent peak and increase
the detection limit.
The initial pulse program used for the 1D 1H NMR affinity screening in the
FAST-NMR method was a presaturation sequence with a composite pulse train prior to
the 90o pulse (figure 4.1B). The presaturation pulse is a low power pulse implemented

131
during the recycle delay at the frequency of the solvent signal. As the presaturation pulse
length is increased there is an increase in solvent suppression. To maximize signal, the
recycle delay is set at 1-5 times larger than the T1 relaxation rate for the analyte. A
recycle delay of 2.0 s (see chapter 2 and 3) is used for the presaturation method.

132

133

Figure 4.1 Solvent suppression for low concentration experiments. (A) A 100 M
sample of bromocresol green in an aqueous buffer prepared with 99.99% D2O. The
residual protons from the water (~1100 mM) squelched the bromocresol green signals
giving one strong peak in the center of the spectrum. (B) The presaturation with
composite pulse water suppression technique is used to selectively suppress the solvent
signal. Quality of solvent suppression is dependent on the power (p19) of the
presaturation pulse (presat) and the pulse length, which is the same as the recycle delay
(d1). A composite pulse (thin vertical black bars) is applied for analyte excitation to
decrease the effect of inhomogeneities in the applied B1 field. (C) A 100 mM sample of
bromocresol green after solvent suppression. The experiment was collected using the
pulse program in (B) with a recycle delay of 2.0 s and 64 scans. The time to collect one
spectrum is approximately 2.25 min. The residual solvent peak can be removed for
clarity during processing, but has a baselinewidth of 117 Hz.
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4.3.1 Optimization of automated data collection. The largest limiting factor for
high-throughput ligand binding studies using the FAST-NMR method is the nearly 8 min
required for sample changing and experimental set up. This correlates to approximately
15 hrs of “dead time” between data collection. A large portion of the time was tied to the
receiver gain adjustment and shimming routine (~3 min). The previously described
method for FAST-NMR (chapter 3) required samples to be prepared in 500 L volumes
to reduce sample requirements. However, this inadvertently required a longer shimming
routine because the sample was not uniformly covering the receiver coil. By preparing
samples at a larger 600

L volume that extends beyond the receiver coil, a shorter

gradient shimming routine was implemented while maintaining good line shape and
linewidth. Using a simple gradient shim routine saved nearly 2 min between samples.
Additionally, setting the receiver gain to a constant value based on the first sample and
removing the automatic receiver gain adjustment saved nearly 1 min of sample set up
time. A total time savings of ~3 min per sample was seen by making small adjustments
to the automatic data collection protocols reducing the total time between samples to ~5
min. For the FAST-NMR library of 113 mixtures this correlates to a savings of ~5.5 hrs,
reducing the total time for sample changing and set up during a FAST-NMR screen to 9.4
hrs.
4.3.2 Improving 1D

1

H NMR screening efficiency. To further increase

throughput of the FAST-NMR screen requires using a 1D 1H pulse sequence that will
give comparable or better results with a shorter recycle delay. The excitation sculpting
pulse sequence for solvent suppression developed by Hwang et. al,13 uses gradient pulses
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to selectively irradiate the water. This removes the dependency on the recycle delay as
found in the presaturation sequence.
I compared the standard FAST-NMR presaturation pulse sequence with the
excitation sculpting sequence to determine if there were any improvements in the ligand
binding analysis. Specifically, I was looking for improvement in water suppression,
increases in signal to noise and overall spectral quality. Spectral quality was determined
by the amount of post-processing editing required. I was also looking for differences in
measured single point binding dissociations constants (KD) as described in chapter 2.
Five replicate samples were made at two different human serum albumin (HSA)
concentrations (0

M and 5

M) containing 50

M naproxen, 5% (v/v) deuterated

dimethyl sulfoxide-d6 (DMSO-d6), 11.1 M 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid
sodium salt (TSP) and 50 mM potassium phosphate buffer pH 7.0 (uncorrected) in
99.98% deuterium oxide.

All samples at 0

M HSA were used for calculating the

average free ligand intensities (IF) and average free ligand linewidths ( F). All samples at
5 M HSA were used for calculating the average bound ligand intensities (IB). A 1D 1H
NMR spectrum using the presaturation sequence and the excitation sculpting sequence
were collected sequentially for each sample. All samples were collected under the same
conditions at a constant receiver gain of 32.
The excitation sculpting method efficiently suppressed the solvent signal such that
no residual solvent signal remained (figure 4.2C&D). The resulting baseline was flat and
did not require any baseline corrections. The presaturation sequence did not completely
remove the residual solvent signal and required post-processing editing of the residual
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solvent signal. Additionally, a baseline correction was needed because of a rolling edge
near 10.0 ppm (figure 4.2A&B).
The signal to noise ratio for both sequences was comparable at the constant
receiver gain set to 32 with the excitation sculpting sequence S/N = 74.9 and the S/N for
the presaturation was 68.8 compared to the methyl peak in naproxen. The presaturation
sequence is limited to a low receiver gain because the residual water signal is still large
relative to the analyte concentration. However, the improved water suppression of the
excitation sculpting method allows a larger receiver gain (1 k). This improves the S/N to
431.6 relative to the methyl peak in naproxen. This was a 6 fold improvement in S/N
compared to the initial presaturation pulse sequence.
The naproxen average linewidth for the presaturation sequence was 3.52 ± 0.5 Hz,
where the average linewidth for the excitation sculpting sequence was to 2.52 ± 0.1 Hz.
The differences are due to removing the residual water signal. For example, without
removing the residual water signal in the presaturation sequence the reference TSP peak
has a half width of 7.79 Hz calculated by the peak fitting routine in ACD labs. Once the
water peak is removed the reference peak linewidth drops to 1.91 Hz. The difference is
caused by the automatic peak fitting routine in ACD misreading the true baseline of the
spectrum, this is due to negative data points in the residual solvent signal (figure 4.2 A)
and the baseline roll at the edge of the spectrum (figure 4.2 B). The excitation sculpting
sequence does not have these issues and therefore the average calculated linewidth is
smaller.
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Figure 4.2. Comparison between two water suppression techniques. (A) The
presaturation pulse sequence of a 50 M naproxen sample in a 99.99% D2O buffer. The
pulse sequence does not completely suppress the residual water signal at 4.69 ppm. (B)
An expanded view of the presaturation spectrum. In addition to not sufficiently
suppressing the solvent signal the presaturation sequence generates a baseline roll at the
edge of the spectrum around 10 ppm. These issues distort the accurate measurement of
the free ligand linewidth and introduce significant error in the KD measurement. (C) The
excitation sculpting sequence efficiently suppresses the solvent signal so no post
processing editing is required. (D) Additionally the excitation sculpting method does not
introduce baseline roll in the spectrum. The total time to collect a spectrum using the
excitation sculpting sequence is approximately 1.25 min compared to 2.5 min for the
presaturation method.
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The difference in measured average linewidth between the two pulse programs
has a dramatic effect on the accuracy in measuring single point binding constants (KD).
The peak height for each spectrum was summed and then averaged to calculate B expt (eq
2.7) and the single point KD (eq 2. 8) (see chapter 2 for method description). The
measured KD for naproxen biding to HSA was 0.36 M using the excitation sculpting
method and -43.7 M using the presaturation pulse. The non-sense KD value from the
presaturation pulse was caused by the over estimation of the free ligand linewidth. In
chapter 2, the average ligand linewidth using the presaturation pulse sequence was 1.8 Hz
and the single point KD was 0.7 ± 1.2. The data for chapter 2 was collected under
analytical conditions with a large number of scans (512) and long experiment time of 33
min per sample. This is not amenable to high-throughput screening. The problem with
accurately measuring a free ligand linewidth under high-throughput conditions severely
limits the utility of the presaturation pulse sequence.
The results from the excitation sculpting sequence show a significant
improvement over the presaturation pulse for the FAST-NMR screening.

Solvent

suppression using this sequence is not dependent on the recycle delay reducing the total
time needed to collect a single spectrum by approximately 1.25 min.

Additionally, the

results from an excitation sculpting sequence do not need post processing solvent filtering
which dramatically improves the single point KD method for high-throughput NMR
ligand affinity screens.
4.3.3 Improving 2D 1H-15N HSQC NMR screening efficiency. The standard
2D 1H-15N HSQC spectrum correlates the amide proton to the amide nitrogen giving a
single peak for each amino acid (figure 4.3). The current method using the standard 2D
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1

H-15N HSQC requires between 1.5-2.5 hrs per spectrum and is therefore a significant

portion of the screening time for FAST-NMR. In addition to the data collection time, the
method requires a minimum of 100 M 15N labeled protein per sample equaling between
1-30 mgs of protein depending on the number of hits from the 1D 1H NMR screen.

Figure 4.3 A standard 2D 1H-15N HSQC Spectrum. The standard 2D 1H-15N HSQC
correlates each backbone amide proton with its corresponding backbone amide nitrogen.
Samples are collected in 95% H2O/5%D2O buffers with a large residual solvent streak
(5.0 ppm). The relative ratio of analyte to solvent signal reduces the overall signal to
noise requiring larger concentrations of analyte and longer data collection times (1.5-2.5
hrs). The sample was 100 M PrgI in 95%H2O/5%D2O buffered solution of 20 mM bisTris pH 7.0).
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To increase the efficiency and versatility of the 2D 1H-15N HSQC screening step
in FAST-NMR, a solvent suppressed 2D

1

H-15N HSQC pulse sequence was

implemented. The sequence uses the WATERGATE and water flip back method for
solvent suppression.15 Suppressing the residual water in 2D 1H-15N HSQC increases the
flexibility for NMR screening. If sample is a limiting factor, the pulse sequence can
detect protein concentrations as low as 5

M with an extended acquisition time. If

sample concentration is not a limiting factor, the pulse program can be used to collect an
NMR spectrum in approximately 20 min at 100 M protein concentration (figure 4.4).
A 5

M sample of

15

N labeled S. aureus nuclease was prepared in a 95%

H2O/5%D2O buffer with 50 mM KPO4 and 300 mM NaCl. Data was collected using the
WATERGATE15/water flip back 2D 1H-15N HSQC16 pulse sequence with 400 real scans,
128 dummy scans, 1 k data points in the 1H dimension and 128 data points in the

15

N

dimension. The sweep width of the spectrum was 17.0 ppm in the 1H dimension and 30.0
ppm in the

15

N dimension. A recycle delay for the pulse sequence was set to 1.0 s. The

total experiment time was 13 hrs. A 100 M sample of 15N labeled S. aureus nuclease
was prepared using the same buffer conditions. An NMR spectrum was collected similar
to the 5 M sample, but with only 8 real scans. The total time to collect a 2D 1H-15N
HSQC at 100

M protein concentration was approximately 20 min. There was no

difference in peak position between the two experiments. No differences were observed
compared to a standard 2D 1H-15N HSQC spectrum of free nuclease at 1.2 mM protein
concentration (figure 4.5C).

The WATERGATE/water flip back 2D 1H-15N HSQC

experiments sufficiently suppressed the residual solvent peak such that no postprocessing editing was required.
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Figure 4.4 Concentration study of the WATERGATE/water flip back 2D 1H-15N
HSQC. (A) A 5 M sample of 15N labeled S. aureus nuclease was prepared in the a 95%
H2O/5%D2O buffer with 50 mM KPO4 and 300 mM NaCl. NMR spectrum was collected
with 400 scans and experiment time was approximately 13 hrs. (B) A 100 M sample of
15
N labeled S. aureus nuclease under the same conditions collected with 8 scans. Total
experiment time was approximately 20 min.
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4.3.4 FAST-NMR screen of S. aureus nuclease. The 19 kDa protein
Staphylococcus aureus nuclease is a well-studied NMR model system and was used to
test the FAST-NMR optimization and validate its functional annotation. 7-9 The goal of
the experiment was to identify nuclease binding ligands using the FAST-NMR screening
methods, to identify the active site of the protein, and to complete a successful CPASS
analysis. The hypothesis was that we would find the same binding site as previously
reported for the nuclease- thymidine-3‟,5‟-diphosphate ligand bound co-structure.7-9
Furthermore, we would identify a preferential similarity between this nuclease‟s ligand
binding site and other nuclease ligand binding sites.
Unlabeled and uniformly

15

N labeled nuclease was expressed and purified as

described in the experimental sections 4.2.6 and 4.2.7. Expression was checked by
comparing induced and non-induced samples of three growth cultures (figure 4.5A). A
total of 75.6 mg/L unlabeled and 23.4 mg/L

15

N labeled purified nuclease was obtained

from 2 L growths. All concentrations were measured by maximum UV absorbance at
of 17,420 M-1 cm-1. A 2D -1H-15N HSQC

280 nm with a molar extinction coefficient,
was collected on the purified sample of

15

N labeled nuclease and compared to the

reported 2D 1H-15N HSQC spectrum7-9 and associated assignments to check for proper
folding of the protein (figure 4.5C).

The spectrum for the expressed nuclease was

comparable to the reference spectrum7-9 with differences most likely accounted for by
differences in buffer, temperature, spectral resolution and the slightly longer sequence of
the expressed nuclease (9 additional N-terminal amino acids, see appendix 4A for
comparison between expressed nuclease and reference sequence).
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Figure 4.5 Expression and purification of S. aureus nuclease. (A) Induced cultures
(lane 3, 5 and 7) of unlabeled nuclease from 3 randomly selected colonies of E. coli
BL21-DE3-codon+(nuc) were compared to non-induced cultures (lane 2, 4, 6). A dark
band was identified in the induced cultures at approximately 19 kDa (MW lane 1). (B)
Purification of the culture media with a his-tag resin gave 5 isolated bands (lane 3-7) at
the same molecular weight as in (A). (C) The expression and purification was repeated
under minimal media conditions for expression of 15N labeled nuclease. A 2D 1H-15N
HSQC was collected on a sample from the purified stock solution (1.2 mM). The protein
spectrum was dispersed indicating a folded protein.
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Unlabeled nuclease was screened against the compound library as described in the
experimental section 4.2.8. A total of 18 ligands were identified in the 1D 1H NMR
screening. Table 4.1 reports the list of all nuclease-binding ligands found in our chemical
library. All nucleotides in the chemical library bound nuclease. Binding of thymidine5‟-triphosphate was indicated by relative changes in peak height between the free and
bound spectrum and the appearance of enzymatic turnover of the ligand (figure 6A).
Two new peaks at 7.32 ppm and 8.3 ppm are visible when the 5 M nuclease is added to
the sample.

Table 4.1 Ligands identified to bind nuclease from a high-throughput NMR screen.
Binding ligand
Adenosine-5‟-triphosphate
Guanosine-5‟-triphosphate
Uracil-5‟-triphosphate
Cytosine-5‟-triphosphate
Thymadine-5‟-triphosphate
3'-5'-cyclic guanosine monophosphate
3'-5'-cyclic adenosine monophosphate
Suramin
Mitoxantrone dihydrochloride
Phosphocholine
4-Hydroxy-3-methoxyphenylglycol
Aquocobalamin
L-leucine
Bepridil dihydrocholoride
Ciprofloxacin
Diminazene
Lumicolchince
Acebutolol hydrochloride
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Confirmation of ligand binding was completed by monitoring changes in 15N and
1

H chemical shifts upon addition of 500 M thymidine-5‟-triphosphate ligand to a 100
M 15N labeled nuclease sample. Binding site residues between nuclease and thymidine-

5‟-triphosphate were identified in a similar manner as described in chapter 3. A total of
17 residues were identified to have greater than 1 standard deviation from the average
chemical shift difference upon addition of the ligand. Of these 17 residues, 6 were
identified in the side chain amide region, 6 residues were unambiguously identified and
the remaining 5 were either not assigned in the reference spectrum or could not be
unambiguously identified. Four of the unambiguously identified residues, F34, R35,
K84, and Y113, were residues found in the active site of the reference structure (figure
4.6B&C). The reference binding pocket is composed of 8 amino acids F34, R35, and
L36, T82, D83, K84, Y115, V114, and Y113. Thymidine-5‟-triphophate was the only
ligand titrated with

15

N labeled nuclease because thymidine-3‟,5‟-diphosphate is the

bound ligand for the reference nuclease structure (PDB 1JOK), which was not in the
FAST-NMR chemical library at the time of screening.
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Figure 4.6 FAST-NMR screen of S. aureus nuclease. (A) Unlabeled nuclease was
screened with the FAST-NMR compound library as described in chapter 2 using the new
pulse sequences as described in section 4.2.8. 18 ligands were found to bind nuclease
with thymidine-5‟-triphosphate (AI single, AII mixture free) showing possible enzymatic
turnover (AIII bound) in addition to a decrease in signal. Two new NMR resonance not
found in the free mixture (AII) are observed in the complex (AIII). The assignment of
these peaks is not clear, but most likely correspond to the formation of thymidine-5‟diphosphate from thymidine-5‟-triphosphate. The non-binding compounds in the mixture
include biotin and acetylsalicylic acid. (B) 17 peaks significantly changed in a 2D 1H15
N HSQC spectrum upon the addition of 500 M thymidine-5‟-triphophate to a 100 M
sample of 15N labeled nuclease. For clarity, an example of the relative change upon
ligand binding for two residues (F34 and R35) is shown (black free nuclease, red ligand
bound nuclease). (C) The residues identified in the 2D 1H-15N HSQC spectrum are
highlighted on the protein structure (1JOK) and used to generate a ligand bound costructure. Structure images were generated with VMD17
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A ligand bound co-structure of nuclease with thymidine-5‟-triphosphate was
generated in the same manner as described in detail in chapter 3. The residues identified
in the 2D 1H-15N HSQC spectrum binding study that overlapped with the known binding
site were used to define the grid search space for AutoDock. The Autodock Filter
program18 was run to select the best conformation. Finally, the ligand bound co-structure
was uploaded to CPASS.5
The best hit for the nuclease-thymidine-5‟-triphosphate docked co-structure was a
Staphylococcus nuclease protein (PDB 1TR5) bound to thymidine-3,-5‟-diphosphate.
The active site similarity score was 47.47% with an average rmsd of 0.69 ± 0.3 Å for the
overlapping active site residues. CPASS did not find the structure used to generate the
ligand bound structure (PDB 1JOK) because the program filters out proteins with ≥ 95%
sequence similarity and/or ligand binding sites with ≥ 80% sequence similarity.
However, recent updates to the CPASS database and software now allow for pairwise
active site comparisons. The pairwise comparison between the docked nuclease costructure and the experimental co-structure bound to thymidine-3‟,5‟-diphosphate had a
pairwise active site similarity score of 48.1% with and an average rmsd of 0.76 ± 0.3 Å
for the overlapping active site residues.
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Figure 4.7 CPASS analysis of S. aureus nuclease. (A) The ligand bound co-structure
for nuclease complexed with thymidine-5‟-triphosphate (yellow) was uploaded to the
CPASS database. (B) The best match was the Staphylococcus nuclease protein (PDB
1TR5) bound to thymidine-3,-5‟-diphosphate (yellow). (C) An overlay of the two active
sites (1JOK blue, 1TR5 red) gave an overall rmsd of 0.69± 0.3 Å and a CPASS similarity
score of 47.47%. The sequence alignment of the two ligand binding sites is shown below
the figures, where the aligned residues are colored blue in A and B. Structure images
were generated with VMD.17
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Appendix 4A. Sequence of S. aureus nuclease. A ClustalW sequence alignment with
the sequence of the expressed nuclease (dNuclease) is shown with the reference nuclease
sequence (refNuclea). The reference nuclease sequence was reported from the PDB ID
1JOK7-9
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Appendix 4B. Comparison of the standard pET-28a(+) and nuclease inserted pET28a(+)–nuc plasmids used for the nuclease expression. (A) Standard pET-28a(+)
plasmid (B) nuclease inserted plasmid. (C) 1% agarose gel of the isolated pET-28a(+)nuc plasmid (lane2), digested plasmid (lane 3) and control pET-28a(+) plasmid (lane 4).
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Appendix 4C. Growth curves for nuclease expression. (A) Expression of unlabeled
nuclease with IPTG induction at 3.5hrs OD600nm 0.67. (B) Expression of 15N labeled
nuclease with IPTG induction at 6.75 hrs OD600nm 0.79. The difference in growth rates
was caused by the difference in growth media.
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CHAPTER 5:
THE STRUCTURE, DYNAMICS AND LIGAND SCREENING OF THE
PRIMASE C-TERMINAL DOMAIN (CTD) FROM STAPHYLOCOCCUS AUREUS

5.1 INTRODUCTION
Bacterial primase (DnaG) is a conserved and essential enzyme responsible for the
synthesis of Okazaki fragments during DNA replication. 1 The protein is composed of
three domains; N-terminal domain responsible for DNA binding, the catalytic core
responsible for synthesis of Okazaki fragments, and the C-terminal domain (CTD)
responsible for the interaction between primase and bacterial helicase (DnaB). 2,

3

Full

length primase is conserved among all organisms and exhibits relatively large sequence
similarity.1,

4, 5

However, the sequence conservation is limited to the N-terminus and

catalytic core.1 The C-terminal domain (primase CTD) is highly variable; even among
similar species.1, 4, 5 The functional consequence of the low sequence conservation of the
C-terminal domain is still unclear, but it could play a role in regulating species-specific
DNA replication.6
The solution structures of primase CTD shows significant variability between
Geobacillus stearothermophilus (PDB 1Z8S) and Escherichia coli (PDB 2HAJ).4,

7

Generally, the primase CTD structure is composed of two sub-domains, an N-terminal
six-helix bundle (sub-domain C1) that is essential for DnaB activity and correct primer
length and a helical hairpin (sub-domain C2) that mediates binding to DnaB.4, 8 The two
solution structures share significant structure similarity at the N-terminal bundle (C1 subdomain) but show a sharp difference in the corresponding C2 sub-domain.4, 7, 8 In E. coli
primase CTD is composed of 7 helices with the two sub-domains connected through a
long ridged helix 6.7 In G. stearothermophilus the helix linking the two sub-domains is
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kinked at a Pro556 residue forming two distinct helices (helix 6 and 7). 4 The recent
structure of the DnaG-DnaB complex shows that both the C1 and C2 sub-domains are
important for binding to helicase.9
The discrepancy in the DnaG CTD structures has yet to be fully resolved.
However, it has been shown that primer synthesis is only carried out when primase CTD
and helicase N-terminal domain (NTD) interact.6

The differences in sequence and

structure of the primase CTD between the two organisms suggest a species-specific
method of replication regulation.6 The S. aureus sequence (see appendix 5A) for primase
CTD is more similar to the G. stearothermophilus sequence with 20% sequence identity
and 58% sequence similarity.

However the sequence similarity between S. aureus

sequence and the E. coli sequence (57% similarity and only 10% sequence identity) is
comparable to the sequence similarity between S. aureus and G. stearothermophilus. The
comparable sequence similarities make direct homology modeling challenging because
either structure is a possible model for S. aureus. But, by comparing the sequence
similarities of the loop region between helix 6 and 7, the proline residue (Pro556) that
forms the kink in the linking helix in G. stearothermophilus is replaced with a glycine in
S. aureus (appendix 5A). Glycine has the second largest propensity (second to proline) to
be found in a loop region.10, 11 Conversely, the E. coli sequence contains a methionine in
the corresponding position consistent with a rigid helix 6. This single amino acid
substitution between the three proteins suggests the S. aureus primase structure is more
likely to be similar to the G. stearothermophilus structure.
The rapid rise in community acquired antibiotic resistance, particularly to S.
aureus, requires the rapid identification of new antibiotic targets and potential drugs. 12
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The primase-helicase interaction is an attractive antibiotic target because it is functionally
conserved in bacteria, essential for DNA replication and the bacterial DnaG-DnaB
interaction is distinctly different from that of eukaryotes. 1, 6 Additionally, the high degree
of sequence variability and differences in structure suggest a possible means to tailor
antibiotic development to a specific organism.
As described in chapter 1, the 1D 1H and 2D 1H-15N HSQC screening methods
used for FAST-NMR was originally developed for high-throughput drug discovery.
However, to specifically find an active site for structure based drug discovery, the
complete backbone resonance assignments and a high-resolution, three-dimensional (3D)
structure are required. In this chapter, I will discuss the NMR determination of the
solution structure for S. aureus primase CTD. I will examine a potential phylum
dependency on the two sub-domain structures using sequence and structure similarities. I
will also report protein dynamics for the conformation of a loop region between the two
sub-domains. Finally, I will discuss the discovery of a potential lead compound that
binds to the C2 sub-domain of primase CTD.

5.2 EXPERIMENTAL
5.3.1 Materials. For the DnaG primase CTD structure determination, NMR
dynamics analysis of the structure, and the NMR ligand affinity screens, purified and
uniformly

13

C,

15

N labeled [U-13C,

15

N] DnaG primase CTD and 5N labeled [U-15N]

DnaG primase CTD was purchased from Nature Technologies (Lincoln, NE) (see figure
5.1A for gel). The dimethyl sulfoxide-d6 (99.9% D) and deuterium oxide (99.9% D)
were obtained from Aldrich (Milwaukee, WI). The 3-(trimethylsilyl)propionic-2,2,3,3-d4
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acid sodium salt (98% D) was purchased from Cambridge Isotope (Andover, MA). The
potassium phosphate dibasic salt (anhydrous, 99.1% pure) and monobasic salt (crystal,
99.8% pure) were purchased from Mallinckrodt (Phillipsburg, NJ). All compounds used
for screening were obtained as described in chapters 3, 4 and elsewhere. 13 Briefly, the
compound library is composed of 437 known biologically active compounds distributed
across 113 mixtures with 3-4 compounds in each mixture.
5.3.2 Apparatus. All NMR experiments used for the protein backbone
assignments of DnaG primase CTD were collected at 298 K on a five channel 600 MHz
Bruker Avance spectrometer equipped with a 5 mm TXI probe. NMR experiments used
for the protein side chain resonances and distance constraints were collected at the Rocky
Mountain Regional 900 MHz NMR Facility on a four channel 900 MHz Varian INOVA
spectrometer equipped with a 5 mm HCN probe. Assignments of the backbone and side
chain resonances were obtained from the following spectra: 2D 1H-15N-HSQC, 2D 1H13

C-HSQC,

HNCO,

HNCA,

CBCACONH,

CBCANH,

HNHA,

HBHACONH,

CCCONH, HCCCONH and H(CCH)-COSY (collected on 900MHz).14 Distance
constraints were obtained from 3D

15

N-edited NOESY and 3D

13

C-editied NOESY

(collected at 900 MHz).14
Hydrogen bond constraints were determined using the (CLEANEX-PM)-FHSQC
experiment.15 A total of 2048 data points were collected in the 1H dimension and 128 data
points were collected in the

15

N dimension. The spectrum was collected with 16

transients and a sweep width of 8012.82 Hz in the 1H dimension and 1613.424 Hz in the
15

N dimension. The mixing time was set to 100 ms with a CLEANEX spinlock power of

2 KHz.
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All NMR experiments for protein dynamics analysis were collected on a Bruker
500 MHz Avance spectrometer (Billercia, MA) equipped with a triple resonance, Z-axis
gradient Cryoprobe.

Experiments used for dynamics study have been described

previously16-18 and included a 2D 1H-15NN HSQC experiment (hsqct1etf3gpsi)designed
to measure T1 relaxation rates with delay times of 0.0 ms, 5.39 ms, 53.92 ms, 134.80 ms,
269.60 ms, 404.40 ms, 539.20 ms, 674.00 ms and 1078.40 ms, a 2D 1H-15N HSQC
experiment (hsqct2etf3gpsi) designed to measure T2 relaxation rates with delay times of
0.0 ms, 17.6 ms, 35.2 ms, 52.8 ms, 70.4 8 ms, 105.6 ms, 123.2 ms, 140.8 ms, 158.4 ms,
176.0 ms, and a 2D 1H-15N HSQC experiment (hsqcnoef3gpsi) designed to measure
NOE enhancements.
The relaxation rates (T1,T2) for each DnaG primase CTD amino acid was
calculated by fitting the intensity of each peak to the intensity decay curve (appendix 5B)
(eq 5. 1) where It is the intensity of each peak at the delay time t, I0 is the initial steady
state intensity
[5.1]
The NOE values were determined by the ratio of peak intensity between the
saturated (Isat) and unsaturated (Iunsat) spectra
[5.2]
All T1, T2 and NOE data measurements were used to calculate an overall
correlation time ( r), order parameters (S2), internal motion ( e) or chemical exchange
(Rex) using the Lipari-Szabo model free method19 implemented by FAST-MODEL
FREE.20
All NMR experiments used for the ligand binding screen were collected on a
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Bruker 500 MHz Avance spectrometer (Billercia, MA) equipped with a triple resonance,
Z-axis gradient cryoprobe and using a Bruker BACS-120 sample changer and IconNMR
software for automated data collection. All 1D 1H NMR spectra were collected at 298K
using the pulse sequence described in chapter 3.

To increase throughput, only 64

transients were signal averaged for each spectrum with 8k data points. All 2D 1H-15N
HSQC spectra were collected at 298K using the standard pulse sequence implemented in
Bruker TopSpin 1.3 with optimized sample specific 90o pulse lengths.
All multidimensional experiments were processed using NMRpipe,21 analyzed
using PIPP22 or CCPNMR.23 All 1D 1H NMR spectra were processed with the ACD/1D
NMR manager v. 12.0 (Advanced Chemistry Development, Inc., Toronto, Ontario). All
ligand protein docking studies were completed as described in chapter 3 and 4.
5.3.3 Sample preparation.

For NMR backbone assignment experiments,

uniformly 13C, 15N labeled [U-13C, 15N] DnaG primase CTD was concentrated to 1.2 mM
in a 95% H2O/5% D2O buffered solution of 100 mM NaCl, 25 mM KPO4 pH 6.64
(uncorrected) using an Amicon ultra centricon (MW cutoff 10 000 Da). 50 mM arginine
and 50 mM glutamine was added to the NMR sample for long term stability. For side
chain experiments uniformly

13

C,

15

N labeled [U-13C,

15

N] DnaG primase CTD was

concentrated to 1.4 mM in the same buffer conditions used for the NMR backbone
assignment experiments.
NMR dynamics data was collected using a uniformly 15N labeled [U-15N] sample
of DnaG primase CTD concentrated to 1.2 mM in a 95% H2O/5% D2O buffered solution
of 100 mM NaCl, 25 mM KPO4 pH 6.64 (uncorrected) using an Amicon ultra centricon
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(MW cutoff 10 000 Da). 50 mM arginine and 50 mM glutamine was added to the NMR
sample for long term stability.
Sample preparation and experimental parameters for the NMR ligand affinity
screen were executed in the same manner as described previously24 and in chapter 3.
Briefly, each ligand mixture (113 total) was screened using 1D 1H NMR at 100

M

ligand concentration with 25 M protein in a 99.99% D2O buffered solution of 20 mM
d19-bis-Tris at pH 7.0 (uncorrected) with 2% DMSO-d6 to maintain ligand solubility and
11.1 µM 3-(trimethylsilyl)propionic-2,2,3,3-d4 acid sodium salt as a chemical shift
reference. 1D 1H NMR spectra for each sample was collected using a pre-saturation
pulse sequence with 64 real transients, 8 dummy transients with 8 K data points, a sweep
width of 11.0 ppm and a recycle delay of 2.0 s. Data was Fourier transformed, autophase and baseline corrected. Each 1D 1H NMR spectrum were compared to the
corresponding free ligand mixture reference spectrum and visually analyzed to identify
binding ligands. A binding event was identified by the decrease in ligand intensity of the
nuclease-mixture relative to the free ligand mixture. Total data collection time including
sample changing was approximately 10 min/spectrum
Additionally, a ligand free 2D 1H-15N HSQC spectrum was collected using the
same buffer conditions with 95% H2O/5% D2O to ensure the protein was properly folded
prior to addition of each ligand.
5.3.4 NMR Structure calculations and refinement. NOE assignments were
obtained by using 3D

15

N-edited NOESY and 3D

13

C-edited NOESY experiments. NOE

intensities were sorted visually into four classes: strong (1.8–2.5), medium (1.8–3.0),
weak (1.8–4.0), very weak (3.0–5.0). Upper limits for distances involving methyl protons
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and nonstereospecifically assigned methylene protons were corrected appropriately for
center averaging. Initial NOE assignment was completed by the program Autostructure 25
which identified 1055 intra-residue, 173 sequential, 312 medium range (1 ≥ 5) and 73
long range (5 >) NOEs. Due to significant peak overlap, even at a high magnetic field
(900 mHz), manual refinement was needed to complete NOE assignment. All torsion
angle constraints were obtained by chemical shift analysis using the TALOS 26 software
program, and measured coupling constants from an HNHA experiment. 27
Hydrogen bond constraints were determined using the (CLEANEX-PM)-FHSQC
experiment.15 The (CLEANEX-PM)-FHSQC spectrum was compared with the 2D 1H15

N HSQC spectrum, where amides with missing peaks were assigned hydrogen bond

constraints. These residues were selected because the (CLEANEX-PM)-FHSQC
spectrum identifies amide residues with fast water exchange rates. The hydrogen bond
distance constraints were set at 2.8 Å between the carboxyl oxygen and the amide
nitrogen, and 1.8 Å between the carboxyl oxygen and the amide proton. Carboxyl groups
within 2.5 Å of the slowly exchanging amide groups were selected to be involved in a
hydrogen bond.
The structures were refined using the hybrid distance geometry dynamicalsimulated annealing method28 with minor modifications29 using the program XPLORNIH30 adapted to incorporate pseudopotentials for 3J(HN-Hα) coupling constants,31
secondary

13

Cα/13Cβ chemical shift constraints,32 and a conformational database

potential.33-35 A total of 1000 structures were calculated. The 20 lowest energy structures
were then subjected to further energy minimization with CNS using explicit water
solvation that included Lennard-Jones and electrostatic potentials using a modification of
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the procedure and forcefield of Nilges. 36, 37 An average DnaG primase CTD structure
was calculated from these 20 structures.
The target function that is minimized during restrained minimization and
simulated annealing comprises quadratic harmonic terms for covalent geometry, 3J(HNHα) coupling constants, and secondary 13Cα/13Cβ chemical shift constraints, square-well
quadratic potentials for the experimental distance and torsion angle constraints, and a
quadratic van der Waals term for nonbonded contacts. The force constant for the
conformational database was kept relatively low (0.5–1.0 kcal/mol) throughout the
simulation to allow the experimental distance and torsion angle constraints to
predominately influence the resulting structures. The force constant for the NOE and
dihedral constraints were 30 times and 10 times stronger than the force constants used for
the conformational database.38 All peptide bonds were constrained to be planar and trans.
There were no hydrogen-bonding, electrostatic, or 6–12 Lennard-Jones empirical
potential energy terms in the target function.

5.3 RESULTS AND DISCUSSION
5.3.1 NMR assignments and secondary structure prediction of primase Cterminal domain from Staphylococcus aureus. The backbone resonance assignments
were completed using the NMR experiments described above ( 1H-15N HSQC, HNCO,
HNCA, HNCOCA, CBCACONH, CBCANH, HNHA, HBHACONH and the 1H-15N
HSQC edited NOESY) and manually analyzed using PIPP 22 and CCPNMR.23 The
backbone resonance assignment was 85% complete with 139 amino acids of the 163
unambiguously assigned in the 1H-15N HSQC (figure 5.1). Unassigned residues in the
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1

H-15N HSQC include M1-H13, D19, E28, H37, L38, M9, T58, R94, E95, E101, P109,

and Y110.

The majority of the unassigned residues correlate to the engineered N-

terminal sequence (MGHNHNHNHNHNHNGGDDDD) for purification, residues M1H13 correlated with the N-terminal his-tag, and residue D19 is part of an engineered
proteolytic cleavage site. Excluding the purification tag the backbone assignments were
94% complete. The ten amino acids found in the primase sequence that were not assigned
were primarily found in unstructured loop regions, turns between two helices or at the
edge of a helix. Residues H37-M39 were in a turn region between helix 1 and 2, residue
T58 was in an unstructured loop region between helix 2 and helix 3 and residues E101,
P109 and Y110 were in an unstructured loop region between helix 5 and helix 6.
Residues R94 and E95 are the second and third residues of helix 5. An exhaustive
analysis of the NMR data set was unable to yield an assignment for these residues,
suggesting the end of the helix may undergo partial unfolding and exchange broadening.
Aliphatic side chain carbon chemical shift assignments were completed using the
CCCONH experiment correlating the preceding (i-1) residue to the following (i)
backbone amide chemical shift.

Aliphatic side chain proton chemical shifts were

completed with the HCCH-COSY and HCCCONH experiments. Aromatic side chain
assignments were completed using the 3D 13C-edited NOESY experiment. The statistics
for resonance assignment include, 139/163 HN, 139/201 N, 139/163 C , 134/168 H ,
128/141

C ,

148/181

C
uploaded to the BMRB.39

H ,
C

85/92

C,

89/160

H and 132/143 CO.

H

C ,

49/64

All assignments will be
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Figure 5.1 Assigned 2D 1H-15N HSQC spectrum of S. aureus primase CTD. (A)
Purification of S. aureus primase CTD, lane 1 MW marker, lane 2 shows the expressed
and purified 13C/15N labeled S. aureus primase CTD used for all studies in this work. (B)
Complete backbone 1H and 15N assignments of the DnaG primase CTD from S. aureus.
The spectrum was fully assigned with the exception of one peak at 1H 7.90 ppm and 15N
120.4 ppm. The peak is large and broad relative to other peaks in the spectrum and is
likely the remaining unassigned his tag residues.
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Secondary structure prediction using the difference in backbone ∆ 13C /13C
carbon chemical shifts between the assigned residues and random coil chemical shifts
predict an all -helical protein with 8 helices (figure 5.2A). Helical structures in primase
CTD include Helix 1 Arg26-Lys36, Helix 2 Asp41-Glu50, Helix 3 Gln60-Glu75, Helix 4
Ile81-Tyr87, Helix 5 Asn91-Gln102, Helix 6 Try110-Lys124, Helix 7 Ile129-Arg141,
Helix 8 Glu146-Glu161. The C1 sub-domain of primase CTD includes Helix 1-6 and the
C2 sub-domain includes Helix 7-8 (figure 5.3B). This is consistent with the S. aureus
DnaG

primase

CTD

homology

modeling

predicted

from

the

Geobacillus

stearothermophilus structure4 and the secondary structure prediction server NetSurfP
(figure 5.2B).40
Of particular interest are the residues between the predicted helices 6 and 7
(residues K124-T128). This region is significantly different in G. stearothermophilus
primase CTD compared to E. coli primase CTD solution structures (PDB 1Z8S and
2HAJ, respectively).7

In G. stearothermophilus, this region is a loop forming two

distinct sub-domains (C1, C2) of primase CTD. In E. coli, the region is a long and rigid
helix. For S. aureus, the experimental secondary structure

13

C

and

13

C chemical

shift differences suggest that region is similar to the G. stearothermophilus structure with
an extend loop region starting at residue Gly125 (figure 5.2).

The

13

C

and

chemical shifts for residues in this region are near random coil chemical shift values.

13

C
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Figure 5.2. Secondary structure prediction for S. aureus primase CTD based on 13C and
13
C chemical shifts. (A) secondary structures in S. aureus primase CTD are predicted based on
differences in measured 13C and 13C chemical shifts compared to random coil chemical shift
values. For ∆13C positive regions represent
helical structure. For ∆13C negative values
indicate helix. The secondary structures are overlaid onto the results showing regions of
helix. (B) The predicted secondary structures in S. aureus primase CTD measured by
NetSurfP.40 Positive regions are the probability of the sequence stretch adopting
helix
secondary structure. Both experimental and predicted secondary structure analysis suggest a loop
region between helix 6 and 7 starting at residue G125.
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5.3.2 Structure calculation and analysis of primase C-terminal domain (CTD) from
Staphylococcus aureus. The solution structure of S. aureus primase CTD was calculated using
1823 distance restraints, 280 dihedral restraints measured by TALOS 26, 256
chemical shift restraints and 82 3JNH coupling constant restraints.

13

Cα/13Cβ carbon

A complete list of the

restraints used for the structure calculation is described in table 5.1. A total of 1000 structures
were calculated from 10 individual sets of 100 structures using XPLOR-NIH30 scripts described
previously.41 The lowest energy structures from each set were consolidated to generate a set of
20 low energy structures which were further refined in a water bath using the RECOORD
scripts37 implemented with CNS.42, 43
The resulting S. aureus primase CTD structures are consistent with the NMR data as
evident by the relatively low rms deviations from experimental distance, dihedral,

13

Cα/13Cβ

chemical shift and 3J(HN-Hα) coupling constant constraints (figure 5.3A). Also there are no
distance violations > 0.5 Å or dihedral angle violations > 5°. The average root-mean square
deviation (RMSD) of the 20 lowest energy structures about the mean coordinate positions is 0.97
± 0.16 Å for all backbone atoms and 1.73 ± 0.39 Å for all heavy atoms with aligned residues 2635, 40-49, 60-75, 82-85, 92-100 and 112-124. The final restrained minimized average structure
of S. aureus primase CTD has an RMSD about the mean coordinate positions of 0.19 Å for all
backbone atoms and 0.49 Å for all heavy atoms.
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Table 5.1: Structural Statistics and Atomic rms Differencesa
A. Structural Statistics
<SA>
rms deviations from experimental distance restraints (Å)
all (1823)
interresidue sequential (|i-j| = 1) (460)
interresidue short range (1 <|i-j| 5) (446)
interresidue long-range (|i-j| > 5) (140)
intraresidue (663)
H-bonds (114)b
rms deviation from exptl dihedral restraints (deg) (280)c,d
rms deviation from exptl C restraints (ppm) (130)
rms deviation from exptl C restraints (ppm) (126)
rms deviation from 3JNH restraints (Hz) (82)
FNOE (kcal mol-1)d
Ftor (kcal mol-1)d
Frepel (kcal mol-1)e
FL-J (kcal mol-1)f
deviations from idealized covalent geometry
bonds (Å) (2684)
angles (deg) (04795)
impropers (deg) (1468)g
PROCHECKh
Overall G-Factor
% Residues in most favorable region of Ramachandran plot
H-bond energy
Number of bad contacts/100 residues

0.046 ± 0.008
0.038 ± 0.008
0.058 ± 0.010
0.074±0.016
0.003±0.008
0.072±0.030
1.644±0.754
1.12 ± 0.05
1.06 ± 0.02
0.83 ± 0.06
212 ± 84.6

(SA )r
0.079
0.096
0.074
0.180
0.004
0.040
0.611
1.08
1.02
1.02
602.59

36 ± 45

6.36

65.63 ± 24

26.38

-553.91 ± 29

-1212.10

0.003±0.0
0.504 ± 0.045
0.441±0.069

0.002
0.035
0.344

-0.13 ± 0.03
80.2 ± 3.1
0.41 ± 0.41
25 ± 5.3

-0.19
85.5
0.45
0.0
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B. Atomic rms Differences (Å)

<SA> vs SA
<SA> vs (SA)r
(SA)r vs SA

C1 Domain (residues 26-124)
backbone atoms
all atoms
1.2 ± 0.1.7
2.00 ± 0.17
1.37 ± 0.19
2.32 ± 0.25
1.02
1.67

secondary structurei
backbone atoms
all atoms
0.70 ± 0.44
2.4 ± 2.40
0.58 ± 0.22
1.52 ± 0.6
0.52 ± 0.33
1.21 ± 0.58
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aThe notation of the structures is as follows: <SA> are the final 20
simulated annealing structures and (SA )r is the restrained minimized mean
structure obtained by restrained minimization of the mean structure SA .
The number of terms for the various restraints is given in parentheses.
bFor backbone NH-CO hydrogen bond there are two restraints: r NH-O =
1.5-2.3 Å and rN-O = 2.5 - 3.3 Å. All hydrogen bonds involve slowly
exchanging NH protons inferred from calculated structures and CLEANX
fast-exchange experiment.15 cThe torsion angle restraints comprise 140
and 140 . dThe values of the square-well NOE (FNOE) and torsion angle
(Ftor) potentials (cf. eqs 2 and 3 in 44) are calculated with force constants of
50 kcal mol -1 Å-2 and 200 kcal mol-1 rad-2, respectively. eThe value of
the quadratic van der Waals repulsion term (Frep) (cf. eq 5 in 45) is
calculated with a force constant of 4 kcal mol -1 Å-4 with the hard-sphere
van der Waals radius set to 0.8 times the standard values used in the
CHARMM 46 empirical energy function. 28, 46, 47 fEL-J is the LennardJones-van der Waals energy calculated with the CHARMM empirical
energy function and is not included in the target function for simulated
annealing or restrained minimization. gThe improper torsion restraints
serve to maintain planarity and chirality. hThese were calculated using the
PROCHECK program. iThe residues in the regular secondary structure are:
, 40-49( , 60-75( , 82-85( 4) 92-100( 5 , 112-124 ( 6 ,
128-143( 7 and 146-162( 8 rmsd values were measured by aligning each
secondary structure element individually and calculating an average and
standard deviation.
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The quality of the S. aureus primase CTD NMR structure was analyzed using
PROCHECK. The results for the average minimized structure (figure 5.3B) show that S.
aureus primase CTD has an overall G-Factor of -0.13 ± 0.03 with no bad contacts, which
are all consistent with a good quality structure. Also, all non-glycine dihedral angles lie
within the expected region of the Ramachandran plot, where 85.5% of the backbone
dihedral residues lie within the most favorable region with 100% of the residues falling in
the allowed region. The PROCHECK analysis of the average minimized structure was
completed with the removal of the N-terminal his-tag. The consistency of the dihedral
angles further illustrates the quality of the structure. The 20 lowest energy structures and
the restrained-minimized average structure will be deposited into the PDB. 48
The S. aureus primase CTD structure is composed of 8 helices.

Helical

structures in primase CTD include Helix 1 Arg26-Lys36, Helix 2 Asp41-Glu50, Helix 3
Gln60-Glu75, Helix 4 Ile81-Tyr87, Helix 5 Asn91-Gln102, Helix 6 Try110-Lys124,
Helix 7 Ile128-Arg141, Helix 8 Glu146-Glu161. The C1 sub-domain of primase CTD
includes Helix 1-6 and the C2 sub-domain includes Helix 7-8 (figure 5.3B).
Conformation of the loop region between the two sub-domains was established by the
lack of sequential NH-NH NOEs in the 2D 1H-15N HSQC edited NOESY and the
presence of exchange peaks for each residue (G125, Q126 and E127) in the CLEANX
experiment.15

The results of the CLEANX experiment suggest these residues are

undergoing exchange with the solvent and therefore not protected by hydrogen bonding;
indicative of a loop structure.
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Figure 5.3 Comparison of the ensemble overlay and average minimized structure.
(A) An overlay of the backbone trace of the 20 low energy, water refined structures
aligned with residues 26-35, 40-49, 60-75, 82-85, 92-100 and 112-124 from the Nterminal C1 sub-domain. (B) A ribbon diagram of the average water refined structure 20.
The two sub-domains are labeled C1 and C2. The C1 sub-domain is composed of helices
1-6 and the C2 sub-domain is composed of helices 7-8. Both structures are colored
according to the secondary structure: red, α-helix; green, loop both images were
generated with VMD.49
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Figure 5.4. Ensemble overlay aligned to either sub-domain C1 or C2. (A) An overlay
of the backbone trace of the 20 low energy structures aligned with residues 26-35, 40-49,
60-75, 82-85, 92-100 and 112-124 from the N-terminal C1 sub-domain. (B) An overlay
of the backbone trace of the 20 low energy structures aligned with residues 128-141 and
146-161from the C-terminal C2 sub-domain. Both structures are colored according to the
secondary structure: red, α-helix; green, loop both images were generated with VMD. 49
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The overall resolution of the protein structure was lower than what is generally
possible with current NMR techniques. This lower resolution is an indication of the
severe peak overlap in the NMR spectra, even at 900 MHz resolution. Figure 5.5A is the
resulting 2D 1H-13C HSQC slice of the aliphatic 3D

13

C-edited NOESY experiment

collected at the Rocky Mountain Regional 900 MHz NMR Facility. The spectrum was
folded to increase resolution with the blue peaks representing the proton-carbon peaks for
the H -C , H -C , H -C , H -C side chain resonances. The orange peaks correspond
to the proton-carbon peaks for the H -C

backbone resonances (for absolute C

chemical shift add 35.804 ppm to each 13C resonance). As an example of the severe peak
overlap, the resolved H -C peaks in figure 5.5A only represent about half of the 163
possible assignments. The remaining peaks are buried in the broad and significantly
intense region between 4.5 ppm 1H and 15.0 ppm 13C.
The severe peak overlap is also seen in the 2D 1H-1H slice of the aliphatic 3D 13Cedited NOESY experiment (figure 5.5B). This is particularly problematic in the region
1.0-2.0 1H and 1.0-2.0 1H corresponding to the H and H side chain resonances of
lysine, leucine, isoleucine and H of valine. These 4 amino acids compose nearly 25% of
the total amino acid composition of S. aureus primase CTD.
The severe peak overlap significantly complicated the complete side chain
assignments with only 56% of H assigned and 76% H assigned. The corresponding
number of long range (>5) NOEs was lower than anticipated (only 140) for a protein of
19.6 kDa; the main cause of the lower structure resolution. Peak overlap was also caused
by degenerate chemical shifts due to an all
protein dynamics (see section 5.3.5)

helical protein and by broader peaks due to
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Figure 5.5. 3D 1H-13C HSQC edited NOESY of S. aureus primase CTD at 900 MHz. (A) The
2D 1H-13C plane of the 3D 13C-edited NOESY spectrum of S. aureus primase CTD shows
significant peak overlap, specifically in the H -C region (orange, note spectrum is folded add
35.804 ppm to all orange peaks for absolute chemical shift). A number of broad and intense
peaks at 15.0 ppm 13C and ~4.5 ppm 1H show severe degeneracy in chemical shifts. (B) The 2D
1
H-1H plane of the 3D 13C-edited NOESY spectrum showing significant peak overlap in the H
and H regions (1.5 ppm 1H and 1.5 ppm 1H)
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5.3.3 Comparison between the three bacterial DnaG primase CTD
structures. In E. coli, the primase CTD is composed of 7 helices with a long helix 6
connecting the C-terminus helix to the N-terminal bundle (figure 5.6 C).7

The G.

stearothermophilus structure is composed of 8 helices with the long helix 6 of E. coli
broken into two helices forming two sub-domains (C1, C2) (figure 5.6B). A flexible loop
region between helix 6 and 7 separates the two sub-domains in G. stearothermophilus.4
The structure of S. aureus primase CTD is also composed of 8 helices with two subdomains (C1, C2) separated by a flexible loop region between helix 6 and 7 (figure
5.6A). Figure 5.6 shows a side-by-side comparison for all three bacterial primase CTD
structures. The residues found in the loop region between helix 6 and 7 are highlighted
on figure 5.6.
A pairwise Dali50 structure based alignment of the three primase CTD structures
shows the S. aureus structure is similar to the G. stearothermophilus structure with a loop
region separating the two sub-domains.

The Z-scores for the pairwise structure

similarities of the three structures are S. aureus-G. stearothermophilus 8.0, S. aureus –E.
coli 6.5 and G. stearothermophilus - E. coli 5.3. The structure overlays are found in
figure 5.7. Structure similarity between the three proteins is limited the N-terminal (C1)
sub-domain. E. coli and G. stearothermophilus have the same overall fold with a
backbone rmsd of 3.2 Å observed for the alignment of the first 6 helices that form an Nterminal helical bundle (C1).4, 7 The same comparison for S. aureus to E. coli gives a
backbone rmsd of 3.4 Å and the comparison between S. aureus and G.
stearothermophilus gives a backbone rmsd of 2.8 Å.
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Figure 5.6. Three bacterial primase CTD structures. The three bacterial primase CTD
structures are reported showing the two different sub-domains and the residue responsible
for the flexible linker. (A) Solution structure of S. aureus primase CTD, (B) solution
structure of G. stearothermophilus primase CTD, and (C) solution structure of E. coli
primase CTD. In both A and B, the two sub-domains are separated by a loop region
linker. In E. coli, the loop region forms a ridged, continuous helix with a methionine
residue in the structurally similar site to S. aureus and G. stearothermophilus.
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Figure 5.7. Structure similarities between the three primase CTD structures. (A).
Comparison between S. aureus (blue) and G. sterarothermophilus (green) primase CTD
gave a Z-score of 8.0and sequence identity of 20%. (B) Comparison between S. aureus
(blue) and E. coli (red) primase CTD gave a Z-score of 6.5 and a sequence identity of
10%. (C) Comparison between G. sterarothermophilus (green) and E. coli (red) primase
CTD gave a Z-score of 5.3 and sequence identity of 14%. (D) Multiple structure
alignment of all three structures shows the conservation in the N-terminal bundle. The E.
coli structure has an extend helix 6, which is broken into two helices in the two
Firmicutes structures. The long helix 6 of E. coli is highlighted to show the primary
difference in the structures.
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As described previously, the only known structure similarity for the two
previously solved primase CTD structures is the N-terminus of the replicateive
helicases.4,

7

The S. aureus primase CTD structure is also similar to the N-terminal

domain of the replicative helicases. As with E. coli and G. stearothermophilus, the
similarity is limited to the N-terminal helical bundle (C1). A comparison of S. aureus
primase CTD with the Dali51,
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database identified the N-terminal domain of the G.

stearothermophilus helicase as having the highest similarity (Z-score of 8.4) to S. aureus
primase CTD. The remaining significant hits included the 3 previously solved primase
CTD structures (1Z8S, 1T3W, and 2HAJ) from G. stearothermophilus and E. coli
respectively. Additionally, the N-terminal domains of DnaB helicase from E. coli (1B79),
H. pylori (3GXV) T. aquaticus (2Q6T) and Bacillus phage spp1 (3BGW) were identified
as structurally similar to S. aureus primase CTD.
5.3.4 Phylum dependency of the helix 6 structure. Similar to G.
stearothermophilus, the S. aureus primase CTD structure also has a loop between helix 6
and 7. Examining the 3 non-redundant structures currently solved for the C-terminal
domain of primase suggests a phylum dependency on the helix 6 loop structure. The
difference in this helix is the primary reason the two Firmicutes structures are more
similar to each other than to the Proteobacteria primase CTD structure. In G.
stearothermophilus, the loop between helix 6 and 7 is composed of the amino acids
Asn554, Arg555, and Pro556.

Conversely, in the S. aureus structure, the loop is

composed of the amino acids Gly125, Gln126, and Glu127.

A multiple sequence

alignment suggests the helix breaking proline appears to be limited to bacillus
organisms.7 Correspondingly, the glycine that forms the loop region between helix 6 and
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7 in S. aureus appears to be limited to other Staphylococcus organisms. Thus, the loop
that forms the C1 and C2 sub-domains in the G. stearothermophilus and S. aureus
primase CTD structures appears to be phylum dependent and the sequence appears to be
species dependent.
To follow this hypothesis further, the secondary structure of primase CTD for 6
different organisms was completed using NetSurfP. 40

The NetSurfP40 accurately

predicted the secondary structure for S. aureus primase CTD (figure 5.2B), supporting its
reliable for accurately predicting secondary structures. In all three Firmicutes sequences
(G. stearothermophilus, S. aureus and B. anthracis), a loop is predicted between helix 6
and 7 that forms two independent sub-domains (figure 5.8). Interestingly, the residues
that form the loop are not highly conserved (figure 5.9). In all three Proteobacteria
sequences (E. coli, Y. pestis and P. aeruginosa), the loop is not present and a long ridged
helix 6 remains (figure 5.8). Again, the residues that make up the ridged portion of helix
6 and are structurally aligned with the loop region in the Firmicutes are not highly
conserved (figure 5.10).

My hypothesis is that primase CTD regulates binding to

helicase in a phylum dependent manner based on structure. Secondly, primase CTD
binding to DnaB helicase is sequentially regulated in a species-specific manner.
The helicase interaction with the CTD of primase is essential for primer synthesis
during DNA replication.2, 53, 54 It has been previously shown that S. aureus helicase will
only stimulate primer synthesis when incubated with the cognate primase 6 suggesting a
species-specific interaction. The observed difference in Firmicutes and Proteobacteria
primase CTD structures reported here could explain the observed species-specific results
of primer synthesis.
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Figure 5.8 Secondary structure prediction of 6 primase CTD sequences. The
secondary structures for 6 primase CTD domains were predicted using NetSurfP. 40 The
probability index ranges from 0-1 with 0 indicating a loop and 1 indicating a helix. Three
Firmicutes sequences (S. aureus Sau, G. stearothermophilus Gst, and B. anthracis Ban)
all predict 8 helices with a loop region between helix 6 and 7 based on lower probablilty
indices forming two sub-domains (C1 and C2). Three Proteobacteria sequences (E. coli
Eco, P. aeruginosa Pae and Y. pestis Ype) all show 7 helices with a ridged helix 6. The
Sau, Eco and Gst structures have all been solved confirming secondary structure
prediction.
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Figure 5.9. Multiple sequence alignment of 3 Firmicutes primase CTD sequences. A multiple sequence alignment was completed
using ClustlW for 3 Firmicutes sequences (Ban, B. anthracis, Gst, G. stearothermophilus, Sau, S. aureus). The residue found in the
loop region predicted by NetSurfP is highlighted yellow. In all 3 sequences a loop is predicted between helix 6 and 7. However, the
amino acid that forms the loop is not conserved. This suggests a structural and sequence method to regulate primer synthesis through
interaction of DnaB helicase.
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Figure 5.10. Multiple sequence alignment of 3 Proteobacteria primase CTD sequences. A multiple sequence alignment was
completed using ClustlW for 3 Proteobacteria sequences (Eco, E. coli, Ype, Y. pestis, Pae, P. aeruginosa). The residues found in
helix 6 that correspond to the residues of the loop region predicted by NetSurfP 40 are highlighted yellow. In all 3 sequences helix 6 is
predicted to be ridged. However, the amino acids that form the helix are not highly conserved. This suggests a structural and
sequence method to regulate primer synthesis through interaction of DnaB helicase.
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5.3.5 Dynamics of the primase C-terminal domain from S. aureus.

The

flexibility of the C2 sub-domain in the G. stearothermophilus structure is thought to play
an important role in the structural differences with the E. coli structure. To determine if
the same flexibility is seen in the S. aureus structure, the dynamics of the protein was
measured using NMR relaxation parameters T 1, T2 and the relative ratio of NOE
enhancement.

All T1, T2 and NOE values were measured on a per residue basis by eq

5.1 and 5.2 respectively and imported into the program FASTModel Free20 to measure
the Lapri-Szabo order parameters19 (figure 5.11 D), which show relative local motions in
the structure compared to the complete structure.
Generally, S2 values are near 1.0 for well folded and ridged structures with S 2
values below 0.8 indicative of local motion within a structure. For S. aureus primase
CTD, the overall model free analysis was very noisy with an average S 2 of 0.83 ± 0.13
for all residues except the his-tag. The large amount of noise in the S 2 data makes
identifying significant local motions within the structure challenging based on order
parameters alone. The C1 sub-domain (residues 21-124) order-parameters were nosier
than the C2 domain (residues 128-163) suggesting more flexibility within the C1 subdomain.

The increased flexibility apparently played a significant role in the lower

resolution of the S. aureus primase CTD structure due to exchange broadening and a lack
of NOE build up, reducing the total number of long range NOEs.
The raw relaxation data provides further support regarding the overall dynamics
of the structure. The average T1 relaxation rate excluding the flexible his-tag residues
was 657.7 ± 115.5 ms (figure 5.11A) and the average T2 relaxation rate was 64.2 ±17.8
ms (Figure 5.8B). The large standard deviations of the relaxation measurements appear
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to be caused by a difference in relaxation rates between the two sub-domains of the
protein. Individually each sub-domain has an average T1 of 716 ± 93.5 ms for C1 and
545.2 ± 53.4 ms for C2. The average T 2 for each sub-domain was 55.5 ±7.3 ms for C1
and 78.0 ±12.6 ms for C2. Residue 146 was excluded in these measurements because of
the increased local motion of the residues in the loop region between helix 7 and 8.
The difference in the average relaxation times for the two sub-domains and the
overall noise associated with the T1 data suggest the structure is undergoing significant
motions. Each sub-domain of the primase CTD is stable and structured as indicated by
the average relative ratios of peak intensities between a NOE enhanced and non-enhanced
spectra (figure 5.11C). For the C1 sub-domain the average ratio excluding loop regions
was 0.96 ±0.13 and the C2 sub-domain was 0.95 ±0.17.
The loop region between helix 6 and 7 (specifically G125) appears to be a pivot
point for a change in average relaxation rates. The change in relaxation rates, the lack of
distance restraints and the in ability to simultaneously overlay the two sub-domains
suggest the two sub-domains act independently of each other on a larger time scale than
the model free analysis. The residues of sub-domain C1 fit model 3, which includes both
S2 , a generalized order parameter that reflects the amplitude of internal motions and R ex,
which accounts for chemical exchange in T 2 measurements. Proteins that fit model three
generally have internal motions on the ms timescale. The observation that sub-domain C1
has a significant Rex contribution accounts for the noise in the S2 plot (figure 5.11D) and
the reduced resolution of the structure. Rex contributions are plotted in figure 5.12. The
residues of domain C2 generally fit model 1, which only contributes S 2 order parameter.
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If the two sub-domains exhibit independent motion relative to each other, this
would result in a separate total correlation times for each sub-domain and contribute to
the overall noise observed in the model free analysis. The measured correlation time (

m)

from the NMR relaxation data for the full protein is 9.8 ns. This is slightly larger than the
predicted 8.2 ns based on molecular weight of 19.6 kDa where

m

≈ MW/24000.55 The

predicted correlation time for the protein based on HYDRONMR56,

57

is 15.8 ns.

HYDRONMR uses the structure of the protein to back calculate the relaxation parameters
and predict a correlation time.

The predicted correlation time is much larger than

predicted based on molecular weight. As described in chapter 2, the molecular weight
approximation is for spherical, globular proteins. Having both measured and predicted
correlation times larger than the approximation value further suggest internal motion
between the two sub-domains (C1, C2). Each sub-domain has a predicted correlation
time using HYDRONMR56, 57 of 10.0 ns for C1 and 3.9 ns for C2. Both predictions are
longer than the predicted correlation times based on the molecular weight approximation,
5.5 ns and 1.9 ns for C1 and C2 respectively.
The dynamic nature of the primase CTD structure could play a role in helicase
binding. It was shown the loop region of G. stearothermophilus becomes more extended
upon binding DnaB helicase N-terminal domain.9 This could also be true for S. aureus
primase CTD, but further analysis will be needed to confirm this hypothesis.

The

difference in dynamics between bound and free G. stearothermophilus coupled with the
phylum specific dependency on the loop region further suggest the primase C-terminal
domain is involved in species-specific regulation of DNA replication.
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Figure 5.11. Dynamics of S. aureus primase CTD. The NMR relaxation parameters T1 (A)
and T2 (B), NOE enhancements (C) and S2 order parameters (D) are plotted per residue. The
graphs show the relative flexibility between the two sub-domains of S. aureus primase CTD. The
C2 sub-domain (residues 129-163) has different relaxation rates relative to the N-terminal bundle
suggesting dynamic motion between the two sub-domains on a longer time scale than standard
Lapri-Szabo Modelfree19 measurements ( > ps-ns).
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Figure 5.12. Contribution of Rex to dynamics of S. aureus primase CTD. The Rex term in
model free analysis contributes to chemical exchange due to ms timescale motions of the protein.
The majority of the C1 sub-domain has a large value for Rex indicating large degree of flexibility.
This increase in chemical exchange caused an increase in overall linewidth leading to large peak
overlap, which can account for the lower resolution of the structure.
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5.3.6 Identification of binding ligands to S. aureus primase CTD. A highthroughput NMR ligand affinity screen of the S. aureus primase CTD was completed to
identify potential inhibitors of the DnaG - DnaB interaction. A total of 12 compounds
(table 5.2) were shown to bind S. aureus primase CTD using the 1D 1H NMR screening
methods described in this dissertation (see chapters 3 & 4).

Two of the ligands,

acycloguanosine and mitoxantrone dihydrochloride were previously identified as
inhibitors of the DnaG - DnaB interaction in herpes simplex virus.58, 59 Additionally, the
compound myricetin was shown to inhibit the bacterial helicases with an IC 50 of 10 M.60
These three compounds were further analyzed for their binding with primase CTD from
S. aureus.
A 2D 1H-15N HSQC spectrum was collected for ligand free primase CTD and a
bound primase CTD-ligand complex for acycloguanosine, mitoxantrone, and myricetin
(figure 5.13). The buffer used for the ligand affinity screen was different from the
structural work, but did not significantly change the 2D 1H-15N HSQC spectrum depicted
in Figure 5.9A. All three compounds showed primase CTD binding based on chemical
shift perturbations in the 2D 1H-15N HSQC spectrum with the addition of the compounds.
Acycloguanosine showed the most promising specific interaction based on the magnitude
and clustering of chemical shift changes (figure 5.13C). Conversely, myricetin showed a
mix of specific and non-specific interactions (figure 5.13B) and mitoxantrone
dihydrochloride induced the formation of large molecular weight aggregates (figure
5.13D).
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Table 5.2 Ligands identified to bind S. aureus primase CTD from a high-throughput
NMR ligand affinity screen.

Binding ligand
(±)-a-Lipoamide
L-Histidine (His)
Acycloguanosine
Sodium DL-lactate
3-Aminopropionitrile fumarate salt
Sodium creatine phosphate dibasic tetrahydrate
mitoxantrone dihydrochloride
Chelerythrine chloride
5,5-Diphenylhydantoin
1-Methylimidazole
Didecyldimethylammonium bromide
(±)-Propranolol hydrochloride
Myricetin
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Figure 5.13. 2D 1H-15N HSQC ligand affinity screen for S. aureus primase CTD inhibitors.
Ligands identified from the 1D 1H NMR line-broadening screen were added to a 100 M
solution of primase CTD to a final concentration of 500 M (black free primase CTD, blue
bound primase CTD). The screening buffer had no effect on the structure or the 2D 1H-15N
HSQC spectrum (A). Myricetin showed a mix of specific and non-specific binding to primase
CTD indicated by a decrease in peak intensity (B). Acycloguanosine bound specifically to
primase CTD (C). Residues corresponding to the acycloguanosine binding site are boxed and
labeled. Mitoxantrone dihydrochloride induced large MW aggregates upon binding to primase
CTD as indicated by a complete loss of primase CTD signal (D).
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The residues in primase CTD showing the largest change upon addition of
myricetin (figure 5.13B) were GLY 16, ASP 17, ASP 19, ASP 20, PHE 21, and LEU 24.
The corresponding HSQC peaks show a decrease in signal intensity upon binding
myricetin, which suggests an exchange broadened non-specific interaction.

These

residues are primarily found in the his-tag and the extreme N-terminus of the primase
CTD structure. In addition to the decrease in intensity of the N-terminus, residues S51,
D53, D55, and F57 also showed a significant change in chemical shift as calculated by
the weighting equation (eq 5.1 see chapter 3 for discussion).
[5.3]
The change in chemical shift upon addition of myricetin to primase CTD suggests
a specific interaction between the protein and the ligand. If the ligand specifically binds
to residues 51, 53, 55, and 57, the non-specific binding of the his-tag can be explained by
a transient effect due to the mobility of the his-tag residues and the proximity of the
ligand bound to helix 51, 53, 55 and 57.
Acycloguanosine was shown to specifically and significantly interact with
primase CTD residues R32, V52, D53, F72, V85, N106, E113, N122, G125, I142, G143,
Q154, V156, E161, R161 and M163. These residues exhibited chemical shift changes
above 1 standard deviation from the average of all residues (figure 5.13C). Importantly,
no decrease in peak intensity was observed, implying a specific interaction.
Mitoxantrone dihydrochloride induced the formation of large molecular weight
aggregates upon addition to primase CTD.

This is apparent from the complete

disappearance of NMR signals in the primase CTD 2D 1H-15N HSQC spectrum,
presumably caused by molecular-weight induced peak broadening (figure 5.13D).
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5.3.7 Comparison between primase CTD ligand binding site and helicase
binding site. The chemical shift differences between free and acycloguanosine bound
primase CTD were mapped to the surface of the average water refined structure (figure
5.14A). The largest chemical shift differences were found on the last two helices of the
structure. This region has been shown to be required for primase CTD binding to the Nterminal domain of the helicase in E. coli and G. steraothermophilus.3, 9, 53, 61 As shown
by Bailey et. al, 9 both the C1 and C2 sub-domains of primase CTD interact with the Nterminus of helicase. Specifically, the binding of the C2 sub-domain to the N-terminal
domain of DnaB helicase is essential for binding the helicase and stimulating primer
synthesis, while interaction of the C1 sub-domain with helicase is essential for correct
primer synthesis.
Using

inference

through

homology,

the

binding

sites

from

the

G.

stearothermophilus structure with helicase were color coded onto the S. aureus primase
CTD structure (figure 5.14B).

The residues that undergo the largest chemical shift

change upon addition of acycloguanosine are in the same region of the helicase binding
sub-domain (C2). There are differences between the two binding sites. Particularly, the
acycloguanosine site appears to be on the opposite face of the C2 sub-domain relative to
the helicase binding sites.

However, the S. aureus helicase binding site was only

identified by inference through homology with G. stearothermophilus. The exact binding
site for S. aureus may be different enough to encompass the acycloguanosine binding
site. This point highlights the challenges of targeting a large protein-protein interaction
sites for drug development.
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Conformation of the acycloguanosine binding site and inhibitory activity can be
achieved through activity assays showing a decrease in primer synthesis, comparative
dynamic studies between free and bound primase CTD in complex with helicase, and the
full structure determination of the ligand bound primase CTD structure. These studies
are beyond the scope of this work. However, identifying a ligand that appears to bind the
C2 sub-domain of S. aureus primase CTD suggests a potential mechanism of inhibiting
primer-induced helicase activity. Acycloguanosine may be a viable lead compound for a
structure-based drug discovery since it may target the essential primase CTD C2 subdomain mediated DnaG-DnaB interaction. Pending the conformation studies, the results
described in this chapter suggest the identification of a new antibiotic drug target; the
interaction between primase CTD and helicase N-terminal domain.
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Figure 5.14. Comparison between ligand binding and helicase binding sites. (A)
The residues that illustrate the largest chemical shift difference upon addition of
acycloguanosine are colored blue on the S. aureus primase CTD NMR solution structure.
(B) The residues that interact with the N-terminal domain of DnaB helicase are colored
based on sub-domain interaction (red C2, blue C1). The helicase interactions are based
on homology transfer between the G. stearothermophilus primase CTD structure
interacting with the N-terminal domain of G. stearothermophilus DnaB helicase.9
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Appendix 5A: Sequence of the S. aureus primase C-terminal domain used in these
studies. The CTD of DnaG primase is approximately 17.2kDa protein (without his-tag,
19.6kDa with his tag). The glycine residue (G125) that is structurally similar to P543 in
the G. stearothermophilus structure is highlighted. The sequence has an additional Nterminal his-tag added for purification shown as lower case.

>S.aureus primaseCTD
mghnhnhnhn hnhnggdddd
DKDTFLNYYE SVDKDNFTNQ
ISDAVQYVNS NELRETLISL
INEKGQETIE SLNHKLREAT
ERM

FDNLSRQEKA
HFKYVFEVLH
EQYNLNDEPY
RIGDVELQKY

ERAFLKHLMR
DFYAENDQYN
ENEIDDYVNV
YLQQIVAKNK
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Appendix 5B. Relative relaxation parameters for the S. aureus primase CTD
structure. Overall, on a per residue basis the T 1 and T2 values were measured to a high
degree of accuracy using eq 5.1 and 5.2 based on the fit quality. (A) T 1 (B) T2.
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CHAPTER 6:
BACTERIAL PROTEIN STRUCTURES REVEAL PHYLUM DEPENDENT
DIVERGENCE

6.1 INTRODUCTION
As highlighted in Chapter 5, selecting the best model protein for a biological
system can be challenging if limited to sequence and structure information alone. The
differences between the primase CTD structures suggest a third constraint, evolution, for
selecting a correct model protein. Quantifiable models of protein evolution are useful for
developing robust tools to identify suitable drug-binding sites, to predict increases in
susceptibility to a human genetic disease, and to study organism niches. Some of the
strongest arguments in favor of evolution draw from studies on

protein sequence

homology.1 Multiple sequence alignments are routinely used to highlight sequence
similarity and variability between organisms and create phylogenetic relationships.2,

3

Protein evolution is a direct result from changes to the protein‟s gene sequence, which are
selected and modulated by a number of factors including structure.4, 5
What is the impact on protein structure as its sequence undergoes genetic drift?
Maintaining the correct protein fold is fundamental to preserving its function,6 but
evolving the sequence would also be expected to result in structural changes.7,

8

The

resulting paradox is that sequence determines a protein‟s structure, but the structure is
relatively invariant over a large range of sequences. This paradox is highlighted by the
tremendous difference between the number of known protein structures versus protein
folds.9 Even though the Protein Data Bank (PDB)10 contains 67,529 protein structures as
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of August, 2010, there are only 1,110 unique topologies and 1,195 unique folds in the
CATH11 and SCOP12 structure classification databases, respectively. The significant
reduction in the number of protein folds relative to the number of protein sequences
implies a strong correlation between structure and function.
While the explicit reason for the reduction in fold space remains unclear, some
have suggested that

protein fold space may be more appropriately described as a

continuum instead of a collection of discreet folds.13 In this manner, a protein fold should
be considered as being plastic, where sequence changes are accommodated by local
perturbations in the structure while maintaining the general characteristics of a particular
fold.14-16 Correspondingly, the genetic drift in a protein‟s sequence may imply a similar
gradual divergence in structure instead of a sudden dramatic transition to a new fold. If
this perspective is accurate, then a comparative analysis of homologous proteins should
identify correlated rates of structure and sequence divergence. Previous studies have
examined structure similarities between homologous proteins, but did not evaluate if
structure divergence is correlated with phylogeny.14-16 In this chapter, I expand on this
previous work by quantifying a maximum structure/sequence similarity between the two
bacterial phyla, Proteobacteria and Firmicutes. I will also discuss the viability of
phylogeny as a suitable constraint for selecting a homology model by showing certain
protein folds are more sensitive than others to changes in sequence.

6.2 EXPERIMENTAL
6.2.1 Cluster of Orthologous Groups (COG) assignment of the Protein Data
Bank (PDB). Assignment of each bacterial protein in the Protein Data Bank (PDB) to a
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COG number in the clusters of orthologous groups17 database required downloading the
complete sequence lists from both databases and running a pairwise Basic Local
Alignment Search Tool (BLAST) comparison. The pairwise protein BLAST search was
run using the Protein Mapping and Comparison Tool (PROMPT v. 0.9.2)18 that allowed
for large pairwise BLAST searching and reported the best match between the two
databases. The BLAST search was run using the BLOSUM62 matrix with a gap penalty
of 11, gap extension penalty of 1, a word size of 5, and a BLAST expectation threshold
(E-value) of 10-9. This E-value was used to unambiguously match genes in the COG
database with proteins in the PDB. All PDB-to-COG matches were reported and stored in
the PROFESS (Protein Function, Evolution, Structure, and Sequence) database
(http://cse.unl.edu/~profess/).19
After matching structures to their representative COG each PDB entry was
matched with its source organism and phylum. The data set was then filtered according to
the number of unique organisms. Specifically, only those COGs with structures from two
or more different source organisms in both Proteobacteria and Firmicutes were analyzed
further.
6.2.2 Pairwise structure comparison. The pairwise structure comparison
program DaliLite v. 2.4.220 was installed on our 16-node Dual Athlon AMD 2.13 GHz
with 1 GB of RAM Beowulf cluster running CentrOS 4.4 Linux with a 2.25 TB RAID
array. A C-shell script matches the PDB files from each Proteobacteria-Proteobacteria
comparison (-/-), Firmicutes-Firmicutes comparison (+/+) and Proteobacteria-Firmicutes
comparison (-/+) and then submits the job to the program DaliLite. Each structural
comparison took approximately 2-10 min, depending on the size and relative similarity of
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structures. The total time to run all 63,504 comparisons was approximately 7 weeks.
The shell script extracts all structural comparison information reported by
DaliLite (comparison files, rmsd, %Sequence ID, Z-score) on a per chain basis. A single
PDB file may contain multiple protein chains, where each chain may have a separate
COG assignment. All structure information is stored in the PROFESS database, which is
parsed to find the largest Z-score for each pairwise structure comparison. The largest Zscore represents the best structure comparison for a pair of proteins and ensures the
correct PDB chains were used for the analysis and the correct COG assignments were
made. All best matches from each COG were used to calculate the Fractional Structure
Similarity score (FSS) described by eq 6.1.

,

[6.1]

where ZAB was the Z-score for comparing proteins A and B, Z AA was the Z-score
when protein A was compared to itself and ZBB was the Z-score when protein B was
compared to itself. Thus, ZAA and ZBB represent the Z-score that can be achieved for
perfect similarity.
6.2.3 Manual filtering and data analysis. Manual refinement of the dataset
included verification of each PDB assignment to a COG and filtering out redundantly
solved structures from the same organism. When multiple structures were reported from
the same organism (or organism with synonymous name), the structure that gave the
largest Dali Z-score within the COG was kept while remaining structures were discarded
from the analysis. This confirmed a single best PDB-to-COG match for each organism.
Manual refinement was accomplished by opening all PDB IDs within a COG and
checking biological information against the PDB (http://www.rcsb.org/pdb/home), COG
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(http://www.ncbi.nlm.nih.gov/COG/) and the NCBI (http://www.ncbi.nlm.nih.gov/) web
servers. Consistency in functional and structural assignment within a COG coupled with
very low E-values between COG and PDB confirmed the best PDB-to-COG match was
made. Additionally, manual refinement was used to verify uniform sample conditions
(i.e., the same ligand bound to all proteins within a COG or all proteins correspond to
wild-type sequences) for cases of redundantly solved structures.
6.2.4 Structure based phylogenetic trees. In addition to pairwise alignment, all
the protein structures from each COG were simultaneously aligned using the multiple
structure

alignment

program

MAMMOTH-multi

(http://ub.cbm.uam.es/mammoth/mult/).21 The resulting aligned structures and the
structure-based sequence alignment was used with in-house software to calculate an allversus-all matrix of per-residue C

distances. Standard boot-strapping techniques were

then applied to the all-versus-all matrix of per-residue C

distances to generate 100

distance-matrix tables. Columns of structure-based sequence alignments with the
corresponding C distances were randomly selected until the total number of columns in
the original sequence alignment was reached. The resulting set of C distances were then
used to calculate a root mean square deviation (rmsd) between each pair of structures in
the matrix. The 100 distance-matrix tables were imported into PHYLIP 3.6822 to generate
a consensus phylogenetic tree and bootstrap confidence levels.
Each set of 100 bootstrapped distance matrices were analyzed by the FitchMargoliash method implemented in PHYLIP. Each matrix was jumbled with 100
replicates using 37 as the random number generator seed. This resulted in 10000 unique
and random distance matrices for each COG. The best tree was identified with the
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program Consense implemented in PHYLIP using the extended majority rule
conservation. Since the bootstrapped trees do not show distance relationship, the original
distance matrix generated by MAMMOTH-multi was used to generate a distance based
phylogenetic tree. Each original distance matrix was jumbled with 100 replicates using
37 as the random number seed. The distance based phylogenetic tree was drawn using the
program Drawtree implemented in PHYLIP.
Representative distance based phylogenetic trees are shown in (figure 6.4). Each
tree was visually inspected and compared with the DaliLite analysis using the bootstrap
values to determine if a tree fit the split, starburst, or split +1. A “split” means the
Firmicutes and Proteobacteria proteins were strongly separated from one another,
“Starburst” means there was little to no evidence for a split according to phyla, and “Split
+1” means there was strong evidence for a split according to phyla with the exception of
one protein
6.2.5 Measuring functional similarity within a COG. Each protein in our
dataset was annotated with the corresponding Gene Ontology23 identification number(s)
found in the PDB. By definition, a strong consensus requires each protein to share the
same set of GO terms. Instead, a weak consensus set of GO terms was generated for each
COG, where only a majority of proteins are required to share the same GO term. A
distance was measured between the weak consensus set and the set of GO terms assigned
to each individual protein. An average, normalized distance is reported for each COG,
where a score of 1 indicates an identical functional classification and a score of 0
indicates a lack of functional similarity. The distance between each protein‟s GO terms
and the consensus GO term set was measured as follows:
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[6.2]
where GOsim is the normalized GO functional similarity score, WC denotes the weak
consensus set of GO terms for the COG, and GO i denotes the set of GO terms set for each
protein in the COG.

6.3 RESULTS
6.3.1 Creating the COG structure families. Current functional annotation tools
available in the PDB include the Gene Ontology (GO)23 and Enzyme Classification
(EC).24 Unfortunately, due to potential for convergence of function, these annotation
tools are not useful for the study of homologous structures. To accurately observe phylum
dependent structure divergence of proteins, it is important to construct a dataset of
functionally similar orthologs. Among the 20 resources for structural classification of
proteins, the clusters of orthologous groups (COGs) scheme is the only one that attempts
to identify orthology25 while providing moderate functional information. Therefore, each
sequence and structure in the PDB was annotated with one COG number. Additionally,
each protein was annotated with GO numbers and the relative functional similarity for
each COG was measured (table 6.1).
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Table 6.1. COG structure families. aCOG Structure Families have two or more
represented structures from among the Firmicutes and two or more from among the
Proteobacteria. bFunctonal similarities are measured by overlapping consensus GO terms
(eq 6.2) c“Split” means the Firmicutes and Proteobacteria proteins were strongly
separated from one another, “Starburst” means there was little to no evidence for a split
according to phyla, and “Split +1” means there was strong evidence for a split according
to phyla with the exception of one protein. The relative functional similarity of a COG is
reported by measuring an average distance between a weak consensus set of Gene
Ontology (GO) annotations and the set of all GO annotations for each protein within a
COG. Perfect functional similarity is reported as a 1, while no similarity is reported as a
0. See appendix 6B for a list of the PDB files associated with each COG. *No CATH
value available for reported structures, CATH values were predicted using a sequence
based search in the CATH database where the best match is reported.
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COG
28

a

39
394
604

605
742
813
1012
1075

1607
1940
2124
2188
446
1057
242
1052
2141

COG Function Annotation
Thiamine pyrophosphate requiring
enzymes
Malate/lactate dehydrogenases
Protein-tyrosine-phosphatase
NADPH:quinone reductase and
related Zn-dependent
oxidoreductases
Superoxide dismutase
N6-adenine-specific methylase
Purine-nucleoside phosphorylase
NAD-dependent aldehyde
dehydrogenases
Predicted acetyltransferases and
hydrolases with the alpha/beta
hydrolase fold
Acyl-CoA hydrolase
Transcriptional regulator/sugar
kinase
Cytochrome P450
Transcriptional regulators
Uncharacterized NAD (FAD) dependent dehydrogenases
Nicotinic acid mononucleotide
adenylyltransferase
N-formylmethionyl-tRNA
deformylase
Lactate dehydrogenase and related
dehydrogenases
Coenzyme F420-dependent
N5,N10-methylene
tetrahydromethanopterin

COG Function
Similarityb
0.59

Phylogenetic
Structure Treec
Split

CATH
3.40.50.970

0.8
0.61
0.88

Split
Split
Split

3.40.50.720
3.40.50.270
3.40.50.720

0.76
0.73
0.87
0.58

Split
Split
Split
Split

3.20.20.80*
3.40.50.150*
3.40.50.1580
3.40.309.10

0.7

Split

3.40.50.1820

0.87
0.31

Split
Split

3.40.0.1820*
3.30.420.40

0.8
0.89
0.85

Split
Split
Split

1.10.630.10
3.40.1410.10
3.30.390.30

0.95

Split

3.40.50.620

0.87

Split +1

3.90.45.10

0.89

Split +1

3.40.50.720

0.76

Split +1

3.20.20.30
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224

3832
110
171
251
346
366
454
491
500
526
590
637
664
745

753
778
784
796
1028

reductase and related flavindependent oxidoreductases
Uncharacterized conserved
protein
Acetyltransferase (isoleucine
patch superfamily)
NAD synthase
Putative translation initiation
inhibitor, yjgF family
Lactoylglutathione lyase and
related lyases
Glycosidases
Histone acetyltransferase HPA2
and related acetyltransferases
Zn-dependent hydrolases,
including glyoxylases
SAM-dependent
methyltransferases
Thiol-disulfide isomerase and
thioredoxins
Cytosine/adenosine deaminases
Predicted
phosphatase/phosphohexomutase
cAMP-binding proteins
Response regulators consisting of
a CheY-like receiver domain and
a winged-helix DNA-binding
domain
Catalase
Nitroreductase
FOG: CheY-like receiver
Glutamate racemase
Dehydrogenases with different

1

Split +1

3.30.530.20

0.56

Starburst

2.160.10.10

0.85
0

Starburst
Starburst

3.40.50.620
3.30.1330.40

0.11

Starburst

3.10.180.10

0.51
0.83

Starburst
Starburst

2.60.40.1180
3.40.630.30

0.5

Starburst

3.60.15.10

0.59

Starburst

3.40.50.150

0.96

Starburst

3.40.30.10

0.7
0.52

Starburst
Starburst

3.40.140.10
1.10.164.10

0.5
0.73

Starburst
Starburst

1.10.10.10
3.40.50.2300

0.93
0.64
0.48
0.92
0.84

Starburst
Starburst
Starburst
Starburst
Starburst

3.30.63.10*
3.40.109.10
3.40.50.2300
3.40.50.1860
3.40.50.720
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225

1151
1309
1396
1404
1733
1846
2159
2367
2730
3693
4948

specificities (related to shortchain alcohol dehydrogenases)
6Fe-6S prismane clustercontaining protein
Transcriptional regulator
Predicted transcriptional
regulators
Subtilisin-like serine proteases
Predicted transcriptional
regulators
Transcriptional regulators
Predicted metal-dependent
hydrolase of the TIM-barrel fold
Beta-lactamase class A
Endoglucanase
Beta-1,4-xylanase
L-alanine-DL-glutamate
epimerase and related enzymes of
enolase superfamily

0.71

Starburst

1.20.1270.30

0.8
0.54

Starburst
Starburst

1.10.357.10
1.10.260.40

0.6
1

Starburst
Starburst

3.40.50.200
1.10.510.10*

0.85
0.83

Starburst
Starburst

1.10.10.10
3.20.20.140*

0.93
0.88
0.89
0.71

Starburst
Starburst
Starburst
Starburst

3.40.710.10
3.20.20.80
3.20.20.80
3.20.20.120
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The development of the PROFESS (PROtein Function, Evolution Sequence and
Structure) database (http://cse.unl.edu~profess)19 contains all PDB-to-COG annotations
along with other biologically relevant information. This includes associating each
structure with its phyla classification, which allowed for the structures from Firmicutes
and Proteobacteria to be easily selected for further analysis.
The most recent COG database was created by finding the genome-specific besthit for each gene in 66 unicellular genomes (50 bacteria, 13 archaea, and 3 eukaryota).
Specifically, the orthologs present in three or more genomes were detected automatically
and then multidomain proteins were manually split into component domains to eliminate
artifactual lumping. The online COG database contains 192,987 sequences distributed
among 4,876 COGs, accounting for 75% of genes in these 66 genomes.
At the time of our COG-to-PDB annotation, the PDB included 45,368 protein
structures (August 2008), although many of them were composed of multiple subunits
(and therefore associated with an even larger number of sequences). The two bestrepresented bacterial phyla, which accounts for nearly one-fourth of all structures in the
PDB, were selected for annotation. The PDB contains 8,298 Proteobacteria protein
structures and 3,416 Firmicutes structures. The sequences for each of these structures
were compared to the COG reference sequences using the Basic Local Alignment Search
Tool (BLAST).26 The initial match between the COG and PDB databases was completed
with an expectation cut-off of 1x10-9 to maximize the likelihood of matching each PDB
with its correct COG. The BLAST similarity matching was required for two reasons, first
the PDB did not list gene names and secondly to capture structures from organisms that
were not present in the COG database. The BLAST comparison matched 82% of the
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Firmicutes and Proteobacteria sequences to specific COGs, resulting in functional
assignments for 2,728 Firmicutes structures and 6,881 Proteobacteria structures. Of
these hits, 27% were 100% identical to the COG reference sequence and 97% matched
with greater than 50% sequence identity. To carry out our comparative study, we selected
only those COGs that contained a minimum of two Firmicutes organisms and two
Proteobacteria organisms. This requirement gave 281 unique COGs with a total of 3,047
bacterial proteins (1,066 Firmicutes and 1,981 Proteobacteria).
6.3.2 Pairwise structure similarity. The pairwise structure comparison tool
DaliLite20 was used to perform 63,504 pairwise comparisons between all of the proteins
in our dataset. In total, the backbone structure similarity corresponded to 31,542
Proteobacteria-Proteobacteria

comparisons

(-/-),

12,674

Firmicutes-Firmicutes

comparisons (+/+), and 19,288 Proteobacteria-Firmicutes comparisons (-/+). All
comparisons were manually filtered within their respective COG to remove all but one
redundantly solved structure (the largest contributor to the size of the dataset), multiple or
non-functionally relevant conformations (mutant protein, non-native experimental
conditions, inhibited ligand complex), and the shorter of two protein structures. The final
dataset contained 48 COGs (table 6.1) with a total of 1,713 structural comparisons with
147 Firmicutes proteins from 58 unique organisms and 176 Proteobacteria proteins from
84 unique organisms (see appendix 6A for complete list of proteins used in this study).
After manual analysis the resulting dataset was predominantly populated with
very low E-values further supporting correct annotation of a structure to the correct COG.
The distribution of E-values is reported in figure 6.1. The histogram shows only 3 PDBto-COG matches with the minimum E-value cutoff, with the majority of the PDB-to-

228
COG matches falling below 1.0E-40.

The median E-value for each COG is reported in

appendix 6B with a range between 4E-16 and 0.

Where an E-value of 0 indicates all

structures within a COG were perfectly matched.

Figure 6.1. Distribution of E-values within manually filtered dataset. A set of Evalues at each division consisted of the total number of PDB-to-COG matches between
the upper and lower bounds. An E-value of 1x10-9 approximately relates to a standard
significance P-value of 1x10-9.
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The resulting Dali Z-scores from the pairwise structure comparisons were plotted
against sequence identity (figure 6.2) to reveal a saturating relationship as the percent
identity rose to 100%. The lowest observed Z-score was 5.7 with a corresponding 16%
sequence identity. This Z-score was still above the minimum cutoff of 2.0 (dashed line)
for matches that were two standard deviations above a random match. This lowest Zscore came from the comparison of two Firmicutes proteins in COG0346
(lactoylglutathione lyase and related lyases): 2QH0 (Clostridium acetobutylicum); and
2QQZ (Bacillus anthracis). The average Z-score for all comparisons was 27 ± 13,
indicating that all structural comparisons were significant.
Since Z-scores increase as a function of the protein length, we normalized this
effect by calculating the Fractional Structure Similarity (FSS) score as described in eq
6.1. The pairwise FSS scores plotted against sequence identity (figure 6.3) resulted in a
hyperbolic curve. All FSS values fell below an upper-limit at each percent identity. In
fact, 20% sequence identity yielded a maximal FSS of 60%. This FSS limit was observed
when all of the data were used (figure 6.3A), when only the pairwise comparisons within
either phyla were used (figure 6.3B and C), or when only the pairwise comparisons
between the two phyla were used (figure 6.3D). The pairwise comparison plot between
the two phyla (figure 6.3D) showed an abrupt cutoff at 61% sequence identity and a 0.84
FSS score. This abrupt cutoff was not an artifact created by culling the dataset, since a
similar plot prior to the manual filtering also demonstrated the same effect (appendix 6C).
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Figure 6.2. The relationship between structure similarity and sequence identity for 48
COGs. Structure similarity is given as the raw Z-score, which increases as the protein length
increases. The comparisons were for all proteins against all proteins, and include the comparison
for each protein against itself. The dashed line identifies a Dali Z-score of 2, which is the
minimal limit for inferring structural similarity.
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Figure 6.3. The fractional structure similarity (FSS) and sequence identity for 48
COGs. FSS was calculated using eq 6.1 to normalize the Dali Z-scores for their different
sizes. The FSS values were plotted against sequence identity for (A) all the pairwise
comparisons, (B) only Proteobacteria-Proteobacteria comparisons, (C) only FirmicutesFirmicutes comparisons and (D) only Proteobacteria-Firmicutes comparisons.
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The protein structures in COG0028 (thiamine pyrophosphate requiring enzymes)
provides a useful example of the structural divergence that occurred after the Firmicutes
and Proteobacteria phyla split. The overall fold is conserved between the phyla while
there are discrete structural elements that are unique to each phylum. The two Firmicutes
structures (figure 6.4A) yield a Z score of 59.6 and an FSS of 0.83, indicating very high
structural conservation. The structure comparison between the 4 representative
Proteobacteria structures (figure 6.4B) yield an average Z-score of 37.7 ± 1.6 and an
average FSS of 0.58 ± 0.03. Again, the structures share a similar fold despite the slightly
lower scores.
Comparison of the structures between the Firmicutes and Proteobacteria (figure
6.4C and D, respectively) phyla yield a lower Z-score of 34.8 ± 1.2 and a lower FSS of
0.49 ± 0.02 then the comparisons within each phylum. This suggests a divergence in
structural details while conserving the overall fold. A detailed analysis reveals localized
differences between the structures from the two phyla (see red highlights in figure 6.4C
and D). In the Firmicutes representative structure, there is a continuous helix compared to
helical breaks and loop insertions in the Proteobacteria structure. This is similar to the Cterminal domain of primase, where a long continuous helix found in the E. coli structure
is broken by a loop region in G. stearothermophilus27-30 and S. aureus (chapter 5).
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Figure 6.4. Comparison of protein structures for COG0028 between two bacterial
phyla. The protein structures for COG0028 thiamine pyrophosphsate requiring enzymes
show (A) the two Firmicutes structures have highly overlapping structures and (B) the
four Proteobacteria structures are very similar to each another. See also the phylogenetic
structure tree for COG0028 in (figure 6.5). On the other hand, the major structural
differences between the Firmicutes and Proteobacteria are highlighted in red on a
representative Firmicutes (C) structure from L. plantarum (Lpl) (PDB ID: 1POW) and
the representative Proteobacteria structure (D) from P. fluorescens (Pfl) (PDB ID:
2AG0).
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6.3.3 COG structure phylogenies. Structure based phylogenies were created
from root-mean square differences (rmsd) in per residue C

positions for optimally

aligned protein structures using MAMMOTH-multi.21 A separate phylogenetic tree was
generated for each COG, where three distinct patterns were observed (table 6.1): 15
exhibited a strong split at the phylum level, 29 exhibited a starburst pattern suggesting
little to no evidence for a split according to phyla, and 4 exhibited a strong split at the
phylum level but with the exception of a single structure (split +1).
The 15 COG phylogenies with strong phylum-splitting patterns had two branches,
one with closely related Firmicutes structures and the other with closely related
Proteobacteria structures. Two examples are COG0028 (Thiamine pyrophosphate
requiring

enzymes)

and

COG0446

(Uncharacterized

NAD(FAD)-dependent

dehydrogenases) (figure 6.5). The structures for both of these COGs are classified in the
CATH system as

3-layer sandwiches, but differ in that COG0028 proteins have a

Rossmann fold topology (figure 6.4) and COG0046 proteins have a FAD/NAD (P)binding domain topology.
The 29 COGs with phylogenetic starburst patterns showed no evidence for the
separation of structures according to phyla (table 6.1). Two examples were COG0491
(Zn-dependent hydrolases) and COG1309 (Transcriptional regulator) (figure 6.5). The
CATH classification for COG0491 Bacillus cereus Zinc-dependent beta-lactamase (PDB
ID: 1BC2)

31

describes it as an

4-layer sandwich with metallo-beta-lactamase Chain

A topology. The large category of beta-lactamases constitutes a collection of enzymes
that can be derived from any one of a group of proteins that bind, synthesize, or degrade
peptidoglycans. The protein structures assigned to COG0491 gave FSS scores with large
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standard deviations, as is evident from the separated clusters within the Proteobacteria
arm of the phylogenetic tree.
The COG1309 structural family falls into one of two CATH topologies, Arc
Repressor Mutant (subunit A) or Tetracycline Repressor (domain 2). Only those
structures similar to the Arc Repressor Mutant (subunit A) topology were used for the
pairwise comparison, since it was the dominant fold in this COG. The protein structures
in the COG1309 structure family gave low FSS scores. However, even with low overall
FSS the average absolute Z-score was 13 ± 2 indicating that it has significant overall
structure similarity. The high FSS deviations of COG0491 structural family and the low
average FSS scores of COG1309 structural family both indicate rapid structural
divergence following the phyla split, consistent with the observed starburst phylogenetic
patterns.
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Figure 6.5. Protein structure based phylogenetic trees highlighting the split and
starburst patterns. The phylogenetic structure trees showed three different patterns:
(top) strong split according to phyla; (bottom) starburst with no clear relationship to a
common ancestor; and (figure 6.6) strong splits with the exception of one outlier. The
Firmicutes protein structures are in blue and the Proteobacteria in black. The bootstrap
values from 100 bootstrap replicates are indicated on branches and represent how often a
branch appeared in the distance matrix. The two examples for the split pattern were from
COG0028 (thiamine pyrophosphate requiring enzymes) and COG0446 (uncharacterized
NAD(FAD)-dependent dehydrogenases). In the case of a strong split, the central
branches were observed more than 95 times out of 100 replicate trials. The two examples
for starburst pattern were from COG0491 (Zn-dependent hydrolases) and COG1309
(transcriptional regulator). For starburst patterns, very few branches were observed in
more than two-thirds of the 100 replicate trials. The organism abbreviations are: A.
hydrophila (Ahy) ; A. tumefaciens (Atu); A. viridians (Avi) ; B. cereus (Bce) ; B.
japonicum (Bja); B. subtilis (Bsu) ; B. thuriagienes (Bth); E. carotovora (Eca); E. coli
(Eco); E. faecalis (Efa); F. gormanii (Fgo); K. pneumonia (Kpn); L. lactis (Lla); L.
sanfranciscens (Lsa); L. plantarum (Lpl); O. formigens (Ofo) ; P. aeruginosa (Pae); P.
fluorescens (Pfl); P. pantotrophus (Ppa); P. putida (Ppu); P. species (Psp); S. aureus
(Sau); S. marcescens (Sma); S. typhimurium (Sty); and X. maltophilia (Xma).
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Four COG structure phylogenies showed a strong split pattern with a single
outlier (figure 6.6). This result provides further evidence for the observation of phyla split
based on structure similarity. The presence of the outlier in a clear split pattern suggests a
horizontally transferred gene (table 6.1) or potential paralog. For all four families
[COG0242 (N-formylmethionyl-tRNA deformylase) COG1052 (Lactate dehydrogenase
and related dehydrogenases), COG2141 (Coenzyme F420-dependent N5,N10-methylene
tetrahydromethanopterin reductase and related flavin-dependent oxidoreductases), and
COG3832 (Uncharacterized conserved protein)] there was a large and significant average
absolute Z-score for all comparisons along with strong BLAST E-values indicating the
correct match was made between COG and PDB. For COG0242, the Bacillus cereus
gene def that encodes the N-formylmethionyl-tRNA deformylase protein (PDB ID:
1WS0) has been previously identified as a gene that has undergone horizontal gene
transfer.32
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Figure 6.6. Protein structure based phylogenetic trees highlighting the split +1
pattern. Protein structure phylogenies of 4 COGs out of 48 had a strong split pattern
with the exception of one outlier structure. The phylogenies were very reliable because
the central branches were observed in 100 out of 100 replicate trials. When one
Firmicutes or Proteobacteria protein structure clusters on a branch with the other
phylum, its structure diverges from its closest relatives while resembling those of the
other phyla. The COGs that fit this pattern are from COG0242 (N-formylmethionyltRNA deformylase), COG1052 (lactate dehydrogenase and related dehydrogenases),
COG2141 (coenzyme F420-dependent N5, N10-methylene tetrahydromethanopterin
reductase and related flavin-dependent oxidoreductases), and COG3832 (uncharacterized
conserved protein). The organism abbreviations are: A. fermentans (Afe); A. tumefaciens
(Atu); B. cereus (Bce); B. halodurans (Bha); B. stearothermophilus (Bst); B. subtilis
(Bsu); C. violaceum (Cvi); E. coli (Eco); E. faecalis (Efa); H. methylovorum (Hme); H.
pylori (Hpy); L. delbrueckii (Lde); L. helveticus (Lhe); M. species (Msp); N. europaea
(Neu); P. aeruginosa (Pae) ; P. species (Psp), S. aureus (Sau); S. pneumoniae (Spn); and
V. harveyi (Vha).
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6.3.4 Structure divergence rates across phyla. As a way to quantify the
relationship between structure difference and sequence difference, each phylogenetic tree
was reduced to a single coordinate by calculating a structure similarity ratio (
sequence identity ratio (

SeqID).

FSS

FSS

and a

was determined for all 48 COGs by calculating an

average FSS score for the Proteobacteria-Firmicutes structure comparisons, Avg(FSS+/-),
and dividing by the sum of the average Proteobacteria-Proteobacteria, Avg(FSS-/-), and
Firmicutes-Firmicutes, Avg(FSS+/+), comparisons:
[6.3]
Similarly, a sequence identity ratio (

SeqID)

was determined by calculating an

average sequence identity for the Proteobacteria-Firmicutes structure comparisons,
Avg(SeqID+/-), and dividing by the sum of the average Proteobacteria-Proteobacteria,
Avg(SeqID-/-), and Firmicutes-Firmicutes, Avg(SeqID+/+), comparisons:
[6.4]
In general, most starburst phylogenies (see representative COG0491 and
COG1309 in (figure 6.5) had a branch length between members of different phyla that
was much shorter than the branch lengths between members within the same phyla. That
is, a starburst phylogeny was expected to have

FSS

and

SeqID

values greater than unity.

Likewise, most split phylogenies had longer branches between phyla than within each
phyla (see representative COG0028 and COG0446 in (figure 6.5) and were expected to
yield

FSS

When

SeqID

FSS

of less than unity.

and

SeqID

for all 48 COGs were plotted versus one another (figure

6.7), the starburst phylogenies clustered around unity for both structure and sequence
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whereas the split phylogenies clustered around 0.85 for structure and 0.70 for sequence.
This indicated that split phylogenies occur when the structure differences are
significantly less than their sequence differences. In addition, the plot of

FSS

versus

SeqID

conformed to a linear relationship regardless of the shape of the phylogenetic tree
indicating that all homologous protein structure differences are constant with respect to
homologous protein sequence differences (

FSS

= 0.55

SeqID

+ 0.45; R2 = 0.7). Thus, this

curve represents the relative structural drift rate for each COG structural family between
the two phyla. The slope indicates that structure branch lengths change approximately
half as fast as sequence branch lengths.

Figure 6.7. Constant rate of structural drift. The relationship between structure and
sequence change was constant regardless of the phylogenetic starburst (x) or split (■)
pattern. Structure changes measured using a structure similarity ratio ( FSS), where the
average FSS between members of the two phyla (Firmicutes versus Proteobacteria) was
divided by the average FSS between members of the same phyla (see eq 6.3). Sequence
change was calculated similarly (see eq 6.4). The best-fit line, FSS=0.55 SeqID + 0.45,
yielded an R2 of 0.70.
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6.3.5 Fold dependency on structure similarity. A plot of FSS vs. sequence
identity for the two most populated CATH families in our dataset (figure 6.8) was used to
investigate if particular protein architectures are more amenable to structural changes.
The largest portion of our data set, 24 of 48 COGs (50%), is represented by CATH 3.40
(

, 3-layer (

) sandwich). Within CATH 3.40, 12 of 24 COGs (50%) are

represented by the starburst phylogenetic tree pattern. The remaining 12 COGs
correspond to 11 splits and 1 split +1 phylogenetic tree patterns.

Figure 6.8. Fold dependency on fractional structure similarity (FSS) and sequence
comparisons. The FSS between two CATH families, CATH 1.10 (●) CATH 3.40 (◊).
CATH 1.10 (mainly , orthogonal bundle) family is apparently limited to approximately
40% sequence identity and 0.6 FSS while CATH 3.40 ( , 3-Layer (
) sandwich)
fills in the complete curve. 87.5% of the COGs (7 of 8) represented by CATH 1.10 give a
starburst structure similarity tree. Contrastingly, only 50% (12 of 24) of the COGs
represented by CATH 3.40 give a starburst structure similarity tree. The remaining 12
COGs formed either split (11 of 12) or split +1 (1 of 12).
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The second most populous CATH family is CATH 1.10 (mainly

, orthogonal

bundle) with 15% of our COGs belonging to this CATH family. Most (85.7%) of the
COGs (6 of 7) in the CATH 1.10 family are represented by the starburst phylogenetic tree
pattern with only 1 COG represented by a split pattern. There appears to be a limit in
structure similarity at approximately 0.6 FSS and a corresponding sequence identity limit
at 40% for CATH 1.10 (figure 6.8, solid circles). This limit is not observed in the CATH
3.40 family (figure 6.8, open diamonds). The sequence and structure similarity limit for
CATH 1.10 combined with a larger percentage of COGs assigned to the starburst family
suggests that CATH 1.10 is more susceptible to mutations that affect the protein
structure. The results suggest a faster evolutionary rate leading to a higher structural
divergence relative to other CATH architectures.

6.4 DISCUSSION
There is an inherent challenge in obtaining an accurate functional annotation for a
large set of proteins from a relatively small number of experimentally determined
functions.33-37 The available functional information is incomplete, ambiguous and errorprone38, 39 and requires multiple sources35 to improve the accuracy in the annotation of a
protein. There is also the complicating factor of correctly distinguishing between
orthologs and paralogs, where it has been previously noted the COG database does
include some paralog members17, 40. Thus, the accuracy of this analysis is fundamentally
dependent on a reliable functional assignment for each protein structure. Given these
challenges, the independent and separate utilization of both COG and GO terms provides
a reasonable and robust approach to identify clusters of functionally similar proteins. The
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overall high sequence (E-value ≤ 10-9, sequence identity ≥ 16%), structure (Z-score > 5.7)
and GO term similarity (0.72 ± 0.21) within each COG supports this conclusion. The lack
of identity for the GO term similarity scores should not be interpreted as evidence for
functional divergence. GO terms are assigned based on a validated source. So, a missing
GO term for a protein is more likely attributed to the fact the protein has not been
explicitly tested for the specified activity. Similarly, a protein being assigned a GO term
does not provide definitive evidence the function is relevant in vivo.41-44
The comparison of homologous protein structures with the same function
provides quantitative evidence that protein structures diverged following the speciation
events that created the modern bacterial phyla of Firmicutes and Proteobacteria. The
abrupt cutoff at 61% sequence identity and 0.84 fractional structure similarity observed
between Firmicutes and Proteobacteria proteins was mirrored by an approximate 60%
protein sequence identity between these two phyla observed by 16S rRNA sequence
similarity.45,

46

Thus, this maximum observed sequence identity imparts limits to the

maximum possible structure similarity between homologus proteins from these two
phyla. This is consistent with prior observations that sequence identity ≤ 40-50%
sometimes results in significant structural and functional differences.7, 8, 47 Furthermore,
the results imply an inherent allowable structural plasticity that does not perturb function.
The random drift after speciation inexorably leads to non-identical structures despite
maintenance of function. There are a number of cases where FSS was below 0.20
indicating a significant structural change. Proteins with completely different folds but the
same function are extreme examples of the plasticity of the structure-function
relationship and include such proteins as peptidyl-tRNA hydrolases (COG1990),48
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pantothenate kinase (KOG2201).49 polypeptide release factors

50

and lysyl-tRNA

synthetases (COG1190),51 these proteins are not in our dataset.
Forty percent of the COGs we examined have evolved slowly enough that it was
possible to generate phylogenetic trees consistent with this ancient split. The other COGs
have either evolved too rapidly or are otherwise subject to few evolutionary constraints to
provide evidence for this split. This distinction between the COGs is clearly apparent
from the comparison of

FSS

and

SeqID

in (figure 6.7). The linear relationship implies a

fixed relative structure drift rate, where structure changes half as fast as sequence across
phyla. This correlation in the divergence of protein sequences and protein structures has
additional ramifications beyond bacterial evolution. Our analysis implies a continuum of
protein folds that adapt to large sequence changes by incurring local structural
modifications.13-16 This continuum of protein folds makes it challenging to apply protein
structural classification to identify function, as has been previously noted.52, 53
Does the nature of the protein‟s three-dimensional structure play a role in protein
structure divergence? Our analysis demonstrates that some proteins evolve slowly and
maintain high sequence identity (>80%) and structure similarity (> 0.80 FSS) while other
proteins exhibit rapid evolution rates where sequence identity is ≤ 20% and FSS ≤ 0.40.
This implies the underlying architecture of a particular protein may be more or less
amenable to amino-acid substitutions in order to maintain functional activity. A specific
protein fold may have a higher intrinsic plasticity that enables it to readily accommodate
sequence changes through local conformational changes without a detrimental impact on
activity. This is exactly what was observed, structural variations were localized to
specific regions as illustrated by the comparison of the COG0028 protein structures see
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(figure 6.4). This is consistent with the observation of different structure divergence rates
within a protein.54,

55

Regions of the protein that do not impact biological activity are

expected to yield a higher divergence rate and incur larger local structural changes.56, 57
As a result, a fold with a relatively high plasticity would experience an elevated structural
diversity between phyla, where the rate of change may closely parallel the mutation
rate.14 Conversely, another fold may be extremely sensitive to amino-acid substitutions,
where minor sequence perturbations may result in a decrease in structural integrity and a
corresponding loss of activity. As a result, the sequence and structure of this protein class
would be relatively conserved. This analysis is consistent with the known range of
protein thermodynamic stabilities,58 and the general observation that most mutations
destabilize protein structures.59
This chapter illustrates the inherent value in solving structures for functionally
identical proteins from multiple organisms. A major challenge in creating our COG-toPDB dataset was the fundamental requirement to have structures from at least two
Firmicutes organisms and two Proteobacteria organisms. Only 48 (~1%) of the 4,876
COGs meet this stringent requirement. The limited number of multiple homologous
structures has partly occurred because structural biology efforts are focused on obtaining
single representative structures for each functional class or protein fold 60

and

understandably biased toward therapeutically relevant proteins.61 If we are to achieve a
more accurate understanding of the relationship between the evolution of protein fold,
protein sequence, and the organisms in which they function, the fields of bioinformatics
and structural biology must expand their focus to include efforts to obtain a more diverse
set of homologous protein structures.
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Appendix 6A. A table of all manually curated proteins used in chapter 6 with their
associated COG annotation, phylogenetic pattern, phylum classification and source
organism.

Split
COG PDB
28 2JI7
28 2AG0
28 1YNO
28 1OZF
28 1V5E
28 1POW

Phylum
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

Source
OXALOBACTER FORMIGENES
PSEUDOMONAS FLUORESCENS
PSEUDOMONAS PUTIDA
KLEBSIELLA PNEUMONIAE
AEROCOCCUS VIRIDANS
LACTOBACILLUS PLANTARUM

39
39
39
39
39

2PWZ
1B8P
1Y6J
1LDN
1EZ4

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes

ESCHERICHIA COLI
AQUASPIRILLUM ARCTICUM
CLOSTRIDIUM THERMOCELLUM
BACILLUS STEAROTHERMOPHILUS
LACTOBACILLUS PENTOSUS

394
394
394
394

2GI4
2FEK
1LJL
1JL3

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

CAMPYLOBACTER JEJUNI
ESCHERICHIA COLI
STAPHYLOCOCCUS AUREUS
BACILLUS SUBTILIS

446

2V3A

Proteobacteria

PSEUDOMONAS AERUGINOSA

446
446
446
446
446
446

1Q1R
1D7Y
2CDU
2BC0
1YQZ
1F8W

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes

PSEUDOMONAS PUTIDA
PARACOCCUS PANTOTROPHUS
LACTOBACILLUS SANFRANCISCENSIS
STREPTOCOCCUS PYOGENES
STAPHYLOCOCCUS AUREUS
ENTEROCOCCUS FAECALIS

604
604
604
604

1WLY
1QOR
1XA0
1TT7

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

BURKHOLDERIA SP. WS
ESCHERICHIA COLI
BACILLUS STEAROTHERMOPHILUS
BACILLUS SUBTILIS

605
605
605
605

2BKB
1DT0
1XRE
1JR9

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

ESCHERICHIA COLI
PSEUDOMONAS PUTIDA
BACILLUS ANTHRACIS
BACILLUS HALODENITRIFICANS
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742
742
742
742

2IFT
2FPO
2FHP
2ESR

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

HAEMOPHILUS INFLUENZAE
ESCHERICHIA COLI
ENTEROCOCCUS FAECALIS
STREPTOCOCCUS PYOGENES

813
813
813
813

1VHJ
1ECP
2AC7
1XE3

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

VIBRIO CHOLERAE
ESCHERICHIA COLI
BACILLUS CEREUS G9241
BACILLUS ANTHRACIS

1012
1012
1012
1012

2HG2
1EYY
1T90
1EUH

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

ESCHERICHIA COLI
VIBRIO HARVEYI
BACILLUS SUBTILIS
STREPTOCOCCUS MUTANS

1057
1057
1057
1057

1YUM
1K4M
2H2A
1KAQ

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

PSEUDOMONAS AERUGINOSA
ESCHERICHIA COLI
STAPHYLOCOCCUS AUREUS
BACILLUS SUBTILIS

1075
1075
1075
1075
1075

1TAH
1OIL
1EX9
2HIH
1KU0

Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

BURKHOLDERIA GLUMAE
BURKHOLDERIA CEPACIA
PSEUDOMONAS AERUGINOSA
STAPHYLOCOCCUS HYICUS
BACILLUS STEAROTHERMOPHILUS

1607
1607
1607
1607

2GVH
1YLI
1Y7U
1VPM

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

AGROBACTERIUM TUMEFACIENS STR. C58
HAEMOPHILUS INFLUENZAE
BACILLUS CEREUS
BACILLUS HALODURANS CProteobacteria25

1940
1940
1940
1940
1940

1Z6R
1Z05
2QM1
2GUP
1XC3

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes

ESCHERICHIA COLI
VIBRIO CHOLERAE O1 BIOVAR ELTOR
ENTEROCOCCUS FAECALIS V583
STREPTOCOCCUS PNEUMONIAE
BACILLUS SUBTILIS

2124
2124
2124
2124
2124

1YRD
1T2B
1Q5E
1IZO
1FAG

Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

PSEUDOMONAS PUTIDA
CITROBACTER BRAAKII
POLYANGIUM CELLULOSUM
BACILLUS SUBTILIS
BACILLUS MEGATERIUM

258
2188
2188
2188
2188

2PKH
2FA1
2OOI
2OGG

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

PSEUDOMONAS SYRINGAE PV. TOMATO STR. DC3000
ESCHERICHIA COLI
STAPHYLOCOCCUS AUREUS
BACILLUS SUBTILIS

Split with HGT
COG PDB
242 2EW7
242 1IX1
242 1ICJ
242 2AI9
242 1WS0
242 1LQY
242 1LM6

Phylum
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes

Source
HELICOBACTER PYLORI
PSEUDOMONAS AERUGINOSA
ESCHERICHIA COLI
STAPHYLOCOCCUS AUREUS
BACILLUS CEREUS
BACILLUS STEAROTHERMOPHILUS
STREPTOCOCCUS PNEUMONIAE

1052
1052
1052
1052
1052
1052

2GSD
2GO1
1GDH
2DLD
1XDW
1J4A

Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes

MORAXELLA SP.
PSEUDOMONAS SP.
HYPHOMICROBIUM METHYLOVORUM
LACTOBACILLUS HELVETICUS
ACIDAMINOCOCCUS FERMENTANS
LACTOBACILLUS DELBRUECKII SUBSP. BULGARICUS

2141
2141
2141
2141
2141

2I7G
1M41
1BRL
2B81
1TVL

Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

AGROBACTERIUM TUMEFACIENS
ESCHERICHIA COLI
VIBRIO HARVEYI
BACILLUS CEREUS
BACILLUS SUBTILIS

3832
3832
3832
3832
3832
3832

1Z94
1XFS
2NN5
2IL5
1XN6
1XN5

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes

CHROMOBACTERIUM VIOLACEUM ATCC 12472
NITROSOMONAS EUROPAEA
ENTEROCOCCUS FAECALIS
STAPHYLOCOCCUS AUREUS
BACILLUS CEREUS
BACILLUS HALODURANS

Starburst
COG PDB
110 2NPO
110 1KRR
110 2IC7
110 1KK5

Phylum
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

Source
CAMPYLOBACTER JEJUNI
ESCHERICHIA COLI
GEOBACILLUS KAUSTOPHILUS
ENTEROCOCCUS FAECIUM

259
171
171
171
171

1XNG
1WXE
2PZB
1KQP

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

HELICOBACTER PYLORI
ESCHERICHIA COLI
BACILLUS ANTHRACIS
BACILLUS SUBTILIS

251
251
251
251
251
251

2IG8
1QU9
1J7H
2EWC
1XRG
1QD9

Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes

PSEUDOMONAS AERUGINOSA
ESCHERICHIA COLI
HAEMOPHILUS INFLUENZAE
STREPTOCOCCUS PYOGENES
CLOSTRIDIUM THERMOCELLUM
BACILLUS SUBTILIS

346
346
346
346
346
346
346
346
346
346
346
346
346
346
346
346
346

2PJS
1R9C
1NPB
1MPY
1LQK
1LGT
1KMY
1F9Z
1EIL
1ECS
2QQZ
2QH0
2P7K
2P25
2I7R
1ZSW
1SS4

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes

AGROBACTERIUM TUMEFACIENS
RHIZOBIUM LOTI
SERRATIA MARCESCENS
PSEUDOMONAS PUTIDA
PSEUDOMONAS AERUGINOSA
BURKHOLDERIA SP.
BURKHOLDERIA CEPACIA
ESCHERICHIA COLI
PSEUDOMONAS SP.
KLEBSIELLA PNEUMONIAE
BACILLUS ANTHRACIS STR. AMES
CLOSTRIDIUM ACETOBUTYLICUM
LISTERIA MONOCYTOGENES
ENTEROCOCCUS FAECALIS
STREPTOCOCCUS PNEUMONIAE
BACILLUS CEREUS
BACILLUS CEREUS

366
366
366
366
366
366
366
366
366
366
366
366
366

1ZJA
1M53
1G5A
1B0I
1WZA
1W9X
1UA7
1PAM
1OT2
1JI1
1HVX
1E3X
1BPL

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes

PSEUDOMONAS MESOACIDOPHILA
KLEBSIELLA SP. LX3
NEISSERIA POLYSACCHAREA
PSEUDOALTEROMONAS HALOPLANKTIS
HALOTHERMOTHRIX ORENII
BACILLUS HALMAPALUS
BACILLUS SUBTILIS
BACILLUS SP.
BACILLUS CIRCULANS
THERMOACTINOMYCES VULGARIS
BACILLUS STEAROTHERMOPHILUS
BACILLUS AMYLOLIQUEFACIENS
BACILLUS LICHENIFORMIS

260

454
454
454
454
454
454
454
454
454
454
454
454
454
454
454
454
454

2Q0Y
2OZH
2GE3
2FT0
2FIW
2EUI
1S3Z
1GHE
2PC1
2OH1
2JDC
2ATR
2AJ6
1Z4E
1Y9K
1U6M
1TIQ

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes

RALSTONIA EUTROPHA JMP134
XANTHOMONAS CAMPESTRIS PV. CAMPESTRIS
AGROBACTERIUM TUMEFACIENS
ESCHERICHIA COLI
RHODOPSEUDOMONAS PALUSTRIS CGA009
PSEUDOMONAS AERUGINOSA
SALMONELLA ENTERITIDIS
PSEUDOMONAS SYRINGAE PV. TABACI
STREPTOCOCCUS AGALACTIAE 2603V/R
LISTERIA MONOCYTOGENES STR. 4B F2365
BACILLUS LICHENIFORMIS
STREPTOCOCCUS PNEUMONIAE TIGR4
STAPHYLOCOCCUS AUREUS
BACILLUS HALODURANS
BACILLUS CEREUS
ENTEROCOCCUS FAECALIS
BACILLUS SUBTILIS

491
491
491
491
491
491
491
491
491
491

2OBW
2GMN
2FM6
2FHX
1X8G
1WUO
1P9E
1K07
2BTN
1BC2

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

SALMONELLA TYPHIMURIUM
BRADYRHIZOBIUM JAPONICUM
XANTHOMONAS MALTOPHILIA
PSEUDOMONAS AERUGINOSA
AEROMONAS HYDROPHILA
SERRATIA MARCESCENS
PSEUDOMONAS SP.
FLUORIBACTER GORMANII
BACILLUS THURINGIENSIS
BACILLUS CEREUS

500
500
500
500
500
500
500
500
500
500
500

2PKW
2P7I
2OYR
2IP2
1PJZ
1NKV
1IM8
2P8J
2GH1
1XXL
1VL5

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes

SALMONELLA TYPHIMURIUM
ERWINIA CAROTOVORA SUBSP. ATROSEPTICA SCRI1043
SHIGELLA FLEXNERI 2A
PSEUDOMONAS AERUGINOSA
PSEUDOMONAS SYRINGAE PV. PISI
ESCHERICHIA COLI
HAEMOPHILUS INFLUENZAE
CLOSTRIDIUM ACETOBUTYLICUM
BACILLUS CEREUS
BACILLUS SUBTILIS
BACILLUS HALODURANS CProteobacteria25

526

2TRX

Proteobacteria

ESCHERICHIA COLI
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526
526
526
526

2I4A
2O7K
2GZY
1NW2

Proteobacteria
Firmicutes
Firmicutes
Firmicutes

ACETOBACTER ACETI
STAPHYLOCOCCUS AUREUS
BACILLUS SUBTILIS
ALICYCLOBACILLUS ACIDOCALDARIUS

590
590
590
590
590

2G84
2A8N
1Z3A
2NX8
1WKQ

Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

NITROSOMONAS EUROPAEA
AGROBACTERIUM TUMEFACIENS
ESCHERICHIA COLI
STREPTOCOCCUS PYOGENES SEROTYPE M6
BACILLUS SUBTILIS

637
637
637
637

2FDR
1TE2
1RQN
1LVH

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

AGROBACTERIUM TUMEFACIENS
ESCHERICHIA COLI O157:H7
BACILLUS CEREUS
LACTOCOCCUS LACTIS

664
664
664
664
664
664

1VP6
1U12
1G6N
1FT9
2HKX
1OMI

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

RHIZOBIUM LOTI
MESORHIZOBIUM LOTI MAFF303099
ESCHERICHIA COLI
RHODOSPIRILLUM RUBRUM
CARBOXYDOTHERMUS HYDROGENOFORMANS
LISTERIA MONOCYTOGENES

745
745
745
745

2PLN
1XHF
2A9O
1MVO

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

HELICOBACTER PYLORI
ESCHERICHIA COLI
STREPTOCOCCUS PNEUMONIAE
BACILLUS SUBTILIS

753
753
753
753
753
753

2ISA
1QWL
1M85
1GGE
2J2M
1SI8

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

VIBRIO SALMONICIDA
HELICOBACTER PYLORI
PROTEUS MIRABILIS
ESCHERICHIA COLI
EXIGUOBACTERIUM OXIDOTOLERANS
ENTEROCOCCUS FAECALIS

778
778
778
778
778
778
778
778

1VFR
2ISJ
1KQD
1F5V
2H0U
2HAY
2B67
1ZCH

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes

VIBRIO FISCHERI
SINORHIZOBIUM MELILOTI
ENTEROBACTER CLOACAE
ESCHERICHIA COLI
HELICOBACTER PYLORI
STREPTOCOCCUS PYOGENES SEROTYPE M1
STREPTOCOCCUS PNEUMONIAE TIGR4
BACILLUS SUBTILIS
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778

2I7H

Firmicutes

BACILLUS CEREUS

784
784
784
784
784
784
784

2FKA
1P6Q
1M5T
6CHY
2I6F
1F51
1QMP

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

SALMONELLA ENTERICA SUBSP. ENTERICA SEROVAR
TYPHIMURIUM
RHIZOBIUM MELILOTI
CAULOBACTER CRESCENTUS
ESCHERICHIA COLI
MYXOCOCCUS XANTHUS
BACILLUS SUBTILIS
BACILLUS STEAROTHERMOPHILUS

796
796
796
796
796

2JFN
2JFX
2JFO
2JFQ
2GZM

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes

ESCHERICHIA COLI
HELICOBACTER PYLORI
ENTEROCOCCUS FAECALIS
STAPHYLOCOCCUS AUREUS
BACILLUS ANTHRACIS

1028 2EWM
1028 2DKN
1028 2CFC
1028 2B4Q
1028 1ZEM

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria

AZOARCUS
PSEUDOMONAS SP.
XANTHOBACTER AUTOTROPHICUS
PSEUDOMONAS AERUGINOSA
GLUCONOBACTER OXYDANS

1028 1WMB
1028 1PWX
1028 1K2W
1028 1GEG
1028 1FJH
1028 1AHH
1028 2UVD
1028 2HQ1
1028 1NXQ
1028 1G6K

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes

PSEUDOMONAS FRAGI
AGROBACTERIUM TUMEFACIENS
RHODOBACTER SPHAEROIDES
KLEBSIELLA PNEUMONIAE
COMAMONAS TESTOSTERONI
ESCHERICHIA COLI
BACILLUS ANTHRACIS
CLOSTRIDIUM THERMOCELLUM
LACTOBACILLUS BREVIS
BACILLUS MEGATERIUM

1151
1151
1151
1151
1151

1JQK
1E2U
1OA0
1SU6
1OAO

Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

RHODOSPIRILLUM RUBRUM
DESULFOVIBRIO VULGARIS
DESULFOVIBRIO DESULFURICANS
CARBOXYDOTHERMUS HYDROGENOFORMANS
MOORELLA THERMOACETICA

1309
1309

2UXH
2HYT

Proteobacteria
Proteobacteria

PSEUDOMONAS PUTIDA
ERWINIA CAROTOVORA SUBSP. ATROSEPTICA
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1309
1309
1309
1309
1309
1309
1309
1309

2G7S
2FBQ
1T33
1PB6
2IU5
2FX0
1Z0X
1VI0

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes

AGROBACTERIUM TUMEFACIENS
PSEUDOMONAS AERUGINOSA
SALMONELLA TYPHIMURIUM
ESCHERICHIA COLI
LACTOCOCCUS LACTIS SUBSP. LACTIS IL1403
BACILLUS CEREUS
ENTEROCOCCUS FAECALIS V583
BACILLUS SUBTILIS

1396
1396
1396
1396
1396

1Y9Q
1Y7Y
2P5T
2B5A
1B0N

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes

VIBRIO CHOLERAE
AEROMONAS HYDROPHILA
STREPTOCOCCUS PNEUMONIAE
BACILLUS CALDOLYTICUS
BACILLUS SUBTILIS

1404
1404
1404
1404
1404
1404
1404
1404
1404
1404
1404
1404
1404
1404
1404
1404

2B6N
1V6C
1S2N
3TEC
2SIC
2IXT
1YU6
1XF1
1V5I
1TEC
1SEL
1SBN
1MEE
1IAV
1DBI
1BH6

Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes

SERRATIA SP.
PSEUDOALTEROMONAS SP. ASProteobacteria1
VIBRIO SP. PA-44
HIRUDINARIA MANILLENSIS
BACILLUS AMYLOLIQUEFACIENS
BACILLUS SPHAERICUS
MELEAGRIS GALLOPAVO
STREPTOCOCCUS PYOGENES
PLEUROTUS OSTREATUS
THERMOACTINOMYCES VULGARIS
BACILLUS SUBTILIS
HIRUDO MEDICINALIS
BACILLUS PUMILUS
BACILLUS LENTUS
BACILLUS SP.
BACILLUS LICHENIFORMIS

1733
1733
1733
1733

2F2E
1YYV
2HZT
1Z7U

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

PSEUDOMONAS AERUGINOSA
SALMONELLA TYPHIMURIUM
BACILLUS SUBTILIS
ENTEROCOCCUS FAECALIS V583

1846
1846
1846

2FBH
2FA5
1JGS

Proteobacteria
Proteobacteria
Proteobacteria

PSEUDOMONAS AERUGINOSA
XANTHOMONAS CAMPESTRIS
ESCHERICHIA COLI

1846 2QWW Firmicutes
1846 2BV6
Firmicutes

LISTERIA MONOCYTOGENES STR. 4B F2365
STAPHYLOCOCCUS AUREUS
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1846
1846

1Z91
1LJ9

Firmicutes
Firmicutes

BACILLUS SUBTILIS
ENTEROCOCCUS FAECALIS

2159
2159
2159
2159

2HBV
2DVT
2QPX
2F6K

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

PSEUDOMONAS FLUORESCENS
RHIZOBIUM SP.
LACTOBACILLUS CASEI ATCC 334
LACTOBACILLUS PLANTARUM

2367
2367
2367
2367
2367
2367
2367
2367
2367
2367
2367

1N4O
1JTG
1JTD
1HZO
1HTZ
1G68
1FQG
1DY6
1BUE
1KGG
1I2S

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes

XANTHOMONAS MALTOPHILIA
STREPTOMYCES CLAVULIGERUS
STREPTOMYCES EXFOLIATUS
PROTEUS VULGARIS
KLEBSIELLA PNEUMONIAE
PSEUDOMONAS AERUGINOSA
ESCHERICHIA COLI
SERRATIA MARCESCENS
ENTEROBACTER CLOACAE
STAPHYLOCOCCUS AUREUS
BACILLUS LICHENIFORMIS

2730
2730
2730
2730
2730
2730

1TVN
1EGZ
2JEP
1QHZ
1LF1
1G01

Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes

PSEUDOALTEROMONAS HALOPLANKTIS
ERWINIA CHRYSANTHEMI
PAENIBACILLUS PABULI
BACILLUS AGARADHAERENS
BACILLUS SUBTILIS
BACILLUS SP.

Starburst
COG PDB
3693 2CNC
3693 1US3
3693 1E5N
3693 2F8Q
3693 2DEP
3693 1R85

Phylum
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes

Source
CELLVIBRIO MIXTUS
CELLVIBRIO JAPONICUS
PSEUDOMONAS FLUORESCENS
BACILLUS SP. NG-27
CLOSTRIDIUM STERCORARIUM
BACILLUS STEAROTHERMOPHILUS

4948
4948
4948
4948
4948
4948
4948

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria

AZOARCUS SP. EBN1
SINORHIZOBIUM MELILOTI
ROSEOVARIUS SP. HTCC2601
DESULFOTALEA PSYCHROPHILA LSV54
ROSEOVARIUS NUBINHIBENS ISM
MESORHIZOBIUM LOTI
AZOTOBACTER VINELANDII AVOP

2QDE
2PPG
2PMQ
2PGE
2PCE
2OZ8
2OZ3
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4948
4948
4948
4948
4948
4948
4948
4948
4948
4948
4948
4948
4948
4948
4948
4948
4948
4948
4948
4948

2OX4
2OO6
2OG9
2NQL
2HZG
2GSH
2DW6
1YEY
1NU5
1MUC
1EC7
1CHR
2P88
2OQY
2OKT
2GGE
2GDQ
1WUF
1WUE
1JPM

Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Proteobacteria
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes
Firmicutes

ZYMOMONAS MOBILIS
BURKHOLDERIA XENOVORANS
POLAROMONAS SP. JS666
AGROBACTERIUM TUMEFACIENS
RHODOBACTER SPHAEROIDES
SALMONELLA TYPHIMURIUM
BRADYRHIZOBIUM JAPONICUM
XANTHOMONAS CAMPESTRIS PV. CAMPESTRIS
PSEUDOMONAS SP.
PSEUDOMONAS PUTIDA
ESCHERICHIA COLI
RALSTONIA EUTROPHA
BACILLUS CEREUS ATCC 14579
OCEANOBACILLUS IHEYENSIS
STAPHYLOCOCCUS AUREUS
BACILLUS SUBTILIS
BACILLUS SUBTILIS SUBSP. SUBTILIS
LISTERIA INNOCUA CLIP11262
ENTEROCOCCUS FAECALIS
BACILLUS SUBTILIS
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Appendix 6B: The median E-value for each COG. A median of 0 represents all proteins
within the COG gave a perfect match to the PDB.
COG Median E-value
28
1E-175
39
1E-121
110
1E-74
171
2.5E-147
242
7E-90
251
4.9E-66
346
1E-56
366
1E-138
394
1.51E-80
446
5E-96
454
4E-72
491
4.5E-26
500
6E-136
526
7E-55
590
8E-78
604
3.5E-113
605
5E-91
637
1E-120
664
4E-16
742
2.5E-89
745
1E-61
753
0
778
1E-117
784
2E-58
796
7E-128
813
4.5E-97
1012
0
1028
3E-66
1052
1E-56
1057
3.5E-109
1075
1E-96
1151
1.5E-147
1309
5E-96
1396
4E-58
1404
1.35E-87
1607
3.5E-72
1733
3E-52
1846
1E-69
1940
4E-155
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2124
2141
2159
2188
2367
2730
3693
3832
4948

2E-48
1.5E-58
1.5E-21
5.02E-84
2E-58
2.1E-59
2E-48
3.75E-50
1E-140
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Appednix 6C: The complete Fractional Structure Similarity (FSS) compared to sequence
identity prior to manual filtering. As in figure 6.3, (A) is all vs. all comparisons, (B) is
the comparisons of Proteobacteria structure against Proteobacteria structure, (C) is the
Firmicutes against Firmicutes and (D) is the Proteobacteria against the Firmicutes. As
stated in the text above the comparisons between Proteobacteria and Firmicutes show an
abrupt cutoff at about 65% sequence identity and 0.85 Fraction Structure Similarity.
Outliers were shown to be comparisons of the same protein from the same organism
solved under non-uniform conditions. The large density of structures a 100% sequence
identity illustrates the propensity of solving structures redundantly from the same
organism and the large spread of data shows the need for manual curation of the dataset
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CHAPTER 7:
A SEQUENCE AND STRUCTURE INDEPENDENT METHOD TO PREDICT
PROTEIN FUNCTION

7.1 INTRODUCTION
The recent explosion in sequenced genomes has revealed a vast number of
proteins that lack a functional annotation.1 Many of these unannotated proteins may play
an important role in human disease and correspondingly, are critical for developing new
therapeutics. Protein sequence and structure similarity methods are currently the most
robust and widely-used tools to annotate a protein of unknown function. 2 Nevertheless,
these methods are limited in scope, prone to errors, and based on a small set of
experimentally characterized proteins.3 Only 40 to 60% of sequences suggest a potential
functional assignment. Moreover, error rates of < 30% occur even with conservative
sequence identities of > 60%. The accuracy of functional annotations decreases
substantially in the twilight zone of 20-35% sequence identity.
Recent attempts to extend functional prediction beyond global sequence and
structure similarity have led to the development of active-site similarity search methods.46

These methods try to identify protein surface structures that interact with biologically

important compounds or other proteins. Protein active-sites that share similar sequence,
structure and bind similar ligands are predicted to be functionally related.

While

promising, current active-site similarity techniques still rely on high-resolution protein
structures to identify and measure functional similarity. 7, 8 The availability of structures
for the entire proteome remains a significant bottleneck for high-throughput functional
annotation of hypothetical proteins.
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In the previous chapters, functional annotation of proteins was discussed in the
presence of sequence, structure and active site information. As shown in chapters 1,3 and
4 these methods are powerful, but have limitations that prevent complete annotation of a
specific genome in a high-throughput manner. Specifically, sequence similarity methods
often fail below 30% sequence identity9, 10 and structure similarity or active site similarity
methods require a high-resolution protein structure. Additionally, functional similarity is
not necessarily dependent on homology. This can lead to similar sequences having
different functions or significantly different sequences with similar functions. 9,

11

The

issues raised above suggest a new approach to function annotation that is independent of
sequence or structure is needed.
Proteins interact with biological compounds to perform specific yet versatile
functions. Identifying and comparing which compounds bind a target protein provides an
alternative method to predict function. In this chapter I discuss the development of a
quantifiable and rapidly adaptable model for protein functional analysis using
experimentally derived ligand binding profiles (LBP). This new approach is independent
of sequence, structural or evolutionary information; therefore, extending the current
analysis of novel genes and predicting ligand binding. A ligand binding profile is defined
as a set of ligands that bind a protein from a high-throughput ligand affinity screen. The
hypothesis is that proteins with similar function will bind a similar set of compounds
from the same high-throughput screening library. A general functional similarity is
identified by clustering proteins similar binding profiles.
In this chapter, I discuss the theory behind the ligand binding profile method and
report screening and similarity results from 19 proteins with a range of functions defined
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by Gene Ontology (GO) terms.12 With the availability of GO terms, many studies relate
functional similarity to protein-protein interactions,13 network prediction,14 prediction of
cellular localization,15 pathway modeling,16 and improving the quality of microarray
data.17 This chapter is the first attempt to relate ligand binding similarity to functional
similarity.

7.2 THEORY
7.2.1 Development of a ligand binding profile scoring function. Measuring a
significant similarity between two ligand binding profiles requires the development or
adaptation of a robust scoring function. Current similarity scoring methods used for
sequence analysis, such as the E-value developed by Karlin and Altschul,18 are also wellsuited for measuring a similarity between ligand binding profiles.
E

Kmne S

[7.1]

Here, the E-value is only dependent on the total number of compounds that bind
each protein (m and n) and the total number of compounds that bind both proteins (S).
Additionally, the probability of finding a significant similarity is proportional to the
probability search space (K) and scoring function (λ).
p )2
q
[7.2]
and
ln
q
p
Unlike sequence similarity, a similarity between ligand binding can be thought of
K

(q

as a binary system (binding vs. non-binding) therefore the probabilities p and q simply
become the probability of finding a hit within a library:

p

1
library size

[7.3]
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and the probability of finding a ligand that binds both proteins:
q

S
mn

[7.4]

The standard E-value also provides a robust measure of the probability. This
shows a significant ligand binding similarity is not due to chance using the standard Pvalue.
P

1 e E

[7.5]

As expected, the ligand binding profile E-value rapidly becomes non-significant
(P > 0.0001) as the probability of finding a ligand that binds both proteins (q) decreases
(figure 7.1). Binding profiles that have a P < 0.0001 are significant at the 99.99%
confidence interval (~E=10-5).

Figure 7.1. E-value response to the probability of finding overlapping ligands
between two proteins. A set of 33,207 randomly generated hypothetical binding profiles
was generated to observe the response of the E-value similarity with probability of
overlapping ligands (q=S/mn) as the probability of finding an overlapping ligand
decreases the E-value rapidly becomes non-significant (E>1x10-5).
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7.3 EXPERIMENTAL
7.3.1 Hypothetical binding profiles. A set of hypothetical binding profiles was
generated to test the E-value scoring method for the ligand binding profiles. To generate
the hypothetical binding profiles, an Excel program was written to generate random
values for m, n and S for 100,000 hypothetical binding profiles. The hypothetical library
size was 437 compounds; random numbers were generated between 0 and 437. The data
set was filtered such that S ≤ m and S ≤ n giving 33,207 comparisons. The data set was
used to compare the E-value response to probablilty of finding an overlapping ligand
(figure 7.1).
7.3.2 Materials. The human serum albumin (HSA) (essentially fatty acid free, ≥
96 % pure), bovine serum albumin (BSA) (minimum 98% agarose gel electrophoresis,
lyophilized), α-amylase from Bacillus lincheniformis (Bli) (500-1,500 units/mg protein,
93-100% (SDS page)), α-amylase from Aspergillus oryzae (Aor) (powder, ~30 units/mg),
α-amylase from Bacillus amyloliquefaciens (Bam) (liquid, ≥250 units/g protein), βamylase from barley (Hvu) (type II-B 20-80 units/mg protein), and β-amylase from sweet
potato (Iba) (Type I-B, ammonium sulfate suspension, ≥750 units/mg protein) protein
samples were all purchased from Sigma (St. Louis, MO). The S. typhimurium PrgI
protein samples and assigned 2D 1H-15N HSQC spectrum were generously provided by
Dr. Roberto DeGuzman (University of Kansas). Staphylococcus aureus primase CTerminal domain (CTD) protein sample was purchased from Nature Technologies
Corporation (Lincoln, NE). H. sapiens diacylglycerol kinase alpha (DGKA), P.
aeruginosa unannotated protein PA1324, S. aureus unannotated protein SAV1430, S.
typhimurium unannotated protein STM1790, H. sapiens ubiquitin-fold modifier-
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conjugating enzyme 1 (UFC1), E. coli unannotated protein YjbR, E. coli unannotated
protein YkfF, B. subtilis unannotated protein YkvR and E. coli unannotated protein YtfP
protein samples were provided by Dr. Gaetano Montelione, Director of the Northeast
Structural Genomics Consortium (NESG, www.nesg.org). The S. aureus nuclease was
over-expressed in house from a cell stock of E. coli Bl21 DE3 codon+ (Stratagene)
containing the pET28(a)+plasmid with the dnuc gene provided by Dr. Greg Somerville
(University of Nebraska-Lincoln) grown in LB broth and purified using a Talon cobalt
affinity resin (Clontech). The deuterium oxide (99.9% D) and the dimethyl sulfoxide-d6
(99.9%

D)

were

purchased

from

Aldrich

(Milwaukee,

WI)

The

3-

(trimethylsilyl)propionic acid-2,2,3,3-d4 (TMS) was purchased from Cambridge Isotope
(Andover, MA). The bis-Tris-d19 (98% D) was purchased from Isotec (Milwaukee, WI).
The compound library was previously complied as described elsewhere 19 .
7.3.2 Apparatus. All NMR data was collected on a Bruker 500 MHz Avance
spectrometer (Billercia, MA) equipped with a triple resonance, Z-axis gradient cryoprobe
and using a Bruker BACS-120 sample changer and IconNMR software for automated
data collection. The screening data for this study was compiled over a 5 year time span in
which two different 1D 1H solvent suppression pulse sequences were used for the
measurement of ligand 1D 1H NMR line broadening. High-throughput NMR screening
spectra for the HSA, BSA, S. aureus primase CTD, PrgI, PA1324, and SAV1430 were
collected at 298 K using 64 transients with a sweep-width of 6009 Hz with 8 K data
points and a 2.0 s relaxation delay using the using a presaturation solvent suppression
pulse sequence (chapter 3 & 5).4,

20-22

High-throughput NMR screening spectra for

DGKA, STM1790, UFC1, YjbR, YkfF, YkvR and YtfP, the 5 amylases and S. aureus
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nuclease proteins were collected at 298 K using 64 transients with a sweep-width of 6009
Hz with 8 K data points and a 1.0 sec relaxation delay using the excitation sculpting 23
method for solvent suppression of the residual H2 O resonance signal (chapter 4).
7.3.3 Sample preparation. All NMR ligand affinity assays were completed by
screening each protein individually with a library of biologically active compounds. The
compound library is composed of 113 mixtures with 3-4 ligands per mixture and is
described in detail elsewhere.19 The screens of HSA, BSA, S. aureus primase CTD, PrgI,
PA1324, and SAV1430 were prepared as previously described.4, 20-22 S. aureus nuclease,
DGKA, STM1790, UFC1, YjbR, YkfF, YkvR, YtfP, and the 5 amylases were screened at
5 µM protein concentration and 100 µM ligand concentration in a screening buffer of 2%
DMSO-d6, 20 mM Bis-Tris pH 7.0 (uncorrected), 11.1 M TMSP in “!00%”D2O.
7.3.4 Binding assay. Ligand binding was identified by a decrease in free ligand
signal upon the addition of protein. The methods for data processing and identifying
binding ligands have been previously discussed in detail in the previous chapters 2, 3, and
4 and references.4, 21, 24 Briefly, data was Fourier transformed, auto-phase and baseline
corrected. Each 1D 1H NMR spectrum were compared to the corresponding free ligand
mixture reference spectrum and visually analyzed to identify binding ligands. A binding
event was identified by the decrease in ligand intensity of the nuclease-mixture relative to
the free ligand mixture.
7.3.5 Ligand binding profiles. A ligand binding profile score was measured for
each protein comparison using equation 7.1. Overlapping binding ligands (S) for every
protein were identified in a pairwise manner for a total of 171 comparisons.

The

probability of finding overlapping ligands between two proteins was calculated using eq
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7.5 Each pairwise E-value was calculated using a library size of 437 compounds (with p
= 1/437 = 0.00229).
7.3.6 Functional similarity measurement. The Uniprot accession number was
obtained for each protein in the study (http://www.uniprot.org/). The list of Uniprot
accession numbers was uploaded to the semantic similarity tool FunSimMat.25 All
reported functional similarities are expressed as the funsim score measured as described.25
Briefly, the funsim score is measure of relative functional similarity between GO terms at
the biological process and molecular function levels of the gene ontology. It ranges from
0 for no functional similarity to 1 for maximal functional similarity

Where, max(BPscore) and max(MFscore) denote the maximal similarity scores
for biological process and molecular function, respectively.

The max(BPscore) and

max(MFscore) scores for the funSim score is computed using simRel. simRel is a
combination of Resnik's and Lin‟s measure of semantic similarity25-27

Where, c1 and c2 are the semantic similarity terms of a protein, maxS(c1,c2) is
the set of common terms, p(c) is the relative frequency of occurrence of a term.
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7.4 RESULTS AND DISCUSSION
7.4.1 Establishing a set of functionally diverse proteins. Chapter 1 discussed
the difficulties with non-uniform methods for functional annotation. The Gene Ontology
Annotation project 28, 29 is becoming the standard representation for functional annotating
of individual proteins. The success of the GO method lies in the hierarchical approach to
protein annotation.

Each protein or gene product is annotated with three levels of

functional similarity, biological process, molecular function and cellular component.
This approach annotates a specific GO number for each level of function which allows
for development of computational functional similarity scoring methods. A number of
methods have been developed to measure functional similarity with the majority of the
methods based on semantic similarity of GO terms. 25, 26, 30-32 In this study the functional
similarity score from FunSimMat 25, 32 was used to measure functional similarly between
19 proteins with a range of functional similarity (appendix 7A).

FunSimMat is a

composite average method for semantic similarity. The composite methods are generally
more biologically accurate33
For the 19 proteins screened in the NMR ligand affinity assay, 13 proteins have a
previously annotated function based on GO terms and 6 proteins have an unknown
function. As a positive control, two sets of functionally related proteins (2 serum
albumins and 5 amylases) were evaluated. A functional similarity score between each
pair of proteins was measured by the semantic similarity tool of GO annotations
FunSimMat (table 7.1).25 The FunSimMat similarity for HSA and BSA was 0.98 and an
average FunSimMat similarity score of 0.69 ± 0.01 was calculated for the amylases. The
remaining 12 proteins exhibited no functional relationship to any other protein in the
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screening set, yielding an average FunSimMat similarity score of 0.1 ± 0.1. A weak
functional similarity was observed between the two albumins and the human protein
ubiquitin-fold modifier-conjugating enzyme 1 (UFC1, Uniprot: Q9Y3C8). However, this
similarity is limited to one overlapping and generic “protein binding” GO number
(GO:0005515).
7.4.2 High-throughput ligand screening of a set of functionally diverse
proteins. To experimentally support the ligand binding profile hypothesis, 19 proteins
were screened by NMR using a chemical library of biologically active compounds. 19
Binding events were identified as previously described by measuring a decrease in ligand
1

H NMR peak intensities in the presence of a protein (figure 7.4). 4, 21 As an example,

figure 7.4 shows the relative responses in binding for HSA and BSA to the non-steroidal
anti-inflammatory drug naproxen. Naproxen was identified from a screen of the entire
ligand library as a binder for both proteins. The relative change in linewidth for naproxen
binding HSA was comparable to naproxen binding BSA. The ligand binding profile
method only uses the identification of binding ligands (hit vs. no hit) to compare
functional similarities. The binary mode of measuring ligand binding similarities makes
the ligand binding profile a high-throughput method for functional annotation.
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Table 7.1 A diverse set of proteins have been screened by 1D 1H NMR line broadening experiments (see methods 7.3.3). The set of
19 proteins is comprised of 2 sets of positive controls (set1=albumins, set2=amylases). Functional similarity between each protein was
measured by the semantic similarity tool FunSimMat. 25 The 6 unannotated proteins in the data were removed from the table for
clarity; there was no measured functional similarity due to the lack of Gene Ontology12 annotations for the proteins. The nuclease
protein was also removed for clarity because there was no functional similarity to any protein in the dataset.
HSA BSA Primase PrgI Aor-A Hvu-B Bam-A Bli-A Iba-B DGKA UFC1
0.98
0.07
0.28
0.05
0.02
0.04
0.04
0.03
0.23
0.49
HSA
0.07
0.28
0.05
0.03
0.04
0.04
0.04
0.25
0.49
BSA
0.2
0.15
0.19
0.19
0.17
0.24
0.15
Primase
0
0
0
0
0
0
0
PrgI
0.64
0.68
0.68
0.67
Aor-A
0.63
0.63
0.71
Hvu-B
0.68
0.63
Bam-A
0.63
Bli-A
0.07
0.22
Iba-B
STM1790
0.03
DGKA
YjbR
UFC1
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Figure 7.4. Proteins with similar function bind similar ligands. Ligand binding is
identified by a decrease in ligand peak intensity upon addition of a target protein. The 1D
1
H NMR spectrum of the non-steroidal anti-inflammatory drug naproxen (I) is shown to
broaden in the presence of H. sapiens serum albumin (HSA) (II) and B. taurus serum
albumin (BSA) (III) indicating a positive binding event. The NMR line broadening
experiments used 100 M ligand and 5 M protein as described in the methods section.
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7.4.3 Ligand binding profiles for a set of functionally diverse proteins. An allvs-all pairwise comparison of the 19 proteins gave a total of 171 ligand binding profile
comparisons with only 11 comparisons giving a significant similarity score (P < 0.0001).
The comparisons with the highest similarity scores corresponded to the set of albumins
(E-value 1x10-58) and the set of amylases (average E-value ~1x10-11). Table 7.2 lists all
protein pairs with a significant ligand binding similarity score along with the
corresponding FunSimMat functional similarity score. The complete list of ligand
binding similarity scores (appendix 7A) shows an abrupt decrease in significance for the
remaining proteins. This correlates with the remaining proteins having no functional
similarity to one another.
As shown in table 7.2, human serum albumin (HSA) and bovine serum albumin
(BSA) had a large number of binding ligands (178 and 171, respectively) compared to the
overall size of the library. The relative hit rate for these two proteins was 40.7% and
39.1%, respectively. With a large hit rate, false similarities may arise if a second protein
serendipitously bound to a small subset of compounds that were shown to bind HSA or
BSA. However, the ligand binding similarity score (eq 7.2) effectively eliminates this
concern by scaling the score based on both the total number of compounds found to bind
each protein and by the number of overlapping binding ligands. As an example, the S.
typhimurium type III secretion system protein PrgI bound to a total of five compounds,
where each compound was also shown to bind HSA and BSA. The corresponding Evalues for the ligand binding profile comparisons between PrgI and HSA (6.9 x 10-2) and
BSA (6.4 x 10-2) were not significant.
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Table 7.2 The number of hits per protein (m and n), overlapping ligands (S), E-values
and functional similarity scores (FunSim) are reported for the significant ligand binding
profiles at 99.99% confidence interval from a comparison of 19 proteins. The set of
serum albumins from H. sapiens (HSA) and B. taurus (BSA) and amylases (Aor, Bam,
Bli, Hvu, and Iba) gave significant similarity. The set of amylases was composed of 3 amylases from A. oryzae (Aor), B. amyloliquefaciens (Bam), and B. licheniformis (Bli)
and 2 -amylases H. vulgare (Hvu) and I. batatas (Iba). A complete list of binding
profiles is reported in the appendix 7A.
Comparison

m/n

S

E-value

Funsim Score

HSA-BSA

178/171

162

2.16X10-58

0.98

Bam-Aor

35/36

22

6.38X10-19

0.68

14

-10

0.63

-15

0.68

-14

0.68

-06

Bam -Hvu
Bli- Aor
Bli - Bam

35/29
28/36
28/35

18
16

1.17X10
1.19X10
1.42X10

Bli - Hvu

28/29

9

3.86X10

0.63

Hvu - Aor

29/36

13

2.98X10-08

0.64

12

-08

0.67

-12

Iba- Aor

29/36

2.98X10

Iba - Bam

29/35

15

7.56X10

0.63

Iba - Bli

29/28

11

2.43X10-08

0.63

12

-09

0.71

Iba - Hvu

29/29

2.45X10
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There was an observed similarity in ligand binding profiles between S. aureus
nuclease and the

-amylases from A. oryzae and B. amyloliquefaciens. However, the

similarity in the ligand binding profiles was limited to the nucleosides in the library.
Additionally, the remaining 3 amylases did not bind these ligands or exhibit a significant
ligand binding similarity to nuclease. The observed ligand binding similarity between the
nuclease and two of the -amylases is potentially due to trace amounts of a nuclease that
may be present in the A. oryzae and B. amyloliquefaciens -amylases samples. This is a
likely occurrence since the samples were purchased as crude mixtures, where sizeexclusion chromatography only yielded a modest improvement in purity.
The ligand binding profiles for all 19 proteins is represented as a heat map in
figure 7.5. Each binding ligand was colored red while each non-binding ligand was
colored white. The heat map shows the overall clustering patterns for each binding
profile. The heat map correlates well with table 7.2 showing that functionally similar
proteins bind a consensus set of ligands from a standardized library of compounds.
Ligands that are not included in the consensus set could either be due to non-specific
binding, differences between sample preparation, or potentially unique and specific
binders.
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Figure 7.5 Heat map summarizing the NMR ligand affinity screens. For 19 proteins:
H. sapiens serum albumin (HSA), B. taurus serum albumin (BSA), A. oryzae -amylase
(Aor), B. amyloliquefaciens -amylase (Bam), B. licheniformis amyloliquefaciens amylase (Bli), I. batatas -amylase (Iba), H. vulgare -amylase (Hvu), S. aureus
nuclease, S. aureus primase C-terminal domain, S. typhimurium type III secretion system
protein (PrgI), S. aureus unannotated protein SAV1430, E. coli unannotated protein
YtfP, P. aeruginosa unannotated protein PA1324, B. subtilis unannotated protein YkvR,
E. coli unannotated protein YkfF, S. typhimurium unannotated protein STM1790, H.
sapiens diacylglycerol kinase alpha (DGKA), E. coli unannotated protein YjbR, H.
sapiens ubiquitin-fold modifier-conjugating enzyme 1 (UFC1), where the albumins are
colored red, the amylases cyan and the remainder of the proteins grey. A binding ligand
is indicated by a red line. The 437 ligands were sorted to maximize the clustering of
binding ligands for the albumins and amylases.
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7.4.4 Future developments to the ligand binding profile method.

Ligand

binding profiles are independent of sequence and structural information and thus provide
an experimental-based approach to predict protein function in a relatively robust and
high-throughput fashion. The results reported herein demonstrate a clear correlation
between ligand binding similarity scores and FunSimMat functional similarity scores.
Specifically, only the set of albumins and amylases gave significant ligand binding
similarity scores. Unfortunately, the ligand binding profile method was unable to
differentiate between the

and

amylase families. A further refinement of the functional

annotation would require a second screening step using a focused library to differentiate
these functional classes. In the case of the amylases, this would involve screening the
proteins with a carbohydrate library, where a subset of the compounds would selectively
bind to the - or -amylase proteins.
The success of the ligand binding profile approach to annotate a protein depends
on a functionally diverse and modestly sized chemical library that differentiates between
various functional classes. Importantly, the methodology used to identify binding ligands
must efficiently eliminate non-specific or irrelevant interactions. This is not the case with
traditional high-throughput screening (HTS) methods that encounter significant falsepositive and false-negative rates. Applying the ligand binding profile technique to HTS
data sets from the High Throughput Screening Laboratory at the University of Kansas
were unsuccessful. Alternatively, NMR ligand-affinity screens provide a direct
observation of a specific interaction between the ligand and protein. As demonstrated, the
preponderance of binding ligands identified from the 19 NMR ligand affinity screens was
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uniquely associated with each functional class and were shown to correlate with the
protein‟s GO terms.
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Appendix 7A Complete list of ligand binding profile scores, - marks indicate no
overlapping binding ligands
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CHAPTER 8:
CONCLUSIONS
8.1 SUMMARY OF WORK
Protein science has always had a long history intertwined with the advancements
in chemistry, biology and physics. Today, with nearly 1350 complete genome sequences
available, our understanding of biology at the molecular level has never been more
complete. While our understanding of biology continues to grow exponentially, we are
still at the beginning of having a truly systematic understanding of Mother Nature‟s most
fundamental secrets. This is most evident by the large functionally unannotated segments
of each organism‟s genome.
The genes (and proteins they encode) found in these functionally unannotated
regions are considered “hypothetical proteins”. Current estimates suggest between 12%50% of the known gene sequences belong to unannotated proteins.1-3 This is true even for
the most highly studied model organisms Escherichia coli. An estimated 50% of the
genes found in the E. coli genome have no experimental annotation.4, 5 Considering the
large degree of biodiversity, it was initially suggested that hypothetical proteins were
adaptations to specific environmental niches and therefore species specific. 6, 7 However,
many hypothetical proteins are not species-specific and homologous sequences are found
in a range of phylogenetic distributions. These evolutionary “conserved hypothetical
proteins” significantly limits our understanding of biology.8
From a pragmatic viewpoint, identifying the functions of these proteins could lead
to new therapeutics; making functional annotation of paramount importance. Considering
the large number of unannotated proteins (~1.5 million), the most popular tools for
functional annotation rely on homology transfer of sequences and structures to
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automatically predict protein function. However, sequence and structure homology does
not always imply functional conservation and these automatic methods often lead to
spurious annotations. Estimates in the error rates suggested nearly 30% of all automatic
functional annotations of enzymes are incorrect. 9

Differences in protein active site

structures leading to different ligand specificities and enzyme efficiencies are suspected
to be a major source of errors in automatic functional annotations. 9-11
The large error rate of automatic functional annotation methods strongly supports
the need for developing new methods that are independent of homology transfer. In this
dissertation I thoroughly tested the hypothesis of using ligand-defined active sites for
functional annotation. In chapter 2, I discussed the theory and experimental validation of
a method to measure single point binding dissociation constants (KD) from 1D 1H NMR.
The primary goal of the project was to develop a method that would be robust for a broad
functional library of compounds to a variety of biological target molecules. The method
was intended as a qualitative screening tool to provide accurate ranking of target
molecules for both drug discovery and functional annotation using the Functional
Annotation Screening Technology by NMR (FAST-NMR) method.
In chapter 3 I used this single point KD method in concert with the FAST-NMR
method to select the best binding ligand to the type three-secretion system protein PrgI
(didecyldimethylammonium bromide, DDAB).

Didecyldimethylammonium bromide

was identified from a compound library using 1D 1H NMR screening techniques and
used to identify the active site of PrgI. Finding the active site of PrgI facilitated the
identification of a functional similarity between PrgI and Bcl-xL using the Comparison of
Protein Active Site Similarities (CPASS) database. 12
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The results from the FAST-NMR screen of S. aureus nuclease in chapter 4
confirmed the use of NMR screening to identify a protein active site and the use of active
site similarities to identify protein functional similarities. Additionally, the successful
identification of a ligand bound S. aureus nuclease structure having the best active site
similarity validated CPASS and using active site similarity as a functional annotation
tool. Finally, the optimization of the initial version of the NMR screening techniques
utilized by FAST-NMR significantly improved the efficiency of the high-throughput
screen.
The rapid rise in community acquired antibiotic resistance, particularly to S.
aureus, requires the rapid identification of new antibiotic targets and potential drugs. 13
The interaction between bacterial primase C-terminal domain and replicative helicase Nterminal domain is an attractive antibiotic target because it is functionally conserved in
bacteria, essential for DNA replication and distinctly different from eukaryotes. 14,

15

Additionally, the high degree of sequence variability and differences in structure suggest
a possible means to tailor antibiotic development to a specific organism. In chapter 5, I
reported the NMR solution structure of S. aureus primase CTD. I use the structure to
show a strong phylum dependency for primase CTD structure similarity and reported a
potential drug lead for further antibiotic development.
In chapter 6, I expanded upon the work of phylum dependent structure similarity
by thoroughly analyzing functionally conserved, orthologous structures.. I quantify a
maximum structure/sequence similarity between the two bacterial phyla, Proteobacteria
and Firmicutes, and discussed the viability of phylogeny as a suitable constraint for
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selecting a homology model. This was supported by showing protein folds are not
uniformly sensitive changes in sequence.
The problems with automatic functional annotation were thoroughly discussed in
this dissertation.

The development of the FAST-NMR method is a significant

advancement towards high-throughput functional annotation but is limited by the
availability of a high-resolution protein structure. In chapter 7, I discussed the
development the ligand binding profile (LBP) method for functional annotation.

A

ligand binding profile is defined as a set of ligands that bind a protein from a highthroughput ligand affinity screen. The hypothesis was proteins with similar function will
bind a similar set of compounds from the same high-throughput screening library. I tested
the method on a set of 19 proteins with a range of functions and reported only proteins
with high degree of functional similarity gave significant LBP scores. The ligand binding
profile method is independent of sequence, structure or evolutionary information and
therefore not limited by the issues of automatic functional annotation discussed in this
dissertation.
As a final thought, the ligand binding profile is not dependent on screening
method or chemical library (provided binding profiles are generated from the same
chemical library). This opens the door for virtual screening methods to identify binding
ligands and compare ligand binding profiles. Virtual screens significantly reduce the
time scale of ligand screening relative to experimental based approaches. The continual
advancements in virtual screening coupled with the ligand binding profile will help make
high-throughput functional annotation a reality.
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